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Abbreviations  
AARS2 Alanyl-tRNA synthetase 2 
ACAD9 Acyl-CoA Dehydrogenase family member 9 
ADC Apparent diffusion coefficient 
AIMPI Aminoacyl tRNA synthetase complex 1 
APOPT1 Apoptogenic protein 1 
ATPAF2 ATP synthase mitochondrial F1 complex factor 2 
ATP5E TP synthase subunit 5 epsilon 
ATP5A1 ATP synthase subunit alpha 1 
BCSIL BCSI homolog,ubiquinol-cytochrome c   reductase complex chaperone 
BOLA3 bolA family member 3 
CABC1 Chaperone activity of bcl complex 1 
COX Cytocrome c oxidase 
COX6B1  Cytochrome c oxidase subunit 6B1 
COA7 Cytochrome c oxidase assembly factor 7 
COX10 Cytochrome c oxidase assembly factor 10 
C14ORF153 Chromosome 14 open reading frame 153 
COX15 Cytochrome c oxidase assembly factor 15 
CPEO Chronic progressive external ophthalmoplegia 
CSF Cerebrospinal fluid 
DARS Aspartyl-tRNA synthetase 
DARS2 Aspartyl-tRNA synthetase 
DTI Diffusion tensor Imaging 
DWI Diffusion weighted imaging 
EARS2 Glutamyl-tRNA synthetase 2 
ECHS1 Short chain enoyl CoA hydratase 
EFG1 Elongation factor G1 
EFTu Translation elongation factor Tu 
FARS2 Phenylalanyl-tRNA synthetase 
FBXL4 F-box and leucine –rich-repeat-4 proteins 
FILS Fatal infantile lactic acidosis 
fMRI functional magnetic resonance imaging 
FOXRED1 FAD Dependent Oxidoreductase Domain  Containing1 
GLRX5 Glutaredoxin 5 
GRACILE Growth retardation, aminoaciduria, cholestasis, iron overload lactic 
acidosis and early death 
HIBCH 3-Hydroxy isobutyryl CoA hydrolase 
KSS Kearns Sayre syndrome  
LARS2 Leucyl-tRNA synthetase 2 
LBSL Leukoencephalopathy with brainstem and spinal cord  involvement  and  
elevated lactate 
LHON Leber’s hereditary optic neuropathy 
LIAS Lipoic acid synthase 
LTBL Leukoencephalopathy with thalamus and  brainstem   involvement and  
high lactate 
LYRM7 LYR motif containing protein 7 
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LRPPRC leucin-rich penta tricopeptide repeat domain  protein 
MARS2 Methionyl-tRNA synthetase 2 
MEDGEL 3-methyl Glutaconic aciduria deafness encephalopathy leigh like 
syndrome 
MELAS Mitochondrial encephalopathy lactic acidosis and stroke like episodes 
MERRF Myoclonic epilepsy ragged red fiber syndrome 
MNGIE Mitochondrial neurogastrointestinal encephalopathy 
MRI Magnetic resonance imaging 
MRS Magnetic resonance spectroscopy 
MTCO1 Mitochondrially encoded cytochrome c oxidase subunit 1 
MTCO2 Mitochondrially encoded cytochrome c oxidase subunit 2 
MTCO3 Mitochondrially encoded cytochrome c oxidase subunit 2 
MTCYB Mitochondrially encoded cytochrome B 
MTFMT Methionyl-tRNA formyl transferase 
MT-TI Mitochondrially encoded tRNA (Isoleucine) 
MT-TL1 Mitochondrially encoded tRNA(Leucine) 
MT-TK Mitochondrially encoded tRNA(Lysine) 
MT-TW Mitochondrially encoded tRNA (Tryptophan) 
NARP  Neuropathy ataxia retinitis pigmentosa syndrome 
NDUFA1 NADH-ubiquinone oxidoreductase 1 alpha  subcomplex subunit 1 
NDUFA2 NADH-ubiquinone oxidoreductase 1 alpha subcomplex subunit 2 
NDUFA9 NADH-ubiquinone oxidoreductase 1 alpha subcomplex subunit 9 
NDUFA10 NADH-ubiquinone oxidoreductase 1 alpha   subcomplex subunit 10 
NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1 
NDUFS2 NADH-ubiquinone oxidoreductase core  subunit S2 
NDUFS3 NADH-ubiquinone oxidoreductase core  subunit S3 
NDUFS4 NADH-ubiquinone oxidoreductase core subunit S4 
NDUFS7 NADH-ubiquinone oxidoreductase core subunit S7 
NDUFS8 NADH-ubiquinone oxidoreductase core subunit S8 
NDUFV1 NADH-ubiquinone oxidoreductase core subunit V1 
NDUFAF2 NADH:Ubiquinone Oxidoreductase Complex  Assembly Factor 2 
NFU1 NFU1 Fe-S cluster scaffold 
OXPHOS Oxidation phosphorylation disorders 
PDHc Pyruvate Dehydrogenase complex 
PGD Peri implantation genetic diagnosis 
POLG1 Polymerase Gamma 
RARS Arginyl-tRNA synthetase 
RARS2 Arginyl tRNA synthetase 2 
RMND1 Required for Meiotic nuclear division protein 1 
SERAC1 serine active site containing 1 
SCO2 Synthesis of cytochrome c oxidase assembly protein 2 
SCO1  Synthesis of cytochrome c oxidase assembly protein 1 
SDH  Succinate dehydrogenase 
SDHA Succinate dehydrogenase complex flavoprotein Subunit A 
SDHB Succinate dehydrogenase complex iron sulfur subunit B 
SDHC Succinate dehydrogenase complex subunit C 
 8 
SDHD Succinate dehydrogenase complex subunit D 
SDHAF1 Succinate dehydrogenase complex assembly factor 1 
SDHAF2 Succinate dehydrogenase complex assembly factor 2 
SDHAF3 Succinate dehydrogenase complex assembly factor 3 
SDHAF4 Succinate dehydrogenase complex assembly factor 4 
SLC19A3 Solute carrier family 19 member 3 
SUCLA2 Succinate CoA ligase ADP forming beta subunit 
SUCLG1 Succinate CoA ligase alpha subunit 
SURF1 Surfeit Locus protein 
TK2 Thymidine kinase 2 
TTC19 Tetratricopeptide repeat protein 19 
TACO1 Translation activator of cytochrome c oxidase1  
TMEM70 Transmembrane protein 70 
TYMP Thymidine phosphorylase 
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1. Inherited metabolic disorders 
Inherited neurometabolic disorders constitute a heterogeneous group of almost sev-
en hundred rare genetic diseases, which manifest with diverse neurological or cog-
nitive symptoms.1 Part of them are amenable to therapy or interventions that direct-
ly target pathogenesis at the cellular and molecular level.2,3 Reaching an accurate 
diagnosis is a necessary prerequisite for implementation of specific therapeutic in-
tervention since these disorders have the potential to cause irreversible injury to the 
developing nervous system.4 In addition, a genetic diagnosis allows reproductive 
choices to prevent the birth of an affected child. The signs and symptoms are often 
nonspecific and heterogeneous making the differential diagnosis challenging to the 
clinician. This is especially true in mitochondrial disorders where considerable clini-
cal, biochemical and genetic heterogeneity exist.5 Nevertheless, a systematic and 
methodical approach often helps to arrive at an early diagnosis even when the 
presentation is nonspecific. The diagnostic algorithms available include clinical, 
biochemical, neuroimaging, morphologic, enzymatic, and genetic approaches. Cur-
rently, whole exome sequencing is becoming the preferred starting strategy, allow-
ing to characterize the genetic defect in the majority of patients and paving the way 
for more focused follow-up clinical or functional investigations, leading to more 
accurate genotype-phenotype correlations and therapeutic interventions. 
Among the several approaches to characterize the pathophysiology and establish 
genotype-phenotype correlations of neurometabolic disorders, neuroimaging inves-
tigations are particularly helpful to the clinician since it gives an objective assess-
ment of the central nervous system structures affected, the different patterns and the 
extent of involvement.6 Especially, magnetic resonance imaging (MRI) has emerged 
as a powerful tool to evaluate the central nervous system in a noninvasive manner in 
the last few decades.4 In addition, it is also one of the easily accessible early diagnos-
tic tools available to the treating physician, which can help in formulating differen-
tial diagnoses and targeted investigations. Pattern recognition on MRI has been 
shown to be an effective way of reaching an early diagnosis in leukoencephalopa-
thies.7-9 Several new disorders have been identified based on the pattern recognition 
and/or whole exome sequencing approaches.10-12 Combination of whole exome se-
quencing and MRI pattern recognition in a cohort of patients with “suspected mito-
chondrial leukodystrophy” has yielded a molecular diagnostic rate in about 65% of 
the patients.13 This exemplifies the importance of linking the genetic data and neu-
roimaging phenotype for accurate genotype-phenotype correlations as well as un-
derstanding the complex imaging appearance of neurometabolic disorders. It is en-
visaged that in the future, brain imaging such as advanced MRI can be used as a 
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biomarker (MR phenotype) to target genetic studies to the most probable defect in 
specific neurometabolic disorders14 or to establish an accurate prognosis or treat-
ment. Exploration of large number of patients and accurate characterization of neu-
roimaging features are needed to identify specific neuroimaging biomarkers and 
patterns. 
2. Magnetic Resonance Imaging in Mitochondrial Disorders 
Mitochondrial oxidative phosphorylation disorders constitute a large heterogeneous 
group of metabolic disorders with an incidence of 1 in 5000 live births.15 Defects in 
more than 250 genes have been identified to date, making disorders of mitochondri-
al energy metabolism the most heterogeneous metabolic disease.15,16 The strategy for 
diagnosis of mitochondrial disorders included a comprehensive and meticulous anal-
ysis of family history, clinical findings, biochemical and histopathological analyses, 
magnetic resonance imaging findings and molecular diagnostic testing, but is cur-
rently shifting towards whole exome sequencing as the first diagnostic step.17,18 
Whole exome sequencing has the highest diagnostic yield, but is neither the fastest 
nor the cheapest approach and might not always be readily available due to the ex-
pensive equipment and specific expertise required. Magnetic resonance imaging 
(MRI) is one of best alternatives to guide more rapid, targeted genetic analysis. It is 
an easily accessible initial tool available to the clinician for interrogating the pres-
ence and pattern of central nervous system changes in patients with mitochondrial 
disorders, which can be specific for the genetic defect.19,20 Even though the tremen-
dous advances in genomics in recent years have simplified the molecular diagnosis of 
mitochondrial disorders, the validation process of numerous variants called by 
whole exome sequencing and progress in prognosis and treatment options will re-
quire meticulous clinical and imaging phenotyping.18  
In addition to the routine T1W and T2W imaging, many advanced imaging 
techniques are available which include diffusion weighted imaging (DWI), diffusion 
tensor imaging (DTI), magnetic resonance spectroscopy (MRS) and functional mag-
netic resonance imaging (fMRI).20-23 Each modality can be combined to gain com-
plementary information regarding the brain’s structural, functional, and metabolic 
dimensions, and how these may be altered in pathologic states.23 
2.1. Anatomical pattern of Injury in Mitochondrial Disorders 
MRI findings in mitochondrial disorders can be specific or non-specific and the 
major anatomical patterns include: 1. Focal lesions in deep gray matter structures 
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which can be further divided into basal ganglia lesions and brainstem lesions; 
2.White matter lesions; 3. Stroke-like lesions; 4. Cortical and cerebellar atrophy. 21-26 
2.1.1. Focal lesions in deep gray matter structures 
Bilateral lesions in the putamen and basal ganglia nuclei are recognized as being the 
most prevalent features of many mitochondrial syndromes.22,25-27 Bilateral symmet-
rical lesions of the basal ganglia and brainstem is the typical feature of Leigh syn-
drome, the most common mitochondrial disorder of childhood.28 The diagnosis of 
Leigh syndrome is based on stringent criteria, which requires that characteristic 
neuropathology or neuroradiology must be accompanied by progressive neuro-
degeneration with: 1. clinical evidence of brainstem and/or basal ganglia dysfunc-
tion, 2. intellectual and motor developmental delay, and 3. abnormal energy me-
tabolism indicated by either a severe defect in oxidative phosphorylation (OXPHOS) 
or pyruvate dehydrogenase complex (PDHc) activity, a molecular diagnosis in a gene 
related to mitochondrial energy generation, or an elevated serum or CSF lactate. 28,29 
In case patients do not fulfill these stringent criteria, a diagnosis of Leigh-like syn-
drome can be considered, particularly in patients with atypical neuroradiology or 
normal lactate level.28,30 
2.1.2. White matter lesions  
Cerebral white matter involvement is more and more commonly seen in childhood 
onset mitochondrial disorders, as indicated by recent papers on mitochondrial leu-
koencephalopathies.11-13,31 Combination of whole exome sequencing and MRI pat-
tern recognition in a cohort of patients with “suspected mitochondrial leukodystro-
phy” has yielded a molecular diagnostic rate in about 65% of the patients.13 The 
features of a mitochondrial leukoencephalopathy or leukodystrophy include cystic 
lesions in the abnormal white matter, additional gray matter lesions, restricted diffu-
sion, contrast enhancement, and elevated lactate on magnetic resonance spectrosco-
py of the brain. 8,32  
2.1.3. Stroke-like lesions 
Stroke-like lesions defined as cortical lesions not confined to defined vascular terri-
tories are characteristic for patients with Mitochondrial Encephalopathy Lactic aci-
dosis and Stroke-like syndrome [MELAS], in most cases caused by the m.3243A>G 
mutation.33 The cortical lesions most commonly occur in the parieto-occipital re-
gion, which may be unilateral or bilateral and may spread to other regions over 
time.34 Diffusion weighted imaging findings have been used to differentiate acute 
from chronic stroke-like lesions.35,36 In the acute stage the initial insufficiency in 
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neuronal energy causes cytotoxic edema and restricted diffusion. Subsequently there 
is development of extra-cellular edema causing increased apparent diffusion co-
efficient. As a result, chronic stroke-like lesions show free diffusion.33,34,36 A ME-
LAS/Leigh Syndrome overlap syndrome, in which there are stroke lesions in combi-
nation with signal changes in deep gray matter structures, has been described in 
association with the m.13513G>A, the m.3243A>G and MT-ND3 mutations.27,37 
Nuclear gene mutations associated with stroke-like lesions include POLG1, TWIN-
KLE, TK2 and CABC1. 38-41 
2.1.4. Cerebral and cerebellar atrophy 
Diffuse cortical atrophy is described in about one third of the patients with encepha-
lomyopathy. Cerebral atrophy has been the sole imaging finding in up to a quarter 
of the patients with respiratory chain deficiencies.25,42 Certain clinical entities, such 
as Alpers syndrome, a severe hepatocerebral disease, caused by mutations in the 
POLG1 gene, can present with volume loss predominantly in cerebellar and occipi-
tal cortices.43 Cerebellar atrophy is a common finding in childhood onset mitochon-
drial disorders and may be the primary neuroimaging findings in some.44 Cerebellar 
atrophy as a predominant feature is also seen in primary CoQ deficiency.45 In addi-
tion to cerebellar atrophy, pontocerebellar hypoplasia has been reported in patients 
with mitochondrial disorders and has emerged as a new phenotype caused by 
RARS2 mutations.46,47 The other patterns include cortical laminar necrosis, thalamic 
signal changes and mineralization and spinal cord signal changes.21,48 49,50 
3. Genotype and MR Imaging Correlations in Mitochondrial Disorders  
3.1. Mutations in nuclear genes 
3.1.1. Complex I deficiency  
Mitochondrial complex I is the largest of the respiratory chain complexes and con-
sists of 45 subunits, 7 of which are encoded by mtDNA and the remaining by 
nDNA.51,52 It is the most common cause of OXPHOS disorders in infants and chil-
dren.51 The clinical syndromes associated with complex I deficiency include Leigh 
and Leigh-like syndrome, leukoencephalopathy, Leber’s hereditary optic neuropathy 
(LHON), fatal infantile lactic acidosis (FILS), hypertrophic cardiomyopathy and 
exercise intolerance. 51 
A retrospective study on MR imaging findings in 30 patients with complex I de-
ficiency secondary to both mitochondrial and nuclear DNA mutations has identified 
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a consistent pattern of abnormalities27, of which bilateral symmetrical brainstem 
lesions were noted in all 30 patients. Striatal lesions were observed in 90% of pa-
tients. Important differentiating points included the presence of isolated stroke-like 
lesions in MT-TL1 patients and presence of necrotizing leukoencephalopathy in 
patients with nuclear DNA mutations27 This is corroborated by data from a system-
atic review of 172 patients with complex I deficiency caused by nuclear DNA muta-
tions, 82 patients had MRI findings available and lesions were distributed over basal 
ganglia (13%), brain stem (24%) and both basal ganglia and brain stem (24%) and 
24% showed leukoencephalopathy.51 The authors supported the notion that brain 
stem lesions are predominant in patients with Leigh syndrome secondary to complex 
I deficiency.  
In conclusion, the MRI findings in patients with complex I deficiency reported 
so far can be broadly divided into: 1. focal bilateral symmetrical brain lesions involv-
ing the basal ganglia, and 2. brain stem lesions, typical of Leigh and Leigh-like syn-
drome with leukoencephalopathy. Focal lesions in deep gray matter structures con-
sistent with Leigh and Leigh-like syndrome have been demonstrated both in com-
plex I deficiency due to mtDNA (see below) and nuclear DNA mutations. Mutations 
in 11 nuclear-encoded (NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, 
NDUFV1, NDUFA1, NDUFA2, NDUFA9, NDUFA10) complex I subunits and four 
assembly factors (NDUFAF2, C8ORF38, C20ORF7 and FOXRED1) have been re-
ported in Leigh syndrome.53 A distinct MRI pattern with predominantly brainstem 
involvement has also been described in patients with mutations in the NDUFA2 
gene.54,55 
Leukoencephalopathy is another characteristic association of mutations in nucle-
ar encoded complex I proteins.56 A review of the MRI data of NDUFS1 or NDUFV1 
patients showed that white matter signal changes was the most prominent finding in 
28/30 patients.56 Other less associated findings included brain stem signal changes 
and striatal lesions. This showed that patients with NDUFS1 mutations present with 
leukoencephalopathy more often than with Leigh syndrome. Other complex I gene 
mutations, including NDUFS8 and NUFAF3, were less often described in association 
with leukoencephalopathy.57, 58 The white matter changes in patients with complex I 
deficiency could also resemble vanishing white matter disease.59-61 Leukoencephalo-
pathy or a mitochondrial leukodystrophy have been described in patients with 
NUBPL mutations as well11, which was characterized by confluent or multifocal 
white matter lesions predominantly affecting the deep frontal and parietal white 
matter sparing the ‘U’ fibers, internal and external capsule. Corpus callosal signal 
changes and swelling were noted in the early MRIs. The extensive signal abnormali-
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ties in cerebellar cortex is a characteristic finding in patients with NUBPL muta-
tions.62  
3.1.2. Complex II Deficiency 
Succinate Dehydrogenase (SDH) is the smallest complex of the respiratory chain and   
includes a flavoprotein subunit (Fp, encoded by SDHA) and an iron-sulfur subunit 
(Fe-S, encoded by SDHB), paired with 2 subunits that anchor the complex to the 
inner mitochondrial membrane (SDHC and SDHD). In addition, the SDH protein 
complex comprises 4 assembly factor proteins (SDHAF1, SDHAF2, SDHAF3 and 
SDHAF4). It is unique in that all the subunits are encoded by nuclear DNA and that 
complex II plays a role in both the mitochondrial respiratory chain and in succinate 
catabolism in the Kreb’s cycle.63 
Two different MRI patterns have been described in complex II deficient patients: 
Leigh syndrome and leukoencephalopathy. Characteristics of SDH related leu-
koencephalopathy were reported recently.64 Clinically, all individuals presented in 
the first two years of life with an average age at onset of 12 months. A rapid deterio-
ration was preceded by febrile illness, injury, vaccination or sometimes by no obvi-
ous preceding event. The imaging findings included extensive cerebral white matter 
hyper-intensity, predominantly involving the frontal, parieto-occipital and posterior 
temporal region, and sparing the juxta cortical fibers. The corpus callosum had a 
swollen appearance and the outer and inner tables were spared. Corticospinal tract 
involvement was common and involved the posterior limb of the internal capsule 
and the transverse pontine fibers with extension into middle cerebellar peduncle. 
Central tegmental tract was seen in some patients, but the dorsal portion of the cer-
vical cord was affected in the majority. Proton MRS demonstrated an abnormally 
elevated peak at 2.4ppm compatible with succinate and was found in areas of affect-
ed white matter. It was noted that involvement of anterior nucleus and pulvinar of 
thalamus and geniculate bodies along with corticopontine and transverse pontine 
fibers and middle cerebellar peduncle was unique to SDH related leukoencephalopa-
thy. The most common cause were mutations in the SDHF1 subunit64,65, but patients 
with SDHA and SDHB mutations can also display this phenotype.64,66 Mutations in 
SDHC, SDHD or other assembly factor SDHF2 were not reported in leukoencepha-
lopathy patients. Leigh syndrome in relation to complex II deficiency has been re-
ported infrequently. Two patients with SDHA mutations67 and one patient with 
SDHFA1 mutation65 had Leigh syndrome, but no detailed magnetic resonance imag-
ing data was available. In an adult patient with an autosomal dominant SDHA muta-
tion with ocular, cardiac and neurologic involvement MRI was normal.68 In another 
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adult patient with histopathological proven complex II deficiency MRI showed iso-
lated pontine signal changes.69 
3.1.3. Complex III deficiency 
Mitochondrial respiratory chain complex III (ubiquinol cytochrome c reductase or 
cytochrome bc1 complex) transfers electrons from coenzyme Q to cytochrome c, 
accompanied by the translocation of protons, which is important for the generation 
of the mitochondrial electrochemical potential. Complex III consists of eleven subu-
nits of which only one is encoded by mtDNA (MTCYB).70 Mutations in nuclear 
genes encoding other structural complex III subunits are extremely rare.71,72 On the 
other hand, several genetic defects have been described in complex III assembly 
factor genes, including TTC19 71, LYRM7 73 and BCS1L 74. 
MRI findings associated with complex III deficiency have been reported in pa-
tients with, TTC19, LYRM7 and BCSIL mutations. The clinical presentation of pa-
tients with TTC19 mutations was broad, with initial presentation from childhood to 
adulthood. Characteristic MRI findings included a variable combination of bilateral 
symmetrical signal changes in basal ganglia, inferior olives, dentate and cortical and 
olivo pontocerebellar atrophy.71,75-80 A multifocal cavitating leukoencephalopathy 
has been described recently in patients harboring mutations in the LYRM7 gene.12,73 
All patients had a similar and distinct MRI pattern of a progressive leukoencephalo-
pathy with numerous small cavitations in the periventricular and deep cerebral 
white matter. There was relative sparing of the subcortical white matter. Corpus 
callosum showed small cysts. Diffusion restriction was present either in diffuse dis-
tribution or in the rim of cysts. Contrast enhancement was variable.  Most of them 
showed a severe complex III deficiency. The phenotypes associated with BCSIL 
mutation is heterogeneous and range from GRACILE (Growth Retardation, Amino 
aciduria, Cholestasis, Iron overload, Lactic acidosis, and Early death) syndrome to 
Björnstad syndrome, an extremely rare inherited disorder characterized by pili torti, 
sensorineural hearing loss and progressive encephalopathy.70 A bilateral symmetrical 
signal change in the putamen and thalami along with supratentorial atrophy has 
been described in a child with progressive encephalopathy and severe complex III 
deficiency due to a BCSIL mutation.81 
3.1.4. Complex IV deficiency 
Complex IV or cytochrome c oxidase (COX) deficiency is one of the most common 
biochemical abnormalities found in mitochondrial disorders, but mutations in the 
mtDNA or nuclear DNA encoding structural subunits of complex IV are rare. Con-
versely, mutations in COX assembly factor often cause COX deficiency and muta-
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tions have been described in the nuclear COX assembly genes SURF1, SCO2, SCO1, 
COX10 and COX15 in severe early infantile phenotypes.82 Most important is the 
SURF1 gene and SURF1 mutations characteristically present with Leigh syndrome.83 
A number of reports describe MRI findings in SURF1 mutation positive patients and 
have tried to identify specific characteristics.84-86 However, no consistent correla-
tions emerged from these studies. A leukoencephalopathy pattern has been de-
scribed in two patients with a SURF1 mutation.87,88 In a family of patients with TA-
CO1 mutations and COX deficiency, brain MRI showed bilateral, symmetric hyper-
intense lesions of the basal ganglia with variable involvement of the subcortical 
white matter.89 TACO1 mutations are also described in a patient with late onset 
Leigh syndrome.90 
Pathogenic mutations in APOPT1 (previously APOP-1 or C14ORF153) are re-
sponsible for a mitochondrial disorder characterized by marked COX deficiency and 
a well-characterized form of cavitating leukodystrophy.31 In the acute stage, signal 
changes were predominantly seen in the posterior cerebral hemispheres and corpus 
callosum, and contained numerous small well-delineated cysts. Multifocal restricted 
diffusion and contrast enhancement and presence of lactate peak on MRS also char-
acterized this acute phase. In the later stages, the abnormalities involved the anterior 
part of the cerebral hemispheres and corpus callosum as well. Follow-up images 
showed atrophy collapse of the cysts and disappearance of the diffusion restriction 
and contrast enhancement and decrease in lactate levels.31 Mutations in the COX10 
and COX6B1 genes, assembly factors of complex IV also caused mitochondrial en-
cephalopathy with cavitating leukodystrophy91,92. Mutations in the SCO2 gene 
caused an infantile cardio-encephalomyopathy with severe COX deficiency in heart, 
brain, and muscle. MRI findings included white matter involvement with later ap-
pearance of basal ganglia lesions93 and bilateral T2 signal changes in the putamen 
consistent with Leigh syndrome.94 
Mutations in the LRPPRC gene, encoding the leucine-rich pentatricopeptide re-
peat domain protein (LRPPRC), involved in post-transcriptional regulation of mito-
chondrial gene expression, causes the French-Canadian variant of COX-deficient 
Leigh syndrome.95 Recently it has been demonstrated that a multisystem mitochon-
drial disease is caused by the mutations in the same gene outside the Saguenay-Lac-
Saint-Jean region of Quebec region.96 In a cohort of 10 patients, in addition to the 
well described features consistent with Leigh syndrome and a cystic leukoencepha-
lopathy neuroimaging, also congenital structural anomalies such as corpus callosal 
agenesis, unfolded hippocampi, cerebellar hypoplasia and pachygyria were ob-
served.97 Recently, mutations in the COA7 gene (C1orf163/RESA1), a putative COX 
assembly factor reported to localize in the mitochondrial IMS, were associated with 
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a progressive neurological disorder characterized by encephalopathy and peripheral 
neuropathy. MRI in this patient showed a leukoencephalopathy associated with 
cavitations.97 
3.1.5. Complex V Deficiency 
Complex V, consisting of 14 nuclear encoded subunits and 2 mtDNA encoded subu-
nits, utilizes the energy of the electrochemical gradient built by translocation of 
protons by complexes I, III and IV to generate ATP. Finally, mutations have been 
identified in three other complex V subunits (mtDNA encoded ATP6 [see below] 
and nuclear encoded ATP5E and ATP5A1) and two assembly factors TMEM70 and 
ATPAF2. 98 The phenotypes included psychomotor retardation, early onset cataract, 
hypotonia and hypertrophic cardiomyopathy. MRI findings have not been described 
in these patients.  
3.1.6. Multiple Complex deficiencies 
Multiple complex deficiencies are among the most frequent finding in patients with 
mitochondrial disorders, mainly caused by mutations in proteins involved in the 
translation of mtDNA-encoded proteins. These include defects in genes involved in 
mtDNA maintenance and replication, mitochondrial or nuclear-encoded defects of 
mitochondrial protein synthesis. In the multiple mitochondrial dysfunctions syn-
drome, the activity of PDHc is also impaired. 
Mitochondrial DNA maintenance and replication  
A common cause of mtDNA maintenance and replication defects are mutations in 
the Polymerase gamma (POLG1) gene, leading to a broad variety of clinical manifes-
tations. MRI findings in POLG1 patients include T2/FLAIR signal changes in the 
cortex, pulvinar of the thalamus, bilateral inferior olivary nucleus, dorsal column 
and mild cerebellar atrophy.43,99,100 Bilateral olivary and pulvinar lesions were char-
acteristic findings noted in a cohort of European patients and in a patient with ataxia 
and palatal tremor form India.99,101 Stroke-like lesions typically seen in patients with 
MELAS have also been described in patients with POLG1, TK2 and TWINKLE relat-
ed mitochondrial disorders. 39,40  
Patients with MNGIE caused by mutations in the TYMP gene showed a unique 
MRI pattern characterized by leukoencephalopathy involving the centrum semiova-
le, pons and basal ganglia with sparing of the ‘U’ fibers with absence of a lactate 
peak.102 Mutations in the gene encoding the ß-subunit of the ADP-forming succinyl-
CoA synthetase (SUCLA2) have been reported to cause mild methyl malonic acidu-
ria (MMA), Leigh-like encephalomyopathy, dystonia and deafness in association 
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with mitochondrial depletion.103 MRI revealed no abnormalities or mild cerebral 
atrophy with enlarged subarachnoideal spaces and widening of the ventricular sys-
tem in the first year of life followed by signal changes in putamen and caudate. Un-
like classical MMA the globus pallidus was spared or less affected.104 Mutations in 
SUCLG1, encoding α subunit of the enzyme, caused a similar disorder with mild 
methyl malonic aciduria dystonia deafness and a Leigh like encephalomyopathy.  
Mitochondrial Translation disorders  
Mitochondrial protein translation is a complex process performed within mitochon-
dria by an apparatus composed of mitochondrial DNA (mtDNA)–encoded tRNAs 
and rRNAs and nuclear DNA–encoded proteins.105 The important disorders in this 
group with specific MRI findings included the mutations in mt-aminoacyl tRNA 
synthetases, MTFMT, LRPPRC (see 3.1.4) and mutations in the mitochondrial elon-
gation factors EFG1 and EFTu. Especially, the clinical phenotypes associated with 
mutations in the aminoacyl tRNA synthase genes are steadily increasing in the re-
cent years. Mutations in eight genes (DARS, RARS, AIMP1, AARS2, DARS2, 
EARS2, LARS2 MARS2, and FARS2) have been implicated in leukodystrophies or 
leukoencephalopathies.106 Mutations in the DARS2 and EARS2 gene caused specific, 
well-characterized patterns of mitochondrial leukoencephalopathy.10,107 Patients 
with leukoencephalopathy with brain stem and spinal cord involvement and elevat-
ed lactate (LBSL) caused by mutations in DARS2 displayed T2/FLAIR signal changes 
in the dorsal column and cortico-spinal tracts, the pyramids, the cerebellar pedun-
cles, the intraparenchymal tract of the V cranial nerve, the posterior arm of the 
internal capsule, and the splenium of the corpus callosum; the U-fibers were 
spared.108 In contrast, leukoencephalopathy with thalamus and brainstem involve-
ment (LTBL), caused by mutations in the EARS2 gene, was characterized by a pecu-
liar MRI pattern which spares the periventricular rim, but affected the deep cerebral 
white matter including corpus callosum, thalamus, basal ganglia, midbrain, pons, 
medulla oblongata, and the cerebellar white matter.10 Patients usually had an early-
onset neuroregression and a biphasic clinical course.  
Hereditary leukoencephalopathy, hypomyelination with brainstem and spinal 
cord involvement and leg spasticity, which is caused by mutations in the aspartyl 
tRNA-synthetase encoding gene DARS, was noted to have steroid responsiveness, 
similar to an acquired demyelinating disorder.109,110 Mutations in the RARS gene, 
coding for the cytoplasmic arginyl-tRNA synthetase (ArgRS), caused hypomye-
lination.111 Complex rearrangements in the MARS2 gene, encoding the mitochon-
drial methionyl-tRNA synthetase, were described in a cohort of patients with auto-
somal recessive spastic ataxia with leukoencephalopathy.112 Mutations in the mito-
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chondrial alanyl-tRNA synthetase 2 gene (AARS2) caused progressive leukoenceph-
alopathy and, in females, ovarian failure, a clinical presentation previously described 
as “ovarioleukodystrophy. 113 MRI showed a leukoencephalopathy with striking 
involvement of left-right connections, descending tracts, and cerebellar atrophy.  
Recessive mutations in the mitochondrial arginyl-transfer RNA synthetase 
(RARS2) gene have been associated with early onset encephalopathy with signs of 
oxidative phosphorylation defects, classified as pontocerebellar hypoplasia 6.47 In the 
first few months cerebellar vermis hypoplasia was the dominant finding and the 
follow-up neuroimaging revealed a progressive pontocerebellar and cerebral cortical 
atrophy. The FARS2 gene encodes the mitochondrial phenylalanyl-tRNA synthetase 
(mtPheRS), which charges the tRNAphe with phenylalanine during mitochondrial 
translation. Mutations in the FARS2 genes have been shown to cause infantile onset 
refractory epilepsy and an Alpers phenotype.114 MRI showed extensive cerebral 
atrophy, subdural collection and signal changes in the putamen and basal ganglia. 
There was relative sparing of the cerebellum.114 In another patient with infantile 
onset epilepsy MRI showed white matter signal changes and thinning of corpus 
callosum.115 The other reported imaging findings included bilateral signal changes in 
the dentate 116 and small focal signal changes in the white matter.117 
Specific MRI patterns have been described in patients harboring mutations in the 
mitochondrial elongation factors EFG1 and EFTu genes.105 Both patients had severe 
lactic acidosis and rapidly progressive, fatal encephalopathy. The EFG1-mutant pa-
tient had early-onset Leigh syndrome, whereas the EFTu-mutant patient had severe 
infantile macrocystic leukodystrophy. Mutations in the MTFMT gene, which en-
codes a mitochondrial methionyl-tRNA formyl-transferase, were first identified in 
two unrelated patients with Leigh syndrome and a combined complex I and complex 
IV deficiency.118 The MRI findings in a larger cohort119 were isolated bilateral sym-
metrical signal changes in basal ganglia or combination signal changes in basal gan-
glia and white matter or white matter signal changes alone.  
Other nuclear causes of multiple complex deficiencies 
A mutation in the RMND1 (Required for Meiotic Nuclear Division protein 1) gene 
causes multiple mitochondrial respiratory chain deficiencies and was first described 
in a patient with severe congenital encephalopathy, peripheral neuropathy, myopa-
thy, and lactic acidosis.120. The clinical features included encephalopathy, renal fail-
ure, cardiac conduction defects and deafness.121-124 Of the 31 reported patients, MRI 
data was available for 22 and 17 of them revealed abnormalities.123 Most common 
observation was white matter signal changes with cystic changes and delayed mye-
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lination. Additional findings were basal ganglia calcification, signal changes and 
infarcts involving the parieto-temporal area. 
Multiple mitochondrial dysfunctions syndrome usually affects complexes con-
taining iron-sulphur (Fe-S) clusters (complexes I, II and III) as well as the pyruvate 
dehydrogenase complex. The genes responsible for the multiple mitochondrial dys-
function syndrome include those involved in the Fe-S cluster assembly homeostasis 
namely NFU1125, BOLA3119,126 and LIAS 126 and IBA57127 and GLRX5126. Mutations in 
all these genes have been associated with leukoencephalopathy of varying severity 
ranging from a progressive lethal cavitating leukoencephalopathy to signal changes 
limited to periventricular region and cervical spinal cord. 
HIBCH is a mitochondrial enzyme that catalyzes the fifth step of valine catabo-
lism, the conversion of 3-hydroxy-isobutyryl-CoA to 3-hydroxyisobutyrate.128 The 
MRI findings in HIBCH patients included bilateral symmetrical signal changes in 
the globus pallidus, brain stem, reduction in white matter volume and cystic change 
in the white matter.128  
Short-chain enoyl-CoA hydratase (ECHS1) encoded by the ECHS1 gene is a mul-
tifunctional mitochondrial matrix enzyme that is involved in the oxidation of fatty 
acids and essential amino acids such as valine.129 The clinical phenotypes of ECHS1 
mutations was in most cases Leigh syndrome, but additional manifestations of deaf-
ness, epilepsy, cardiomyopathy and optic atrophy were reported as well.130 A milder 
phenotype characterized by exercise induced paroxysmal dystonia has also been 
described.131 The MRI findings in patients included bilateral symmetrical signal 
changes in basal ganglia, cerebral atrophy and white matter signal changes, which 
varied in severity from punctate signal changes in centrum semiovale to 
periventricular and subcortical signal changes.130  
Mutations in the SERAC1 gene, encoding a phosphatidylglycerol remodeler es-
sential for both mitochondrial function and intracellular cholesterol trafficking, are 
responsible for MEGDEL syndrome (3-Methyl Glutaconic aciduria, Deafness, En-
cephalopathy, Leigh-like syndrome), an infantile-onset dystonia deafness syn-
drome.132 A typical MRI pattern of basal ganglia involvement with a distinctive evo-
lution during the course of the disease has been described.133 The first structure to 
be affected was the globus pallidus followed by swelling of the caudate nucleus and 
the putamen. The signal changes in putamen spared the mid-dorsal putamen, which 
is referred to as the “putaminal eye”. This finding was reported to be present in all 
patients with MRI available after first year of life.133 
Mutations in the FBXL4 gene that encodes the F-box and leucine-rich-repeat-4 
proteins have been shown to cause a slowly progressive mitochondrial encephalomyo-
pathy characterized by lactic acidemia, congenital hypotonia, and microcephaly. MRI 
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brain demonstrated variable combinations of cerebral atrophy, corpus callosal thin-
ning, signal changes in white matter, basal ganglia and ventricular dilatation.134, 135 
3.2. Mutations in the mtDNA 
3.2.1. Point mutations in protein encoding genes  
Mutations in six mtDNA-encoded complex I subunits (ND1, ND2, ND3, ND4, ND5 
and ND6) have been identified in patients with Leigh syndrome. Stroke-like lesions 
and MELAS syndrome have been reported in ND1, ND5 and ND6 mutations.136-138. 
Leber’s hereditary optic neuropathy is another clinical phenotype resulting from 
specific mutations in mtDNA-encoded complex I subunits, manifesting as painless 
subacute bilateral visual loss usually in early adulthood, but with reduced pene-
trance, affecting more males than females.139 The 3 most common mtDNA mutations 
are m.3460G>A, m.11778G>A and m.14484T>C. Discrete small white matter lesions 
resembling multiple sclerosis have been typically described in LHON patients and 
are known as LHON-MS.140 Extensive white matter signal changes have been de-
scribed in a patient homoplasmic for the m.14484T>C mutation.141  
A blinded observational study of LHON and LHON-MS patients showed similar 
conventional brain MRI appearances both groups.139 There is a strong gender predi-
lection in the susceptibility of LHON-MS. Females are more prone for developing 
LHON-MS than males.139 Another study has reported that the white matter lesions 
in LHON-MS were atypical, being larger with indistinct borders, had a tubular ap-
pearance with a large longitudinal extension and a small transverse diameter, lack of 
black holes on T1W images and contrast enhancement.140 Neuropathology in a pa-
tient with m.14484T>C mutation has shown demyelinating plaques as well as mito-
chondrial pathology. MRI findings in this patient were characterized by large cavi-
tory lesions with a frontal predilection.141 These reports indicated that white matter 
lesions in majority of the LHON-MS patients resembled that of multiple sclerosis, 
but could also show atypical features such as cavitating leukoencephalopathy as in 
other mitochondrial leukoencephalopathies.  
The only mtDNA encoded subunit of respiratory chain complex III is the 
MTCYB. The variety of clinical presentations associated with cyt-b mutation is 
largely unexplored.70 Though the most common phenotypes described is myopathy, 
myoglobinuria and exercise intolerance, CNS manifestations have been described as 
well, but only MRI studies were reported, showing cerebral atrophy and small brain 
infarcts.142 
There are three mtDNA encoded subunits of respiratory chain complex IV 
(MTCO1, MTCO2 and MTCO3). The magnetic resonance imaging findings in 
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MTCO1 mutation patients included diffuse cerebellar atrophy and T2 signal changes 
in the basal ganglia143, cortical atrophy in the tempero-occipital region 144 and 
stroke-like lesions. 145 MTCO2 mutations are rare and the reported MRI findings 
included corpus callosal agenesis and brain atrophy in a patient with early onset 
multisystem disease 146 and normal MRI observations in a boy with myopathy.147 
Reports on MTCO3 gene mutations are also limited.  These mutations have been 
identified in a patient with Leigh syndrome148 and bilateral symmetrical lesions in 
basal ganglia, cerebral and cerebellar atrophy on MRI. Mild Cortical and cerebellar 
atrophy with enlargement of the subarachnoid space has also been described in oth-
er patients with MTCO3 mutations.149 
ATP6 is one of the two mtDNA encoded subunits of complex V and the only 
complex V subunit or assembly factor in which mutations were identified in patients 
with Leigh syndrome. Six different mutations have been reported in the ATP6 gene 
150, which is the cause of 5-6% of patients with Leigh syndrome.151 The most com-
mon ATP6 mutation is the m.8993T>G mutation. High mutation loads (>90%) usual-
ly cause maternally inherited or de novo Leigh syndrome while lower levels (50– 
60%) cause less severe phenotypes like NARP. MRI findings include variable com-
binations of bilateral symmetrical signal changes in basal ganglia and mild cerebral 
and cerebellar atrophy.152,153 
3.2.2. Point mutations in tRNA genes 
Mitochondrial tRNA mutations cause a variety of phenotypes. The most common 
mutation is the m.3243A>G in the MT-TL1 gene, resulting in MELAS syndrome and 
stroke-like lesions on MRI. Stroke like lesions have also been described in MT-TH 
mutations.154,155 Other phenotypes include Leigh or Leigh-like syndrome caused by 
MT-TI 156 MT-TK 157 and MT-TW 158 gene mutations. A novel m.14724G>A muta-
tion in the mitochondrial tRNA glutamic acid gene has been reported to cause leu-
koencephalopathy.159 A recent brain MRI study of 34 patients with the m.8344A>G 
mutation in MTTK, revealed cerebral and/or cerebellar atrophy in 43 % of the pa-
tients160, while another study reported a lower frequency of atrophic changes.161 
Cavitatory leukoencephalopathy has been described in a single patient with the 
m.8344A>G mutation in MTTK.162 
3.2.3. Large mtDNA deletions  
The best-known disorders caused by large single deletions in the mtDNA are Kearns 
Sayre syndrome (KSS), Pearson Marrow Pancreas syndrome and chronic progressive 
external ophthalmoplegia (CPEO). Characteristic imaging findings in Kearns Sayre 
syndrome include symmetric high T2/FLAIR signals in cerebral and cerebellar white 
Chapter 1 
24 
matter with involvement of the brain stem, globus pallidus and thalamus.163 Brain 
MRI in chronic progressive external ophthalmoplegia patients displayed cerebral 
atrophy and white matter signal changes.164 
4. Role of MRI in Prognosis and Treatment of Mitochondrial Disorders 
Apart from the diagnostic evaluation, MRI provides a useful non-invasive way of 
assessing the timing, extent, and potential reversibility of neural injury.22 Magnetic 
resonance spectroscopy has also been used to monitor the effect of treatment.17,25 
Even though most of the imaging studies are based on cross sectional examinations, 
studies do report on follow up imaging studies.26,60 showing that the lesions may 
remain static, progress to involve more regions or increase in severity or they may 
also show regression in lesions. Progressive increase in affected areas and increase in 
rarefaction in follow up MRIs have been demonstrated in patients with mitochon-
drial leukoencephalopathy secondary to LYRM7 mutations.12 Novel imaging tech-
niques have been particularly helpful to monitor the nature and progress of the le-
sions.165 Follow up studies using diffusion weighted imaging and diffusion tensor 
imaging in a child with mitochondrial leukoencephalopathy, revealed a stroke-like 
pattern with an initial strong reduction of the ADC followed by elevated values after 
clinical recovery165.  Diffusion weighted imaging is particularly helpful to differenti-
ate acute lesions with restricted diffusion from older/chronic lesions in patients with 
MELAS.34-36, 166, 167 This is helpful in identifying stroke-like lesions before the onset of 
episodes clinically. In addition, repeated MRI using DTI may show progressive 
spread of the cortical lesion to the surrounding cortex for a few weeks, even after 
the onset of symptoms.  An additional diagnostic value of this technique is the ob-
servation of lactate accumulation in brain areas that appeared normal on MR images, 
related to an exacerbation of patient symptoms. None of the patients in remission 
had a lactate peak demonstrated in the non-affected white matter. This makes 1H 
MR spectroscopic study a useful investigation of relapse episodes.168 
Even though there have been major advances in our understanding of the patho-
physiology of mitochondrial diseases and diagnosis as outlined above, clinical man-
agement of these conditions remains largely supportive.169 A systematic Cochrane 
review found no evidence of an effective intervention for any mitochondrial disor-
der.170 However, there are a few disorders, caused by specific gene defects, which are 
amenable for specific intervention or prevention. Examples include the biotin thia-
mine responsive basal ganglia disease due to mutations in SLC19A3, riboflavin re-
sponsiveness in ACAD9 mutations and CoQ10/idebenone administration to treat 
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CoQ10 deficiency.171-173 Of these disorders, SLC19A3 is particularly important, since 
there are fairly specific diagnostic findings on MRI and timely treating can be life-
saving. For the remainder, the major focus currently is on maintaining optimal 
health by preventing episodic exacerbation during times of physiologic stress and 
avoiding mitochondrial toxins.174,175 A further application of the MRI is the evalua-
tion of the therapeutic intervention after a diagnosis has been made. Magnetic reso-
nance spectroscopy (MRS) is an especially valuable tool in monitoring the therapy. 
Few studies have utilized MRS to monitor the brain levels of lactate in patients with 
MELAS and other non-syndromic mitochondrial disorders after therapeutic inter-
vention with oral creatine phosphate176, dichloro acetate177, ketogenic diet and mito-
chondrial cocktail178. Similarly brain lactate reduction has also been reported in 
patients with Leigh syndrome after dichloroacetate therapy179 MRI has also been 
helpful in demonstrating that L-arginine infusion at the hyperacute phase protects 
the prolonged MRI abnormality in MELAS.180 
The most widely used treatment options employed in mitochondrial disorders 
are targeted to reduce the oxidative stress and energy failure. Proposed supportive 
treatments include agents that are used to enhance the respiratory chain function by 
increasing the substrate delivery (carnitine, niacin, thiamine and the synthetic com-
pound dichloroacetate), agents that enhance electron transfer within the respiratory 
chain (riboflavin and coenzymeQ10 and the synthetic compound derived from CoQ, 
idebenone and EPI-743). Alternative strategies include biochemical ‘bypass’ of spe-
cific respiratory chain complexes, such as with the use of succinate, vitamin C and 
vitamin K and ‘energy buffering’.  Several promising small molecules have been 
developed for treatment in mitochondrial disorders. EPI-743 is a vitamin E ana-
logue, which has been tried in mitochondrial disorders.181 Initial open label studies 
with EPI-743 in Leigh syndrome, LHON and other mitochondrial disorders have 
shown promising results.181-184 MRI has not been used for therapy monitoring in 
these studies. Various other small molecules for treatment currently being evaluated 
in clinical studies include KH176, MTP-131, RP103, benzafibrate, RG2133, lipoic 
acid, RTA408 and curcumin.185-187 
Gene therapy although technically challenging provides new therapeutic options 
for, including mtDNA and nDNA related primary mitochondrial disorders. The 
strategies employed for mtDNA related disorder include replacing mutated mtDNA 
with reconstructed DNA, selective degradation of mutated mtDNA, heteroplasmic 
shifting by introducing wild-type mtDNA, or the use of restriction endonucleases to 
eliminate specific mutations in the mtDNA.188,189 The transmission of mitochondrial 
disease, due to inherited nuclear gene mutations can prevented by prenatal diagno-
sis. For mtDNA mutations, this is more complex. For de novo mutations with low 
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recurrence risk, prenatal testing can be offered, whereas for inherited heteroplasmic 
mutations preimplantation genetic diagnosis (PGD) generally is the best option. 
Novel assisted reproductive technologies, such as cytoplasmic transfer, germinal 
vesicle transfer, pronuclear transfer, or spindle transfer are under development in 
order to prevent transmission for carriers of homoplasmic mtDNA mutations or very 
high heteroplasmic mutations.190 
5. Aims and Outline of the thesis 
Based on available literature, reviewed above, it is evident that major MRI findings 
in mitochondrial disorders can be grouped into, deep gray matter lesions suggestive 
of Leigh and Leigh-like syndrome, cavitatory leukoencephalopathy and stroke-like-
lesions and atrophic changes. Table 1 summarizes the major imaging findings and 
the underlying genetic defect. Stroke-like episodes were only observed, when genet-
ic defects occurred in mtDNA replication and translation, but overlap existed among 
the other categories. Presumed, convergence at the level of neuroimaging in patients 
with heterogeneous clinical, biochemical and genetic findings is depicted in Fig.1-4, 
showing MRI characteristics of mitochondrial disease, but it is obvious that more 
detailed studies are required to elucidate further genotype-phenotype correlations. 
There has been a remarkable growth in genomics-based diagnosis and develop-
ment of new and promising therapeutic strategies in the field of mitochondrial med-
icine. The past decade also has witnessed a substantial advance in brain imaging and 
its application in human diseases. Imaging and genetic studies have been the main 
stay in the investigation of many mitochondrial disorders.  “Imaging genetics” has 
emerged as an important research frontier to identify and characterize genetic vari-
ants that influence the anatomical or functional brain imaging findings in patients 
with psychiatric and neurological disorders. Noninvasive brain imaging techniques 
provide an objective and reproducible way of grouping highly heterogeneous clini-
cal observations and genetic etiologies into the same diagnostic group such as 
‘Leigh’s syndrome’ or ‘mitochondrial leukoencephalopathies’. Combining the genetic 
data and neuroimaging phenotype will make imaging a better diagnostic tool for 
more effective treatment and prognosis definition. Longitudinal neuroimaging fol-
low-up data will be valuable in characterizing and defining prognosis in mitochon-
drial diseases. As more and more genetic etiologies are defined neuroimaging find-
ings can be better utilized to understand the prognosis and effectively monitor the 
therapeutic efficacy over time 
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Table 1: MR imaging findings and genotype correlations in mitochondrial disorders 
Classification MRI finding Leigh & 
Leigh-like syndrome 
Leukoencephalopathy Stroke-Like 
lesions 
Nuclear DNA mutations 
Complex 1    
 Structural Subunits NDUFA2, NDUFA4, 
NDUFA9, NDUFA10, 
NDUFA12, NDUFS1, 
NDUFS2, NDUFS3, 
NDUFS4, NDUFS7, 
NDUFS8, NDUFV1 
NDUFS1, NDUFV1 
NDUFS8, NDUFAF3 
- 
 Assembly factors NDUFAF2, NDUFAF5, 
NDUFAF6, FOXRED1 
NUBPL - 
Complex II    
 Structural Subunits SDHA SDHA, SDHB - 
Assembly factors SDHAF1 SDHAF1  
Complex III     
Structural Subunits - -  
Assembly factors TTC19, BCS1L LYRM7  
Complex IV    
Structural Subunits - -  
Assembly factors COX10, COX15, 
SURF1, SCO2, PET100 
SURF1, COX10, COX6B1, 
COA7  
 
 
Nuclear DNA mutations    
Complex V    
Structural Subunits -   
Assembly factors -   
Multiple complex 
deficiencies 
   
Mitochondrial translation 
disorders 
LRPPRC, C12orf65, 
GFM1, IARS2, 
MTFMT, TACO1, 
TRMU, TSFM, FARS2, 
EFG1 
TACO1, APOPT1, 
DARS2, EARS2, DARS, 
RARS, AIMP1, AARS2, 
MARS2, EFTu 
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Table 1 continued 
Classification MRI finding Leigh & 
Leigh-like syndrome 
Leukoencephalopathy Stroke-Like 
lesions 
Mitochondrial DNA 
maintenance & 
Replication 
SUCLG1, SUCLA2 TYMP, RRM2B, POLG, 
MPV17 
POLG, TK2, 
TWINKLE 
Others HIBCH, ECHS1, 
SERAC1, FBXL4 
NFU1125, BOLA3 119, 126 
LIAS 126 IBA57127 GLRX5 
126, HIBCH 
Primary mtDNA Mutations 
tRNA mutations MT-TI, MT-TK, MT-
TW, MT-TV, MT-TL1 
MT-TK MT-TLI,MT-TH 
Structural subunits ND1, ND2, ND3, ND4, 
ND5, ND6, 
COXIII,ATP6 
- ND1, ND5, ND6 
tDNA Rearrangements - Single deletions -
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Fig.1 Mitochondrial Leukoencephalopathy in patients with different genetic etiologies 
A. T2W MRI in a 2 year old boy with a compound heterozygous mutation (c.1324C>C/T, + c.236A>A/C)
in NDUFS1
B. T2W MRI in a 3 year old girl with homozygous mutation (c.2032T>G, p. Tyr678Asp) in NDUFS2 
C. T2 FLAIR MRI in 6 year old girl with homozygous mutation (c.1156C>T, p. Arg386Cys) in NDUFV1 
D. T2W MRI in a 3 year old girl with a homozygous mutation (c.295C>T, p.R99W ) in BOLA3 
E. T2 FLAIR image in a 3 year old girl with homozygous mutation (c.2T>C, p.M1T) in LYRM7 
F. T2W MRI in a 10 year old girl with a homozygous mutation (c.148C>T,p.Arg50 Trp) in MPV17 
Fig.2 MRI in a 2 year old child with MEDGEL syndrome and homozygous mutation [c.442C>T,p.R148Ter] 
in SERAC1. A.T2W axial image showing bilateral symmetrical signal changes in putamen with a character-
istic sparing in the middorsal  part giving rise to “putaminal eye” B.T2W coronal sequence demonstrates 
cerebellar atrophy 
A B 
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Fig.3 MRI brain in 2 year old boy with Leigh like syndrome, methyl malonic aciduria and deafness with a 
homozygous mutation in SUCLA2. A.T2W axial view shows bilateral symmetrical signal changes in 
putamen B.T2W coronal view shows cerebellar atrophy 
 
Fig.4 MRI brain in a 2 year old boy with paroxysmal exercise induced dystonia, leigh like syndrome and 
compound heterozygous mutations in the ECHS1 gene. (5’ splice site variation, c.619+1delG & a missense 
variation c.463G>A (p.Gly155Ser) in exon 4. A:T2W axial image showing bilateral symmetrical signal 
changes in globus pallidi. B&C: Diffusion weighted imaging and ADC maps demonstrating restricted 
diffusion in globus pallidi. 
 
From the current literature, it is evident that even though there has been a tremen-
dous advancement in the molecular diagnosis of patients with mitochondrial disor-
ders, many areas remain unexplored especially in central nervous system imaging. 
Though pattern recognition has been attempted in some of the mitochondrial leu-
koencephalopathies, literature on comprehensive neuroimaging studies in large 
cohorts and phenotype genotype correlations is sparse. Many of them are cross sec-
tional studies and follow up imaging data are not reported. An important question 
faced by the treating physician is whether the prognosis of mitochondrial disorders 
A B 
A B C 
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can be predicted based on different imaging phenotypes. There are only very limited 
studies which have attempted correlation of prognosis and the imaging findings. In a 
study on Leigh’s syndrome, it was shown that the presence of brain stem lesions 
decided a rapidly progressive course and mortality.162 The other large group of paedi-
atric mitochondrial disorders, mitochondrial leukoencephalopathy also pose a chal-
lenge in terms of prognostication. The same genetic mutations have shown to cause 
diseases with variable clinical course.191 It is worthwhile to look for anatomical fac-
tors or patterns on MRI, which determine the variable clinical course in diseases 
caused by the same mutations. More comprehensive and descriptive imaging studies 
are available to achieve this. 
Another avenue, which remained largely unexplored, is the inclusion of MRI 
studies in natural history studies. Mitochondrial disorders exhibit extreme heteroge-
neity at all levels of diagnostic evaluation. The severity of the disease and clinical 
course vary even in patients with same genotype. Lack of natural history studies is 
an important factor impeding the correct prognostication and counseling in patients 
with mitochondrial disorders. MRI has an important role in natural history studies 
because of its non-invasive nature and the ability to define the anatomical pattern of 
brain injury overtime. This can also define if the clinical findings and the course 
have anatomical substrates and are correlated. The advantages of the newer imaging 
techniques to define the metabolic states of the brain and white matter integrity will 
further enhance its usefulness. It is worthwhile to correlate the clinical course and 
MRI in addition to the various clinical scales used. Unfortunately the follow up im-
aging studies are rarely available in patients with mitochondrial disorders even in 
natural history studies.192 Follow up MRI studies in specific subgroup of the patients 
are required to strengthen the natural history studies. 
The presence of neuroinflammation evidenced on MR imaging in patients with 
mitochondrial leukoencephalopathies requires further exploration. Primary demye-
linating disorders and mitochondrial leukoencephalopathies are considered distinct 
disorders, but may pose diagnostic challenge to clinicians especially in the early 
stages. The multifocal confluent nature of the white matter lesions, contrast en-
hancement and diffusion restriction on MRI indicates neuroinflammation. To fur-
ther support this notion, many of these patients apparently respond to immunomod-
ulation. Follow up studies on mitochondrial leukoencephalopathies have shown that 
the evidence of inflammation may persist or may disappear. It will be worthwhile to 
study the inter-relationship between mitochondrial disease and episodic CNS in-
flammation. It is likely that mitochondrial dysfunction leads to possible immune 
activation. The role of long-term immunomodulation in the treatment of the in-
flammatory response is unknown. Comprehensive MRI studies are required in pa-
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tients with mitochondrial leukoencephalopathies to define and ascertain the pres-
ence of neuroinflammation in mitochondrial disorders. 
Management of mitochondrial disorders is mostly supportive at present, but 
there are many small molecules, which are under development, which may ulti-
mately become available to the physicians for use.187 There are various ways of mon-
itoring the effectiveness of therapy. Most clinical trials use clinical scales including 
the Newcastle adult and pediatric mitochondrial disease scales.181,182 Presence or 
absence of lactate peak has been used in some studies to monitor the effect of the 
therapy. When more and more molecules are available for use it becomes imperative 
to develop tools to objectively assess the effect of the therapy. Two important MRI 
phenotypes in mitochondrial disorders include Leigh syndrome and leukoencepha-
lopathies. Both the disorders have well defined neuroimaging features though the 
severity and extent of involvement can vary. Even though there is heterogeneity in 
biochemical and genetic levels there is convergence at the imaging levels in most of 
the disorders. For example, presence of multifocal confluent lesions with cavities in 
the affected white matter, contrast enhancement and presence of lactate peak are 
common features, which define mitochondrial leukoencephalopathy caused by vari-
ous rare genetic etiologies. This convergence at the level of magnetic resonance 
imaging phenotypes is a potential factor, which can be used for monitoring the ef-
fect of therapy in a large number of patients with different genetic etiology. It also 
allows studying the common pathophysiological dysfunction leading to the CNS 
manifestation and its course.  
In conclusion the current data in the arena of neuroimaging in mitochondrial 
disorders is largely insufficient to address several concerns faced by clinician during 
evaluation and management of mitochondrial disorders. More comprehensive phe-
notypic analysis and follow up of patients to define the course, prognosis and natural 
history are required. MRI, being the most easily available tool to investigate the 
presence of central nervous system lesions needs to be utilized further in prognosti-
cation and therapy monitoring. This is also essential to translate the great advance-
ment in the field of molecular diagnosis to bedside management of the patients. 
Therefore, the overall aim of the thesis is to correlate magnetic resonance imaging 
both to genetic defects and disease manifestations, in order to guide the prognosis and 
therapy.  
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Specific aims are 
1. To correlate magnetic resonance findings in patients with mitochondrial disor-
ders and peripheral neuropathy with the underlying genetic defect 
2. To discriminate mitochondrial disorders from other metabolic disorders by spe-
cific imaging findings  
3. To apply MRI for predicting prognosis and therapy in specific subsets of patients 
In Chapter 1 the current literature on the MR imaging findings is reviewed in rela-
tion to the underlying genetic defect and accompanying biochemical or other ab-
normalities. Several areas remain unexplored with respect to the central nervous 
system imaging in patients with mitochondrial disorders. Comprehensive studies 
describing the neuroimaging findings in large cohorts with genotype phenotype 
correlations are limited, necessitating further studies in this field. There is sparse 
literature on the role of magnetic resonance imaging in prognostication and therapy 
monitoring. Detailed phenotypic analysis is required to define the clinical course 
and prognosis in mitochondrial disorders. With these shortcomings in mind detailed 
analyses of three important neurological manifestations in mitochondrial disorders 
were undertaken. (chapter 2-4). In Chapter 2, comprehensive analysis of the magnet-
ic resonance imaging findings in a cohort of patients with mitochondrial disorders is 
described. The anatomical patterns of injury in the whole cohort were studied with 
respect to atrophic changes involving the cerebrum and cerebellum, signal intensity 
changes in the basal ganglia, brainstem, white matter, spinal cord and cerebral cor-
tex. Analysis of special sequences were done in a number of patients including, 
magnetic resonance spectroscopy (MRS), diffusion weighted imaging (DWI) and 
susceptibility weighted imaging (SWI) so as to understand the metabolic status and 
pathophysiological process underlying the MRI changes. Finally, MRI findings in 
three important genotypes were separately analyzed to identify specific correlations 
with the clinical course. Next, in chapter 3, the genetic basis of peripheral neuropa-
thy in mitochondrial disorders was studied. Detailed analysis of the clinical and 
electrophysiological characteristics of peripheral neuropathy in three important 
genetic groups were analyzed and correlations were established. Apart from corre-
lating MRI data to the genetic cause in mitochondrial disease, we investigated the 
specificity of the MRI data for mitochondrial disorders compared to other metabolic 
disorders, focusing on hypertrophic olivary degeneration (Chapter 4) This was stud-
ied in a large cohort of 125 children with different neurometabolic disorders. Rou-
tine MRI sequences (T1 weighted, T2-weighted and fluid attenuated inversion re-
covery sequences) were analyzed for the presence of bilateral symmetrical olivary 
nucleus hypertrophy and central tegmental tract or dentate nucleus signal changes. 
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Specifically, we examined whether the presence of hypertrophic olivary degenera-
tion on MRI could differentiate mitochondrial disorders especially Leigh and Leigh-
like syndrome from other neurometabolic disorders in children. Finally, in Chapter 
5, the prognostic and therapeutic significance of phenotype, genotype and MRI find-
ings in patients with mitochondrial epilepsy were studied. This study specifically 
examined if there were anatomical correlates on MRI in patients with mitochondrial 
epilepsy which can predict the course and therapeutic response. In Chapter 6 we 
analyzed the clinical course and MRI findings in a cohort of children with mito-
chondrial leukoencephalopathy with special reference to evidence of immunological 
dysfunction. The study examined the clinical and MRI factors which differentiates 
mitochondrial leukoencephalopathies from an acquired demyelinating syndrome 
and also brought out the response to immunomodulation. In Chapter 7 the findings 
of these studies are discussed in a broader perspective of application in the clinical 
practice and future research. 
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Abstract  
Background: Large studies analyzing magnetic resonance imaging correlates in dif-
ferent genotypes of mitochondrial disorders are far and few. This study sought to 
analyze the pattern of magnetic resonance imaging findings in a cohort of genetical-
ly characterized patients with mitochondrial disorders. 
Methods: The study cohort included 33 patients (age range 18 months–50 years, M:F 
0.9:1) with definite mitochondrial disorders seen over a period of 8 yrs. (2006–2013). 
Their MR imaging findings were analyzed retrospectively. 
Results: The patientswere classified into three groups according to the genotype, 
Mitochondrial point mutations and deletions (n = 21), SURF1 mutations (n = 7) and 
POLG1 (n = 5). The major findings included cerebellar atrophy (51.4%), cerebral 
atrophy (24.2%), signal changes in basal ganglia (45.7%), brainstem (34.2%) & 
whitematter (18.1%) and stroke like lesions (25.7%). Spinal cord imaging showed 
signal changes in 4/6 patients. Analysis of the special sequences revealed, basal gan-
glia mineralization (7/22), lactate peak on magnetic resonance spectrometry (10/15), 
and diffusion restriction (6/22). Follow-up images in six patients showed that the 
findings are dynamic. Comparison of the magnetic resonance imaging findings in 
the three groups showed that cerebral atrophy and cerebellar atrophy, cortical signal 
changes and basal ganglia mineralization were seen mostly in patients with mito-
chondrial mutation. Brainstem signal changes with or without striatal lesions were 
characteristically noted in SURF1 group. There was no consistent imaging pattern in 
POLG1 group. 
Conclusion: Magnetic resonance imaging findings in mitochondrial disorders are 
heterogeneous. Definite differences were noted in the frequency of anatomical in-
volvement in the three groups. Familiarity with the imaging findings in different 
genotypes of mitochondrial disorders along with careful analysis of the family histo-
ry, clinical presentation, biochemical findings, histochemical and structural analysis 
will help the physician for targeted metabolic and genetic testing. 
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1. Introduction  
Mitochondrial disorders are clinically and genetically heterogeneous group of disor-
ders resulting from dysfunction of the respiratory chain complexes.1 The wide range 
of clinical, biochemical and genetic heterogeneity often pose diagnostic challenge to 
the clinician.2 The current strategy for diagnosis and classification of mitochondrial 
disorders includes a comprehensive and meticulous analysis of family history, clini-
cal findings, biochemical and histopathological analyses, magnetic resonance imag-
ing findings and molecular diagnostic testing.3 Among these, magnetic resonance 
imaging (MRI) is one of the easily accessible initial tools available to the clinician for 
interrogating the presence and pattern of central nervous system changes in patients 
with mitochondrial disorders.4,5  Apart from the structural imaging, the advanced 
imaging techniques also help to define the anatomical lesions, metabolism and he-
modynamics in these patients.6,7   
The central nervous system is the second most frequently affected system after 
the muscular system in mitochondrial disorders.8 The neurological manifestations 
are extremely diverse reflecting the wide range of neuropathological changes and 
the same is extrapolated in the heterogeneous magnetic resonance imaging findings9 
Studies have classified the magnetic resonance imaging findings based on the pheno-
types10,11 respiratory chain abnormalities.12-14 and genetic findings.15,16  Studies on 
genetically characterized patients have suggested that certain neuroanatomical in-
volvement may suggest the underlying genetic etiology.15 This study sought to ana-
lyze the magnetic resonance imaging patterns in a cohort of genetically character-
ized patients with mitochondrial disorders.  
2. Patients and Methods:  
The institutional ethics committee of National Institute of Mental Health & Neuro-
sciences, Bangalore, India approved the study protocol. Over a period of eight years 
(2006-2013) a total of 605 patients were recruited as part of a study on neurological 
disorders associated with mitochondrial DNA mutations. All patients underwent a 
complete clinical and laboratory evaluation and follow up by a single clinical team 
(ABT, PSB, SS, MN). Patients were recruited into the study when clinical, biochemi-
cal, histopathological, magnetic resonance imaging, nerve conduction studies, elec-
troencephalography and evoked potential studies suggested a diagnosis of mitochon-
drial disorder. Standard definitions were used for the phenotypic characterization of 
the classical mitochondrial syndromes as specified in the supplementary table (Table 
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S1). Complete mitochondrial genome sequencing was done in all the patients. Ge-
netic evaluation also included sequencing of the nuclear genes, POLG (n=304) and 
SURF1 (n=91). Mitochondrial gene sequencing revealed 128 variations in 135 pa-
tients, which included known pathogenic mutations (n=20), benign polymorphisms 
/possible disease associated mutations (n=37) and novel variations (n=70). Mitochon-
drial rearrangements were looked for in eight patients and one showed single large 
deletion. POLG screening revealed mutations in 24 patients (POLG1 n=12, POLG2 
n=12) and SURF1 screening in seven patients. Patients without mutations, novel 
mutations & benign polymorphisms, patients with myopathic presentations and 
those without an MRI available for review were excluded. The final cohort included 
33 patients with a definite genetic diagnosis. All had clinical features consistent with 
a mitochondrial disorder along with the presence of a mitochondrial or nuclear 
mutation and /or muscle biopsy showing histopathological evidence of ragged red 
fibers, ragged blue fibers, complete COX deficiency & respiratory chain complex I-
IV deficiencies less than 20%. 
2.1. Magnetic resonance imaging:  
Magnetic resonance imaging was done on Aera 1.5 Tesla MRI scanner (Siemens 
Medical Systems, Erlangen, Germany, n=10)/ Achieva 3 T MR imaging scanner 
(Philips Medical Systems, Netherlands, n=15) using standard protocols and methods 
described previously.17 For eight patients, Magnetic resonance imaging acquired 
elsewhere were reviewed. MRI findings were evaluated by two neurologists 
(ABT&PSB) and one neuroradiologist (HRA) independently. The sequences ana-
lyzed included T1W, T2W, and FLAIR sequences for all. The special sequences, 
diffusion weighted imaging (DWI, n=24), Susceptibility weighted (SWI)/ venobold 
sequences/ Gradient echo imaging (n=20), Magnetic resonance spectroscopy (n=16) 
and Magnetic resonance angiography (n=6) were reviewed whenever available. 
Contrast study was available in 22 patients and spinal cord imaging in six.  
3. Results:  
The study included 33 patients (Age range, 7mo-50yrs; Male: female ratio, 0.9:1) 
with mitochondrial disease and definite genetic diagnoses seen over a period of eight 
years (2006-2013). The clinical diagnosis, genetic and MRI findings of the entire 
cohort is summarized in Table 1.  
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3.1. Phenotypic features:  
The clinical syndromes included mitochondrial encephalopathy lactic acidosis and 
stroke like episodes (MELAS, n=7), MELAS-Leighs overlap syndrome (n=2) Myo-
clonic epilepsy ragged red fiber syndrome (MERRF, n=4), Leigh and Leigh like syn-
drome (n=9), Kearns Sayre syndrome (KSS, n=1), Lebers hereditary optic neuropathy 
(LHON) plus syndrome (n=1), Neuropathy ataxia, retinitis pigmentosa (NARP) syn-
drome (n=1), Sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO) 
syndrome (n=1), and mitochondrial spinocerebellar ataxia epilepsy syndrome 
(MSCAE, n=2) .The rest of the patients had  non syndromic diagnoses.  
3.2. Genetic findings:  
The patients were divided into three groups according to the genotype; mitochon-
drial point mutations and deletions (n=21; Point mutations-20, single deletion-1); 
SURF1 mutations (n=7, homozygous mutations in six and heterozygous mutations in 
one); POLG1 mutations (n=5, homozygous mutations in POLG1-5, combined 
POLG1&POLG2 mutation in one)  
3.3. MRI findings:  
Salient findings in each patient are summarized in Table1. The summary of the find-
ings in the whole cohort and the frequency of involvement of various structures in 
each group are shown in Table 2. The major findings included cerebellar atrophy 
(54.5%), cerebral atrophy (24.2%), basal ganglia lesions (48.4%), brainstem signal 
changes (36.3%), stroke like lesions (25.7%) and white matter lesions (18.1%). Four 
of the six patients who underwent spinal cord imaging showed signal changes. 
Analysis of the special sequences revealed, basal ganglia mineralization (7/20), lac-
tate peak on MRS (10/15), and diffusion restriction (6/22). Analysis of the magnetic 
resonance spectroscopy did not reveal any other findings other than lactate peak. 
3.4. Magnetic resonance imaging findings & genotype correlations  
Cerebral & Cerebellar atrophy: Cerebral and cerebellar atrophy was mostly noted in 
patients with mitochondrial mutations. None of the patients in the SURF1 group 
had cerebral or cerebellar atrophy. Severe cerebral atrophy along with ventricular 
dilatation was seen in two children with MELAS who had an earlier age of onset and 
long duration of the illness (Fig.1). The blood heteroplasmy levels of the MELAS 
patients ranged from 50-90% (n=8). The heteroplasmy levels did not correlate with 
the age of onset or severity of the disease. On the other hand, cerebral atrophy was 
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prominent in three patients with longer duration of illness (Patients, 2, 6 & 8). Cere-
bellar atrophy was prominent in patients with LHON plus, NARP, and Kearns Sayre 
syndrome.  
Basal ganglia and thalamic lesions: The abnormalities were in the form of either sig-
nal changes or mineralization (Table 2). Unilateral or asymmetric lesions were seen 
in two. Signal intensity changes in the basal ganglia were seen in both mitochondrial 
and nuclear DNA mutations. Blooming of the globus pallidus on susceptibility 
weighted /veno-bold sequences, as noted in 7/20 patients were more commonly seen 
in patients with mitochondrial DNA mutations than in the nuclear mutations. Fol-
low up imaging in the patient with m.8363 mutations showed progressive atrophy 
and mineralization of the basal ganglia (Fig.2). Unilateral Thalamic involvement on 
the same side of the stroke like episode occurred in two patients with MELAS and 
bilateral thalamic involvement in SURF1, POLG1 and m.13514 mutation one each. 
Brain stem lesions: This involved specific nuclei and anatomic structures and mostly 
associated with SURF1 mutations (Fig.5a-f) but also was noted in patients with 
MTDNA mutations and POLG1. The inferior olivary nuclei signal changes were 
consistently noted in patients with SURF1 mutation, but also was noted in POLG1 
and m.13514G>A mutations. The other specific tract commonly involved was the 
central tegmental tract.  
Cortical stroke like lesions: The combination of cortical lesions along with bilateral 
globus pallidi calcification and atrophy was commonly seen in patients with the 
m.3243A>G mutations (Fig.1). Diffusion restriction was seen in four stroke like le-
sions suggesting acute nature of the lesions. The location of the cortical lesions were 
temporal, occipital, parietal and frontal. The posterior part of the temporal lobe was 
most commonly involved though the anterior and medial parts were also involved. 
Contrast enhancement of these stroke like lesions was noted in two. Patients with 
chronic lesions and longer duration of the illness had small cortical lesions compared 
to patients with short duration of the illness (Patient 2&8.Fig.1a-c). The additional 
sites of involvement in m.3243 mutations included bilateral symmetrical basal gan-
glia lesions (n=2; Fig.1b) and thalamic lesions ipsilateral to the side of the stroke like 
lesions (n=2, Fig.1e) and speck of cerebellar cortical hyperintensity. Laminar necro-
sis was noted in one (Fig.1d).  Six patients underwent magnetic resonance angiogram 
during the stroke like episodes and all revealed normal findings. MRS showed a 
lactate peak in 7/8 strokes like lesions. Mineralization of the basal ganglia in the 
form of calcification evident on CT scan and blooming on susceptibility weighted / 
venobold sequences were present in 7/8 of patients with stroke like lesions and 
m.3243A>G mutation (Fig.1c). In the patient with POLG related disorder the corti-
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cal lesions were associated with bilateral globus pallidi signal changes and cerebral 
atrophy, but the associated mineralization of basal ganglia was absent.  
Leukoencephalopathy as the main or only abnormality occurred only in one patient 
with Kearns Sayre syndrome (Fig.4). Non specific white matter abnormalities were 
in the form of posterior periventricular signal changes with cyst formation, and focal 
white matter signal changes. Cerebellar white matter involvement was seen in four 
patients. The extent of cerebellar white matter signal changes also varied from speck 
of hyperintensity to signal changes in the peri-dentate white matter and subcortical 
region.  
Spinal cord signal changes: Four of the six patients who underwent spinal cord imag-
ing showed signal changes. In the mitochondrial group this was noted in one patient 
with m.11778G>A and LHON plus syndrome & in one patient with single deletion 
and Kearns Sayre syndrome. Dorsal column degeneration was seen in all while lat-
eral column abnormality occurred in addition in patient with m.11778G>A (Fig.3) 
mutation. 
Mineralization: Susceptibility weighted imaging revealed mineralization in 13/22 
patients. Pattern of mineralization in this cohort was heterogeneous and included, 
bilateral globus pallidi calcification, punctate basal ganglia calcification and diffuse 
dense calcification of caudate and putamen. Mineralization was seen in both 
MTDNA mutations (n=12) and POLG1 (n=1), but none of the patients with SURF1. 
Follow up study: Follow up scans were available in 6 patients. All showed progres-
sive changes either in the form of progressive volume loss in the involved structures 
(Fig.2) or the appearance of new anatomical lesions. 
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Table 2: Summary of the Magnetic Resonance Imaging findings in Patients with Mitochondri-
al Disorders. 
Neuro-imaging Findings All (N=33) MT-DNA 
(n=21) 
SURF1 (n=7) POLG1 (n =5) 
 Cerebellar atrophy 
   Mild 
   Mod-Severe 
18 (54.5%) 
13 
5 
15 
10 
5 
- 
- 
- 
3 
3 
- 
 Cerebral atrophy 8 (24.2 %) 8 - - 
  Basal ganglia Signal   
   Changes 
16 (48.4%) 10 5 1 
     Caudate 
  T2 signal changes 
  Mineralisation 
10 
3/22 
5 
2 
5 
-
- 
1
     Putamen 
   T2 signal changes 
   Mineralisation 
10 
3/22 
5 
2 
5 
- 
- 
- 
1 
     Globus Pallidus 
   T2 Signal changes 
   Mineralisation 
3 
7/22 
1 
8 
1 
- 
1 
1 
Stroke like lesions 9 (25.7%) 8 - 1
Supra-tentorial white matter 
  Leukoencephalopathy 
        Non specific white 
matter  
  signal changes 
6 
2 
4 
2 
3 
1 
1 
- 
- 
Thalamus 3 2 - 1
Subthalamic nucleus 4 - 4 -
Brainstem  12 (36.3%) 4 7 1
    Substantia Nigra 4 1 3 -
    Tectal Plate 
    hyperintensity 
4 2 2 -
    Inferior Olivary 
    Nucleus 
9 1 7 1 
Dentate Nucleus 5 1 3 1 
Cerebellar white matter 3 1 2 - 
Spinal cord signal changes 4/6 2/3 2/2 -/1 
Lactate Peak on MRS 10/15 9/10 1/3 -/2 
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Fig 1 Spectrum of MRI findings in patients with m.3243 A>G mutations: 
1a-c MRI brain in patient 8 with MELAS Leighs overlap syndrome: a) FLAIR image demonstrating cere-
bral atrophy, multiple cortical lesions. b) bilateral symmetrical basal ganglia signal changes and c. miner-
alization on SWI imaging. 1(d–f)- MRI brain in Patient 3: d) T1W image demonstrate cortical laminar 
necrosis (Arrow). e) FLAIR image shows stroke like lesions and pulvinar lesions (Arrow). f) The lesions 
show free diffusion on apparent diffusion coefficient (ADC) maps 
Fig 2 Progressive basal ganglia signal changes and atrophy and mineralization in a 40 year old lady with 
m.8363G>A mutations (Patient 13) a) MRI brain at presentation shows bilateral signal changes in caudate
and putamen (FLAIR) b) MRI after six months-signal changes are persisting but there is atrophy c) T2W
MRI, four years after the onset of the disease shows progressive atrophy and gliotic changes in the MRI.
d) Susceptibility weighted imaging shows mineralization of the basal ganglia. 
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Fig. 3. Spinal cord signal changes in a 17 year old girlwithm.11778GNAmutation (Patient 10). 3a) 
T2Wsagittal image shows longitudinally extensive signal changes in the spinal cord and 3b) dorsal mid-
brain and 3c) T2W axial images of the spinal cord demonstrating the selective lateral and dorsal column 
signal changes. 
Fig.4.4a–d Leukoencephalopathy in KSS(Patient21).4a) Bilateral symmetrical signal changes in white 
matter on T2Wimages. 4b) FLAIR sequences showing brainstem signal changes. 4c) T2W sequences 
showing tectal plate hyperintensities. 4d) T2W coronal images showing bilateral symmetrical signal 
changes in cerebellar white matter. 
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Fig. 5. Spectrum of MRI findings in patients with SURF1 mutation. 5a–c (Patient 22). T2W images show-
ing bilateral symmetrical signal changes in caudate, putamen, tectal plate, inferior olivary nucleus and 
cerebellarwhitematter. 5d–f (Patient 26) FLAIR (5e), T2Waxial (5f) nd axial spinal cord (5f) images show-
ing bilateral symmetrical signal changes in dentate, inferior olivary nucleus and dorsal column. 
Chapter 2 
64 
Supplementary Table: Definitions of well-characterized Mitochondrial syndromes based on 
phenotypes. 
Mitochondrial 
Syndromes 
Clinical & Radiological 
features  
Histopathological, Biochemical & 
Genetic characteristics 
Mitochondrial 
Encephalomyopathy 
Lactic Acidosis and 
Stroke like Episodes 
(MELAS) 
Age of onset <40 years 
Stroke-like episodes  
Seizures and/or dementia 
Short stature  
Lactic acidosis 
Cortical stroke like lesions on 
Magnetic resonance imaging 
findings, bilateral basal ganglia 
calcification 
Histopathology: Ragged Red and 
Blue fibers on muscle biopsy. 
Strongly SDH positive vessels 
Biochemical: Multiple complex 
deficiencies 
Genetic: m.3243 A>G mutation of 
tRNAleu 
Myoclonic Epilepsy with 
Ragged Red Fibres 
(MERRF) syndrome 
Onset around late childhood to 
adulthood.  
Progressive myoclonic epilepsy  
Myopathy with ragged red 
fibers  
Slowly progressive dementia  
Cerebellar ataxia.  
Additional features: Optic 
atrophy, Bilateral deafness, 
Peripheral neuropathy, 
Spasticity, Multiple lipomata  
Histopathology: Ragged red and 
ragged blue fibers on muscle biopsy. 
Biochemical assay: consistent 
protein synthesis defect in 
complexes 1 and 4. Few cases may 
show deficiencies of complexes 3 
and 2.  
Genetics: m.8344G>A and 
m.8356T>C of tRNAlys
Leigh’s syndrome Progressive neurologic disease 
with motor and intellectual 
developmental delay  
Signs and symptoms of brain 
stem and/or basal ganglia 
disease  
Raised lactate concentration in 
blood and/or cerebrospinal 
fluid (CSF)  
One or more of the following: 
Characteristic features of Leigh 
syndrome on neuro-imaging  
Typical neuropathologic 
changes: multiple focal 
symmetric necrotic lesions in 
the basal ganglia, thalamus, 
brain stem, dentate nuclei, and 
optic nerves.  
Typical neuropathology in a 
similarly affected sibling 
Heterogeneity in biochemical and 
genetic findings.  
Disruption of complex IV, also 
called cytochrome c oxidase or 
COX, is the most common cause of 
Leigh syndrome. The most 
frequently mutated gene in COX-
deficient Leigh syndrome is called 
SURF1. 
The most common mitochondrial 
DNA mutation in Leigh syndrome 
affects the MT-ATP6 gene 
Magnetic Resonance Imaging findings in Mitochondrial disorders 
65 
Supplementary Table: Continued 
Mitochondrial 
Syndromes 
Clinical & Radiological 
features  
Histopathological, Biochemical & 
Genetic characteristics 
Leigh-like syndrome This term is often used for 
individuals with clinical and 
other features that are strongly 
suggestive of Leigh syndrome 
but who do not fulfill the 
stringent diagnostic criteria 
because of atypical 
neuropathology (variation in 
the distribution or character of 
lesions or additional presence 
of unusual features such as 
extensive cortical destruction), 
atypical or normal 
neuroimaging, normal blood 
and CSF lactate levels, or 
incomplete evaluation 
Same as that of Leighs syndrome 
MELAS-Leighs overlap 
syndrome 
Patients manifest clinical 
features of MELAS & Leighs 
syndrome. Clinical 
presentation could be variable  
MRI shows features of both MELAS 
& Leighs syndrome and includes 
cortical stroke-like lesions and 
bilateral symmetrical lesions of 
basal ganglia and brainstem. 
Alpers syndrome Hypotonia 
Seizures 
Liver failure 
Genetics: POLG1 mutations 
Neurogenic muscle 
weakness, ataxia, 
retinitis pigmentosa 
(NARP) syndrome 
Neurogenic muscle weakness. 
Electromyography (EMG) and 
nerve conduction studies may 
demonstrate peripheral 
neuropathy (which may be a 
sensory or sensorimotor axonal 
polyneuropathy).  
Ataxia. Cerebral and cerebellar 
atrophy may be noted on MRI.  
Retinitis pigmentosa. 
Histopathology often normal 
Genetics: Most common are point 
mutations in the ATPAse 6 gene of 
mitochondrial DNA 
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Supplementary Table: Continued 
Mitochondrial 
Syndromes 
Clinical & Radiological 
features  
Histopathological, Biochemical & 
Genetic characteristics 
Kearns Sayre syndrome Progressive External 
ophthalmoplegia, onset at age 
<20 years  
Pigmentary retinopathy 
One of the following: High 
CSF protein, cerebellar ataxia, 
heart block  
Additional features include 
diabetes, hearing loss, 
myopathy 
 
Histopathology: Ragged Red & blue 
fibers in muscle biopsy 
Genetics: Large single deletion 
Leber’s Hereditary Optic 
Neuropathy (LHON) 
Bilateral, painless, subacute 
visual failure that develops 
during young adult life.  
Males are four to five times 
more likely to be affected than 
females 
Genetics: 90% have one of three 
point mutations of mitochondrial 
DNA: m.3460G>A, m.11778G>A, or 
m.14484T>C. 
Mitochondrial 
spinocerebellar ataxia 
Epilepsy syndrome 
Onset usually in teenage  
Progressive gait unsteadiness 
due to combined cerebellar 
and sensory ataxia 
Epileptic seizures  
Head ache often migrainous in 
nature 
Most commonly due to mutations 
in POLG1 gene 
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Discussion 
The present study analyzed the brain MRI findings in a cohort of patients with mi-
tochondrial disorders and compared the findings in three important genotypes of 
mitochondrial disorders, namely mitochondrial point mutations and deletions, 
POLG1 and SURF1. The major studies on magnetic resonance imaging findings in 
cohort of patients with mitochondrial disorders have used varied classification sys-
tems and differ in the frequency of involvement of the anatomical structures12-16 
Most of the studies have utilized a classification system, which include progressive 
cerebral and cerebellar atrophy, signal changes in deep gray matter, white matter 
and cortex. In a study on forty children with respiratory chain enzyme deficiencies, 
rapid progression of the atrophy involving all structures of the brain with variable 
involvement of the deep gray and white matter involvement were the most frequent 
findings.14 On the other hand, wide spread white matter hyperintensity, supratento-
rial cortical atrophy and cerebellar atrophy were the major findings in the study by 
Barragan-Campos et al.,12 Myelin abnormalities also figure out as an important find-
ing especially in studies involving children. In a recent study, which involved child-
hood onset mitochondrial disorders, the major findings included cerebral cortical 
involvement, basal ganglia/ diencephalic lesions and predominant lesions in the 
white matter.15 In the present series, cerebellar atrophy was predominant followed 
by basal ganglia and brainstem signal changes. The proportion of different pheno-
types or genotypes in each study may explain the difference in frequency of the 
anatomical structure involvement in various studies. In addition to the usual ana-
tomical areas stressed in previous studies our study also brings out the spinal cord 
signal changes in a significant proportion of the patients who underwent spinal cord 
imaging. 
Studies analyzing magnetic resonance imaging findings and genotype correla-
tions in large cohorts are far and few. In the study by Lebre et al, unique with its 
genotype correlations, the brain MRIs of thirty patients carrying known mutations 
in genes involved in complex I were compared with the brain MRIs of patients car-
rying known mutations in genes involved in the pyruvate dehydrogenase (PDH) 
complex as well as patients with MT-TL1 mutations.16 The study highlighted the 
predominant brain stem signal changes with at least one striatal anomaly in patients 
with complex I deficiency.16 These findings if present along with cortical lesions and 
cerebellar atrophy indicated a mitochondrial DNA mutation. Necrotizing white 
matter signal changes also correlated with complex I nuclear mutations. The present 
series showed that the findings associated with mitochondrial mutations were cere-
bral and cerebellar atrophy and cortical signal changes and basal ganglia mineraliza-
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tion. SURF1 mutation patients had the brain stem signal changes with or without 
the basal ganglia signal changes. No consistent pattern emerged in patients with 
POLG1 related disorder. 
The presence of cerebral & cerebellar atrophy as a major finding in the present 
study underscores the role of mitochondrial dysfunction in neurodegeneration. Dif-
fuse cortical atrophy is described in about one third of the patients with encephalo-
myopathy6 and cerebral atrophy has been the sole imaging findings in upto a quarter 
of the patients with respiratory chain deficiencies.14 Even though the understanding 
of mechanisms underpinning the neurodegenerative changes are limited, post mor-
tem examination of brain of patients with mitochondrial disorders have given robust 
evidence for the neurodegenerative changes occurring in mitochondrial disorders.18 
In the New-Castle series of 15 brains dissected at postmortem from patients with 
genetically diverse mitochondrial disorders, evidence of atrophy was present in 12 
with 50% having MELAS syndrome secondary to m.3243 mutations. It is notewor-
thy that in the present study the most severe cerebral atrophy was noted in two 
pediatric patients with m.3243A>G mutations and a long-standing disease of more 
than five years. Previous neuroimaging studies also have highlighted cerebral atro-
phy in long standing disease of patients with m.3243 mutations and the degree of 
atrophy did not correlate with the number of stroke like episodes.7,19 Both sudden 
loss as well as gradual attrition of the neuronal cells have been suggested as the 
mechanism. In the present study, the levels of heteroplasmy did not correlate with 
the age at onset or severity of the disease. The relationship of mtDNA mutation load, 
mitochondrial dysfunction and neuropathological features has been studied earlier 
in patients with MELAS 20. There appeared to be no correlation between the hetero-
plasmy levels to cause COX deficiency within single neurons and the degree of pa-
thology in affected region.20 It is unclear why patients with particular mutations 
show greater susceptibility to neurodegeneration. Progressive neuronal atrophy is 
also a feature of POLG related disorder and an Alpers syndrome phenotype.15 None 
of the patients in this series had Alpers syndrome phenotype and may explain the 
absence of atrophy in POLG group. 
Cerebellar atrophy was the primary neuroimaging abnormality in a large series 
of pediatric patients.21 Even though cerebellar atrophy has been described in patients 
with cytochrome c oxidase deficiency and SURF1 deficiency, none of the patients 
with SURF1 deficiency in our series had cerebellar atrophy. Cerebellar atrophy as a 
predominant feature is also seen in primary CoQ deficiency.22 In addition to cerebel-
lar atrophy, pontocerebellar hypoplasia also has been reported in patients with mi-
tochondrial disorders and has now been emerged as a new phenotype of mitochon-
drial disorders caused by RARS2 mutation.23,24 Cerebellar atrophy was a prominent 
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finding in patient with the m.9185T>C mutation. This patient presented with histo-
ry of visual impairment, ataxia and parasthesias. Evaluation showed muscle weak-
ness, retinitis pigmentosa, peripheral neuropathy and cerebellar ataxia suggesting 
neurogenic muscle weakness, ataxia retinitis pigmentosa (NARP) syndrome. This 
mutation in the ATPase gene is described only in few families and reported to cause 
heterogeneous phenotypes including Leighs syndrome, NARP, Charcot Marie Tooth 
disease, spinocerebellar ataxia, episodic weakness and motor neuron disease.25, 29 MRI 
findings in patients with the m.9185T>C mutation include that of Leighs syndrome, 
cerebellar atrophy and normal findings.25, 27-29 
The stroke like lesions, cortical lesions not confined to defined vascular territo-
ries were seen with the m.3243A>G mutations and in a child with POLG1. The 
characteristics of the stroke like lesions in m.3243 mutations in this cohort were in 
accordance with the literature.30-32 Diffusion weighted imaging findings of the stroke 
like lesions depended on the time of imaging and diffusion restriction was seen only 
in those who have imaged at the acute stage. The initial insufficiency in neuronal 
energy causes cytotoxic edema and subsequent development of extra cellular edema 
increase the apparent diffusion coefficient. As a result those who are imaged later in 
the course of the stroke like episodes shows free diffusion of the lesions.30-32 Peculiar 
vascular changes known as mitochondrial angiopathy has been suggested as the 
pathogenic basis of the brain lesions in MELAS.33 This mitochondrial angiopathy 
was characterized by marked accumulation of mitochondria in the cell bodies of 
smooth muscle cells and endothelial cells. In addition, numerous smooth muscle 
cells in the tunica media also showed degeneration or necrosis, sporadically or in 
clusters. These abnormalities were most prominent in the walls of pial arterioles and 
small arteries up to 250 μ in diameter and were less frequent and severe in the larger 
pial arteries, intracerebral arterioles and small arteries.33 Electron microscopic stud-
ies of brain capillaries in another patient with MELAS has shown hypertrophy of the 
endothelial cells, increased mitochondria in sub endothelial space and narrowing of 
the capillary lumen”.34  These studies suggest the unique nature of the vascular le-
sions in MELAS patients.  
The patients with bilateral symmetrical basal ganglia signal changes and 
m.3243A>G mutation may represent MELAS-Leighs overlap syndrome. The ME-
LAS/LS overlap syndrome has been previously described in association with 
13513G>A mutations in three patients.35 Brain autopsy in one case revealed infarct-
like lesions in the cerebral cortex, basal ganglia and brainstem providing further 
insight into the distribution of the pathological lesions in MELAS/LS overlap syn-
drome.35 Clinical features in these patients are characterized by features of both ME-
LAS & Leighs syndrome and presentation could be variable depending on the rela-
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tive contribution of the MELAS, Leighs or both. Our patients had presented with 
features of MELAS and the neuroimaging has revealed bilateral symmetrical basal 
ganglia lesions in addition to stroke like lesions. Both the patients developed brain-
stem dysfunction towards the end stage of the disease. This pattern of lesions also 
have been described in patients with complex I deficiency secondary to mitochon-
drial mutations.16 
The additional findings of laminar necrosis and thalamic involvement noted in 
the cohort of 3243 mutation patients have been highlighted earlier.36,37 Mitochondri-
al diseases are the third common cause of laminar necrosis after cerebral ischemia 
and hypoxia.36 Though most frequently described in MELAS, it has also been de-
scribed in TK2 related and TWINKLE related mitochondrial disorders.38,39 Thalamus 
is one of the areas other than cortical lesions involved in MELAS and at times may 
mimic Creutzfeld Jacob disease.40 Thalamic involvement as a sign of mitochondrial 
disorders have been also noted in POLG1 related disorders. It typically involves 
pulvinar and often occurs ipsilateral to the stroke like lesions.41 
Pattern of mineralization in this cohort was heterogeneous and included, bilat-
eral globus pallidi calcification, punctate basal ganglia calcification and diffuse dense 
calcification of caudate and putamen. Mineralisation was seen in both MTDNA mu-
tations and POLG1, but none of the patients with SURF1 probably due to the early 
age of these patients. It is noteworthy that susceptibility weighted imaging revealed 
mineralization in all patients with m.3243 mutations who have undergone the test. 
Globus pallidus hypointensity on T2 weighted images has been described as the 
earliest finding in patients with MELAS.42 Neuropathological studies have shown 
that the calcification in the basal ganglia is localized to the walls of the blood vessels 
within the basal ganglia.18,34 The neuronal populations are spared and there are no 
intraneuronal calcium deposits. This suggests the role of mitochondrial dysfunction 
causing mineralising microangiopathy as reported in one of the patients in this co-
hort earlier.43 
Focal necrotic lesions involving the brainstem has been consistently reported in 
patients harboring complex I deficiency and both nuclear and mitochondrial DNA 
mutations.16 Present study showed brainstem signal changes in all the three groups. 
but significantly with SURF1 mutations. Inferior olivary nucleus was the most 
commonly involved nuclei in the brainstem. Hypertrophic olivary degeneration in 
patients with SURF1 & POLG1 mutation as well as in children with mitochondrial 
disorders has already been highlighted.17, 44 
Spinal cord involvement is a recognized feature of certain mitochondrial disor-
ders.45  The Spinal cord signal changes, as the predominant manifestation of mito-
chondrial disorder is an exceptional finding and reported in patients with clinical 
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diagnosis of Leber’s hereditary optic neuropathy and in patients with m.3460 muta-
tions.46 Similar to the patient described by Jaros et al, the spinal cord signal changes 
in our patient with m.11778G>A mutation was localized to the posterior and lateral 
columns.46 Spinal cord degeneration confined to posterior column is also seen in 
POLG1 related disorders and has been supported by histopathological studies.47,48 
Spinal cord pathology is also reported in patients with mitochondrial myopathy 
encephalopathy, lactic acidosis and stroke like episodes syndrome.49 Spinal cords 
showed spongy state due to the presence of distended myelinated fibers with en-
larged periaxonal spaces. The affected fibers had extensive microvacuolation of the 
inner myelin sheath with occasional vesicular changes. There was also presence of 
macrophages near the degenerated myelin and stripping of the myelin lamelle by 
macrophage. Prominent morphological changes were also observed in oligodendro-
cytes. Authors concluded that demyelination secondary to degeneration of oli-
godendrocytes occurs in MELAS. The long segment demyelination, as observed in 
our patient also support this. Identifying the mitochondrial etiology in patients with 
primary spinal cord involvement has important therapeutic and prognostic implica-
tions. 
Leukoencephalopathy in the context of mitochondrial disorders have been large-
ly described in mitochondrial syndromes associated with KSS, MNGIE and in pa-
tients harboring mutations in the gene encoding complex I, complex II and complex 
IV assembly factors.50,51 They are increasingly recognized in various tRNA acyl syn-
thase deficiencies.52  The presence of leukoencephalopathy in this cohort was less 
compared to the earlier and recent reports and was noted in one patient each from 
the primary mitochondrial group & SURF1. One reason for the less number of pa-
tients with leukoencephalopathy in this series may be due to lack of screening for 
the complex I nuclear mutations. Myelinopathy or white matter disease as seen in 
our patient is described as the hallmark of Kearns Sayre syndrome.53 Experimental 
studies have suggested preferential loss of myelin associated glycoprotein in patients 
with KSS to account for the leukoencephalopathy.54 Leukoencephalopathy as seen in 
the patient with SURF1 mutation has been described earlier.55 Leukoencephalopathy 
in the context of SURF1 & POLG1 mutation is described earlier, but less commonly 
reported in POLG1 patients.56,57 
MRI findings in POLG1 patients were heterogeneous and there was no con-
sistent pattern. Three patients had the p.L304R mutation in a homozygous state as 
reported previously in patients with South East Asian ethnicity and in a French 
cohort.58,59 Findings in previous reported POLG1 cohorts include stroke like lesions 
as in MELAS, bilateral inferior olivary nucleus degeneration, dorsal column degen-
eration and mild cerebellar atrophy.60-63 Bilateral olivary lesions and pulvinar lesions 
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were noted in the patient with p.W748S + p.E1143G mutation as reported in Euro-
pean patients.60 This patient also had a homozygous p.R369G mutation in POLG2.  
This POLG2 mutation has proven pathogenicity by reducing affinity of the p55 ac-
cessory subunit for the p140 catalytic subunit of POLG by 4.5 fold. Since POLG1 
and POLG2 act in tandem in mtDNA replication, mutations in POLG2 might have 
exacerbated POLG1 dysfunction and stalled DNA replication, resulting in the clini-
cal phenotype.64 
All patients with SURF1 mutation had Leighs syndrome and the imaging findings 
were mainly characterized by variable combination of bilateral symmetrical signal 
changes in the basal ganglia, brainstem, dentate nuclei and cerebellar white matter. 
In a large retrospective multicenter study on children with cytochrome c oxidase 
deficiency, 47 children had SURF1 mutation. All children with SURF1 mutation had 
Leighs syndrome as defined by the bilateral symmetrical signal changes in the basal 
ganglia and /or in the brain stem.65 Similar to the study by Bohm et al, all patients 
with SURF1 mutation in the present study also had a Leighs syndrome phenotype. 
Two patients had normal MRI findings. Mitochondrial disorders may follow a 
very slowly progressive course and the neuroradiological findings may be subtle or 
atypical initially.10 The need for regular and vigilant follow up and serial studies in 
patients with mitochondrial disease has been stressed earlier.65 All follow up scans in 
this series showed progressive changes either in the form of volume loss in the in-
volved structures or appearance of new anatomical lesions. These findings indicate 
that the changes are dynamic in nature and follow up imaging studies should be 
carried out routinely in patients with mitochondrial disorders.  
In conclusion this study highlights the heterogeneous magnetic resonance imag-
ing findings of genetically well-characterized cohort of patients with mitochondrial 
disorders. Definite differences were noted in the frequency of anatomical involve-
ment in the three groups. Limitations of the study include the small sample size and 
the fact that the nuclear gene screening was limited to two genes. Nevertheless, this 
study is important since constantly growing number of genes implicated in mito-
chondrial dysfunctions requires regular reevaluation of correlations between the 
genotype and the magnetic resonance imaging phenotypes. Analysis of the brain 
MRI correlates of newly discovered genetic alterations might establish more robust 
and specific imaging phenotypes, helping with a more confident diagnosis. Familiar-
ity with the imaging findings in different genotypes of mitochondrial disorders 
along with careful analysis of the family history, clinical presentation, biochemical 
findings, histochemical and structural analysis will help the physician for targeted 
metabolic and genetic testing. 
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Abstract 
Background: There are relatively few studies, which focus on peripheral neuropathy 
in large cohorts of genetically characterized patients with mitochondrial disorders. 
This study sought to analyse the pattern of peripheral neuropathy in a cohort of 
patients with mitochondrial disorders.  
Methods: The study subjects were derived from a cohort of 52 patients with a genet-
ic diagnosis of mitochondrial disorders seen over a period of 8 years (2006-2013). All 
patients underwent nerve conduction studies and those patients with abnormalities 
suggestive of peripheral neuropathy were included in the study. Their phenotypic 
features, genotype, pattern of peripheral neuropathy and nerve conduction abnor-
malities were analysed retrospectively.  
Results: The study cohort included 18 patients (Age range: 18 months-50 years, M:F- 
1.2:1). The genotype included mitochondrial DNA point mutations (n=11), SURF1 
mutations (n=4) andPOLG1 (n=3). Axonal neuropathy was noted in 12 patients (sen-
sorimotor: n=4; sensory: n=4; motor: n=4) and demyelinating neuropathy in 6. Phe-
notype-genotype correlations revealed predominant axonal neuropathy inmito-
chondrial DNA point mutations and demyelinating neuropathy in SURF1. Patients 
with POLG related disorders had both sensory ataxic neuropathy and axonal neu-
ropathy. 
Conclusion: A careful analysis of the family history, clinical presentation, biochemi-
cal, histochemical and structural analysis may help to bring out the mitochondrial 
etiology in patients with peripheral neuropathy and may facilitate targeted gene 
testing. Presence of demyelinating neuropathy in Leighs syndrome may suggest 
underlying SURF1 mutations. Sensory ataxic neuropathy with other mitochondrial 
signatures should raise the possibility of POLG related disorder. 
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1. Introduction 
Mitochondria have a number of essential roles in neuronal growth, survival and 
function.1 In addition to maintaining energy milieu within the cell body, dendrites 
and axons, mitochondrial ATP production also supports synapse assembly, genera-
tion of action potentials and synaptic transmission in peripheral nerves.2 The peculi-
ar morphological features of peripheral nerves such as small cell body, arborizing 
dendrites with elaborate anchors and thin long axons necessitates specialized mech-
anisms to efficiently distribute mitochondria to distal areas of nerves.1 Mitochondria 
are concentrated on the nodes of Ranvier and nerve terminals and transmission of 
energy across long distances in peripheral nerves is facilitated by both anterograde 
and retrograde mitochondrial transport.3 This is regulated by a continuous process of 
mitochondrial fusion and fission referred to as mitochondrial ‘dynamics’. Abnormal-
ities in mitochondrial dynamics are being increasingly identified as a cause of pe-
ripheral nerve dysfunction and they form an important subgroup of mitochondrial 
neuropathies with a Charcot-Marie-Tooth (CMT) disease like phenotype.4 Given the 
important role of mitochondria in neuronal function, peripheral neuropathy is often 
seen in patients with mitochondrial disorders.5,6 Peripheral neuropathy is reported 
in one-third of patients with mitochondrial disorders, but is often under-recognized 
due to overwhelming involvement of the central nervous system.7 The severity of 
neuropathy varies from mild or subclinical, to severe and may be the main or only 
feature of a mitochondrial disorder.8 
Molecular genetic classification of peripheral neuropathies related to mitochon-
drial disorders is still evolving. Peripheral neuropathy is uncommon and a non-
prominent feature of disorders arising from point mutations of mitochondrial DNA 
(mtDNA).3,8,9 However neuropathy is a predominant feature in neuropathy, ataxia, 
and retinitis pigmentosa (NARP) syndrome secondary to mutations in Mitochondrial 
Encoded ATP Synthase 6 (MTATP6).10,11 Neuropathy is more frequently related to a 
defect in nuclear DNA (nDNA) especially in nuclear-mitochondrial inter-genomic 
communication disorders.12 In addition peripheral neuropathy occurs as a unique or 
sole manifestation in disorders of mitochondrial dynamics associated with mutations 
in Mitofusin-2 (MFN2) and Ganglioside-induced Differentiation Associated Protein-
1 (GDAP1).6 
The recognition of mitochondrial disorder as the underlying etiology of periph-
eral neuropathy is important in clinical practice for targeted metabolic and genetic 
testing. Phenotype genotype correlations in mitochondrial neuropathies are still 
evolving and need to be defined further. This study reports the profile of peripheral 
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neuropathy in a cohort of patients with genetically characterized mitochondrial 
disorder. 
2. Patients and methods:  
The Institute Ethics Committee of National Institute of Mental Health and Neuro-
sciences, Bangalore, India, approved the study protocol. The recruitment and selec-
tion of the patients were done as per the methods described previously.13 Over a 
period of eight years (2006-2013) a total of 605 patients were recruited as part of a 
study on neurological disorders associated with mitochondrial DNA mutations. All 
patients underwent a complete clinical and laboratory evaluation and follow-up by a 
single clinical team (ABT, PSB, SS, MN). Patients were recruited into the study 
when a comprehensive evaluation, with serum lactate, muscle histopathology, res-
piratory chain complex assays, brain magnetic resonance imaging, nerve conduction 
studies, electroencephalography and evoked potential studies, tailored to the clinical 
phenotype suggested a probable diagnosis of mitochondrial disorder. The evaluation 
also included estimation of fasting blood sugar, thyroid function tests, and serum 
vitamin B12 levels as a part of diagnostic work up of peripheral neuropathy.  
Standard definitions were used for the phenotypic characterization of the classi-
cal mitochondrial syndromes. Complete mitochondrial genome sequencing was 
done in all the patients. Genetic evaluation also included sequencing of the nuclear 
genes: Polymerase gamma 1 and 2 (POLG 1 and 2) (n = 304) and Surfeit Locus Pro-
tein 1 (SURF1) (n = 91). Mitochondrial gene sequencing revealed 128 variations in 
135 patients, which included known pathogenic mutations (n = 20), benign poly-
morphisms/ possible disease associated mutations (n = 37) and novel variations (n = 
70). Mitochondrial rearrangements were looked for in eight patients and one 
showed single large deletion. POLG screening revealed mutations in 24 patients 
(POLG1 n = 12, POLG2 n = 12), while mutations in SURF1 were noted in seven. All 
52 patients with a genetic diagnosis underwent nerve conduction studies and those 
patients who had electrophysiological evidence of neuropathy (n=18) were included 
in final analysis. Their phenotypic features, nerve conduction abnormalities and 
genetic diagnoses were reviewed. 
2.1. Nerve conduction studies:  
Nerve conduction studies were performed using standard techniques. Median, ulnar, 
common peroneal and sural nerve recordings were done. Difference in recorded 
values greater than two standard deviation  from the mean values standardized at 
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our laboratory was considered abnormal (supplementary table 1).The normative 
values have been collected using the methods described previously.14,15 For children 
included in the study, we used the reference values given by Parano et al and Gam-
storp et al.,16,17 Based on the nature of electrophysiological abnormalities, patients 
were categorised to (i) axonal or demyelinating neuropathy; and (ii) sensory, motor 
or sensorimotor neuropathy. Demyelination in children was defined using the crite-
ria for Chronic Inflammatory Demyelinating Polyneuropathy by Nevo  et al.,18 
3. Results: 
There were 18 patients (Age range: 18 months-50 years, M:F- 1.2:1) in the study. 
The phenotypes, genotypes and the type of neuropathy of these patients are summa-
rised in Table 1. Consanguinity was noted in 10 (50%) and a positive family history 
in 5 (25%). Phenotypes included Leighs and Leigh like syndrome (n=5), Myoclonic 
Epilepsy with Ragged Red Fibers syndrome (MERRF,n=4), Mitochondrial Encepha-
lopathy Lactic Acidosis Stroke like syndrome (MELAS,n=3), and one patient each of 
ataxia neuropathy, Mitochondrial Spinocerebellar Ataxia Epilepsy (MSCAE), Neu-
ropathy Ataxia Retinitis Pigmentosa syndrome (NARP), chronic progressive oph-
thalmoplegia, Lebers Hereditary Optic Neuropathy (LHON)plus syndrome, and 
sensory ataxic neuropathy, dysarthria, ophthalmoparesis (SANDO) syndrome. Signs 
of peripheral neuropathy such as wasting of the distal muscles of the lower limb, 
weakness and hyporeflexia were noted in 14 (77.8%) patients. Positive sensory 
symptoms were present in two and autonomic symptoms in one. One patient with 
MERRF syndrome (Patient 3) had diabetes. Diagnostic evaluation for other causes of 
peripheral neuropathy was negative in rest of the patients. 
3.1. Genotypic Findings: 
The genotype of patients included: Mitochondrial point mutations, n=11; SURF1 
mutations, n=4 ; and POLG1 Mutations, n=3. 
3.2. Histopathological findings:  
One patient underwent nerve biopsy (Patient 1), which showed significant loss of 
large fibers in Kulchitsky Pal stain. Other findings included schwann cell prolifera-
tion and regenerating clusters.  
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3.3. Nerve conduction abnormalities:  
Details of nerve conduction studies of the entire cohort is given in supplementary 
table 1. Axonal neuropathy was noted in 12 (66.6%) patients. This could be further 
classified as sensory axonal (n=4, 22.2%), motor axonal (n=4, 22.2%) and sensorimo-
tor axonal (n=4, 22.2%). Sensorimotor demyelinating neuropathy was noted in six 
patients (30%). Majority had axonal neuropathy which was length dependent and 
involved the sensory more than motor nerves. In majority of the patients, neuropa-
thy was mild and was detected based on the presence of signs of neuropathy and 
confirmed by electrophysiological studies. Positive sensory symptoms were noted in 
two patients, one with NARP syndrome and other with MELAS syndrome. Three 
patients had a sensory ataxic neuropathy and their genetic analysis revealed muta-
tions in POLG1 (n=2) and m.8363A>G (n=1). 
3.4. Peripheral neuropathy, phenotype and genotype correlations. 
3.4.1. Mitochondrial point mutations:  
Of the 20 patients with a known pathogenic mutation in the mitochondrial DNA, 11 
patients (55%) had evidence of peripheral neuropathy. Most common type of neu-
ropathy in patients with mitochondrial DNA point mutations was axonal neuropa-
thy of sensorimotor, motor or sensory type. The only exception was a patient with 
mutation in m.9185T>C, who had demyelinating neuropathy. This patient presented 
with visual impairment, ataxia and paresthesias. Evaluation showed neurogenic 
muscle weakness, ataxia, retinitis pigmentosa and peripheral neuropathy suggesting 
NARP syndrome. All patients with m.8334A>G mutation in our cohort showed 
evidence of axonal neuropathy. On the other hand, only three patients out of nine 
patients with MELAS syndrome (33.3%) had evidence of neuropathy. 
3.4.2. SURF1 mutations:  
Of the seven patients with SURF1 mutation, four (57.1%) showed evidence of de-
myelinating neuropathy. 
3.4.3. POLG mutations:  
Of the 24 patients with POLG related disorders, three (12.5%) had peripheral neu-
ropathy. Two patients had clinical features of sensory ataxic neuropathy, while in 
the third patient, the neuropathy was subclinical. The patient with SANDO clinical-
ly had an ataxic neuropathy but the nerve conduction studies showed a demyelinat-
ing peripheral neuropathy. In the cohort of patients with mutations in POLG1, five 
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patients manifested with chronic progressive ophthalmoplegia (CPEO) of which two 
had peripheral neuropathy. Of the remaining three patients without peripheral neu-
ropathy only one patient had an autosomal dominant CPEO while the rest had iso-
lated PEO. 
Table 1: Phenotype genotype and type of peripheral neuropathy in patients with mitochon-
drial disorders 
Sl. 
No 
Age at 
diagnosis 
/Gender 
Gene Mutation Diagnosis Type of 
Neuropathy 
1 *12 yrs/ F mt-tRNALys m.8344G>A  MERRF Sensory Motor 
Axonal 
2 *8 yrs/ M mt-tRNALys m.8344G>A  MERRF Sensory motor 
axonal 
3 41 yrs/ M mt-tRNALys m.8344G>A  MERRF Sensory Axonal 
4 28 yrs/ M mt-tRNALys m.8344G>A  MERRF Sensory Axonal 
5 17 yrs/ M mt-tRNALeu n.3243A>G MELAS Sensory motor 
Axonal 
6 11 yrs/ F mt-tRNALeu n.3243A>G MELAS Motor Axonal 
7 36 yrs/ F mt-tRNALeu n.3243A>G MELAS Sensory axonal 
8 13 yrs/ M mt- RNA Lys m.8363A>G,  Mitochondrial 
recessive ataxia, 
syndrome 
Sensory Axonal 
9 16 yrs/ F mt-ND4 m.11778 G>A  LHON plus 
syndrome 
Motor Axonal 
10 7 yrs/ F mt-ND5 m.13514A>G  Leigh like 
syndrome 
Motor Axonal  
11 50 yrs/ M Mt-ATP6 m.9185 A>G  NARP Sensory motor 
demyelinating 
12 6 yrs/ M SURF1 c.531-533delTAAA Leighs syndrome Sensory Motor 
Demyelinating 
13 3 yrs/ F SURF1 
 
c.G180R 
 
Leighs syndrome Sensory Motor 
Demyelinating 
14 3 yrs/ F SURF1 
 
c.792_793delAG Leighs syndrome Sensory Motor 
Demyelinating 
15 18 mo/ M SURF1 c.531_533delTAAA Leighs syndrome Sensory motor 
Demyelinating 
16 10 yrs/ M POLG1 c.911T>G SANDO syndrome Sensory motor 
demyelinating 
17 26 yrs/ M POLG1 c.911T>G CPEO Sensory motor 
demyelinating 
18 6 yrs/ F POLG1 c.911T>G Mitochondrial 
spinocerebellar 
ataxia epilepsy 
syndrome 
Motor axonal  
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*Siblings,NARP-Neurogenic weakness, ataxia, and retinitis pigmentosa, MERRF- myoclonic epilepsy with 
ragged-red fibers, LHON-   Leber's hereditary optic neuropathy, MELAS- Mitochondrial encephalopathy 
lactic acidosis and stroke like episodes, CPEO - Chronic progressive external ophthalmoplegia, ND-Not 
done, RRF-Ragged Red fibers, RBF-Ragged Blue fibers, COX- cytochrome C oxidase 
Supplementary Table 1: Details of the nerve conduction studies in patients with mitochondrial 
disorders 
Pt No Age/Gender/ 
Diagnosis 
Median 
CMAP 
DL/ 
Amp/ 
CV 
Ulnar 
CMAP 
DL/ 
Amp/C
V 
    CP 
DL/ 
Amp/ 
CV 
Median 
SNAP 
DL/   
Amp/    
CV 
Ulnar 
SNAP 
DL/ 
Amp/ 
CV 
Sural 
SNAP 
DL/ 
Amp/ 
CV 
Type of 
Neuropathy 
1 *12 yrs/ F 3.2/10.5/
39 
3.6/6.8/ 
47.2 
3.8/0.9/ 
44.9 
2.5/6/  
50 
2.8/8/ 
48.9 
Absent Sensory 
Motor Axonal 
2 *8 yrs/ M 2.6/9.9/ 
45.9 
3.0/8.4/ 
50.0 
Absent 2.8/12/ 
46.2 
2.7/14/ 
51.4 
Absent Sensory motor 
axonal 
3 41 yrs/ M 3.9/14.8/
58.1 
2.8/7.1/ 
59.6 
4.2/4.6/ 
45.6 
Absent Absent Absent Sensory 
Axonal 
4 28 yrs/ M 2.7/14.3
4/50 
2.5/8.1/ 
57 
3.7/2.5/ 
44 
2.7/1.8/ 
52 
2.3/1.3/ 
52 
3.5/0.5/ 
40 
Sensory 
Axonal 
5 17 yrs/ M 3.2/9.5/ 
64.5 
2.6/4.4/ 
60 
5.1/0.8/ 
52.0 
Absent Absent Absent Sensory motor 
Axonal 
6 11 yrs/ F 3.2/12.9/
51.9 
2.8/5.4/ 
48.3 
4.4/1.9/ 
47.5 
2.6/58/ 
46.2 
1.9/54/ 
41.7 
2.4/27/ 
45.8 
Motor Axonal 
7 36 yrs/ F 4.0/14.6/
53.5 
3.6/7.5/ 
57.1 
4.9/4.4/ 
41.8 
Absent Absent Absent Sensory 
axonal 
8 13 yrs/ M 3.2/11.2/
63.2 
2.2/6.5/ 
60.8 
3.8/2.5/ 
50.9 
2.8/4.3/ 
46.4 
1.8/4.2/ 
52.1 
2.6/2.1/ 
53.8 
Sensory 
Axonal 
9 16 yrs/ F 3.5 
/6.5/42.1  
ND 5.4/0.6/ 
45.8 
ND 2.8/10.2/
42.9 
1.6/7.2/ 
56.2 
Motor Axonal 
10 7 yrs/ F 3.9/7.3/ 
50 
2.6/8.1/ 
58.3 
Absent 1.4/40/ 
65.2 
1.4/46/ 
62.5 
2.8/28/ 
53.6 
Motor Axonal  
11 50 yrs/ M 3.5/16/ 
52.1 
3.3/8.3/ 
45.8 
7.6/0.6/ 
36 
3.4/22/ 
38.2 
2.8/17/ 
37.9 
3.6/10/ 
36.1 
Sensory motor 
demyelinating 
12 6 yrs/ M 2.4 / 3.2/  
21.6 
ND      3.9/2.2 / 
22.9 
Absent ND Absent Sensory 
Motor 
demyelinating 
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Supplementary Table 1: continued 
Pt No Age/Gende
r/ 
Diagnosis 
Median 
CMAP 
DL/ Amp 
/CV 
Ulnar 
CMAP 
DL/ 
Amp/CV 
CP 
DL/ 
Amp/ 
CV 
Media
n 
SNAP 
DL/   
Amp/    
CV 
Ulnar 
SNAP 
DL/ Amp/ 
CV 
Sural 
SNAP 
DL/ Amp/ 
CV 
Type of 
Neuropath
y 
13 3 yrs/ F 4.3 /4.6 / 
45.5 
1.7/7.1/ 
51.2 
2.5/4.9/ 
48.6 
2.8/14/
30.4 
ND 2.2/17/ 
31.8 
Sensory 
Motor 
Demyelina
ting 
14 3 yrs/ F 4.1 / 6.7 / 
48.6 
3.8/4.2/ 
47.5 
3.4 / 
3.1/41.4 
2.9 / 
16/ 
37.9 
2.7/ 
16/36.2 
3.1/9.6/ 
35.5 
Sensory 
Motor 
Demyelina
ting 
15 18 mo/ M 3.4/ 8.2/ 
32.1 
2.2 
/6.1/32.7 
2.8 / 3.7 
/32.8 
2.2 / 
13.4/ 
31.4 
1.6/12.7/ 
31.5 
Absent Sensory 
motor 
Demyelina
ting 
16 10 yrs/ M 4.1/7.6/ 
48.4 
2.8/6.5/ 
48.6 
5.5/3.4/ 
38.9 
4.4/5.1
/27.3 
4.0/6.5/ 
25 
Absent Sensory 
motor 
demyelina
ting 
17 26 yrs/ M 3.5/9.5/  
54 
2.9/7.3/ 
52.7 
7.1/4.1/ 
43.9 
3.4/2.5
/48.5 
ND Absent Sensory 
motor 
axonal 
18 6 yrs/ F 4.1/17 
/53.2 
2.1/14.5/ 
50.1 
4.2/1.8/ 
44.3 
2.8/26/
51.8 
2.1/18/ 
50.6 
3.2/8/44.3 motor 
axonal   
Normat
ive data 
(Mean±
2 SD) 
DL  
Amp. of 
CMAP/SN
AP  
Velocity 
 2.6 ± 0.5 
 14.5 ± 3.4  
 58.7± 3.8 
2.0 ± 0.5  
10.9 ± 2.6  
59.9± 4.8  
 
3.6 ± 0.5  
8.02 ± 
2.9  
51.1± 
5.5  
 
-29.9 ± 
8.1 
59.5 ± 
4.2  
 
22.5 ± 6.7  
56.2 ± 4.1  
 
21.5 ± 8.5 
48.4 ± 4.7 
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4. Discussion:  
This study analyzed the pattern of peripheral neuropathy in a cohort of genetically 
characterized patients with mitochondrial disorders. There are relatively few studies 
which focus on peripheral neuropathy in large cohorts of genetically characterized 
patients with mitochondrial disorders.8,9 Analysis of clinical features pertaining to 
peripheral neuropathy showed that the neuropathy was less severe and part of the 
multisystem involvement in majority of the patients. Symptomatic neuropathy was 
seen only in minority of the patients. The most common type of peripheral neuropa-
thy noted in this cohort was the axonal neuropathy of sensory, motor or sensorimo-
tor type as reported previously in the literature.6,8 Eventhough the phenotype geno-
type correlations are difficult to ascertain due to the small number of patients har-
bouring mutations in SURF1 and POLG1 genes, it is evident that the axonal neurop-
athy was the commonest type seen in patients with mitochondrial DNA point muta-
tions and demyelinating neuropathy in patients with SURF1. Patients in the POLG1 
group had both axonal and demyelinating neuropathy. 
All patients with SURF1 mutations in the current study clinically had Leighs 
phenotype with demyelinating pattern on electrophysiology. There are few reports 
on the nerve conduction studies and detailed morphological observations in Leighs 
syndrome.19 In four unrelated children with Leighs syndrome and cytochrome c 
oxidase (COX) deficiency, sural nerve biopsy revealed loss of myelinated and unmy-
elinated axons along with evidence of primary demyelination and remyelination.20 It 
has also been noted that the prevalence of peripheral neuropathy is more in COX 
deficient Leigh syndrome patients compared to children with Leighs syndrome with 
pyruvate dehydrogenase (PDH) deficiency or m.8993T>C mutations.21 Peripheral 
neuropathy has been reported in Leigh syndrome patients with COX deficiency and 
SURF1 mutation.22,23 In the report by Santoro et al, ultrastructural examination re-
vealed large number of mitochondria with enlarged and rounded cristae in Schwann 
cells.23 SURF1 mutations have also been implicated in the etiology of demyelinating 
CMT disease too.24 In a multicentric study on patients with SURF1 deficiency, of the 
patients who underwent nerve conduction studies, 81% had peripheral neuropa-
thy.25 While demyelinating neuropathy was seen in seven, axonal neuropathy was 
seen only in two. The pathogenetic mechanism underlying the propensity for 
SURF1 mutation to cause a demyelinating neuropathy is not clear. 
Mutations in POLG1, a nuclear gene encoding the catalytic subunit of mitochon-
drial polymerase gamma leads to various neurological phenotypes which often in-
cludes peripheral neuropathy.26 Sensory neuronopathy is a common feature in pa-
tients with POLG1 related disorders and in some patients may be a presenting fea-
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ture.27 Two of the three patients with POLG1 mutations in the present study pre-
sented with a sensory ataxic neuropathy. A clinical phenotype dominated by neu-
ronopathy leading to severe sensory ataxia and dysarthria and ophthalmoparesis in 
patients with SANDO is reported in literature and was also noted in the present 
study.28 Neuropathological studies have demonstrated severe respiratory chain defi-
ciency and neuronal loss in dorsal root ganglia due to mitochondrial depletion and 
accumulation of mtDNA.27 Nerve biopsy reports in POLG1 related disorder are lim-
ited and have shown myelinated fiber loss, clusters of regenerating fibers, myelin 
modifications and onion bulb like formations.27 
Peripheral neuropathies resulting from point mutations in mtDNA are common, 
but form a non-prominent feature of the phenotype. In the present study peripheral 
neuropathy was seen in patients with m.3243A>G, m.8334A>G, m.8363A>G, 
m.11788G>A and m.9185A>G and m.13514A>G mutations as reported in literature. 
The common type of neuropathy associated with m.3243A>G mutation is axonal, 
but rarely demyelinating neuropathy is also reported.9,29 In contrast to the MELAS 
cohort, axonal neuropathy was noted in all four patients with m.8334A>G muta-
tions. In MERRF, peripheral neuropathy either affects only the sensory nerves or 
both motor and sensory modalities and is usually slowly progressive.30 Demyelinat-
ing disease of both central and peripheral nervous system have been reported in a 
patient with m.8334A>G mutation.31In a large cohort of patients with m.8334A>G 
mutation, peripheral neuropathy was noted in 14.7% of the patients.32 The patient 
with m.8363A>G mutation in our study had an ataxia neuropathy phenotype as 
reported by Pineda et al. 33 In the latter study, authors  have suggested that a mito-
chondrial disease should be considered in the differential diagnosis of children with 
heredo-ataxic syndrome and peripheral neuropathy of unknown origin. 
Maternally inherited mutations in MTATP6 gene cause a range of phenotypes of 
varying severity.34 Isolated neuropathy associated with m.9185T>C or m.8993T>C 
mutations is recognized.10,11 In the current study, only one patient had m.9185A>G 
mutation in MTATP6. The clinical phenotype was consistent with NARP syndrome 
and nerve conduction showed a demyelinating sensory motor neuropathy. The fre-
quency of m.9185A>G mutation in a large cohort of genetically undiagnosed CMT2 
patients was 1.1%.35 Even though the pattern of neuropathy in most reported pa-
tients with MTATP mutation is sensorimotor axonal type, isolated demyelinating 
neuropathy has also been reported.10 
Demyelinating neuropathy has been earlier described in LHON patients with 
m.11778 G>A mutation.36 In contrast, our patient with LHON plus syndrome and 
m.11778G>A mutation had sensorimotor axonal neuropathy. It has been suggested 
that demyelinating neuropathy should be considered part of the clinical spectrum of 
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LHON patients secondary to m.11778G>A mutations.36 It is interesting to note that 
our patient presented with a spastic dystonic syndrome and optic atrophy. Spinal 
cord degeneration in LHON has been reported earlier.37  
Other well recognized mitochondrial syndromes associated with peripheral neu-
ropathy which did not figure out in this study include mitochondrial neurogastroin-
testinal encephalopathy secondary to TYMPmutations, mutations in C10Orf2 en-
coding twinkle helicase and the mitochondrial CMT disease secondary to MFN2 and 
GDAP mutations.6 Ataxic neuropathy and SANDO have been described in associa-
tion with mutations in C10Orf2 encoding twinkle helicase.38 Screening of MFN2 and 
GDAP1 mutations in the entire cohort would have yielded more patients with these 
disorders and may be possible in the future as the facilities are expanding. It is 
acknowledged that the small number of patients with each individual genes is a 
limitation of the study. Nevertheless, this study brings out the phenotypic spectrum 
and electrophysiological abnormalities in a cohort of patients with mitochondrial 
disorders. Peripheral neuropathy especially of the sensorimotor axonal type as part 
of multisystem involvement may point to a mitochondrial etiology. Specific pattern 
of neuropathy along with other clinical findings may direct genetic testing for muta-
tions in specific genes. For instance, the presence of demyelinating neuropathy in 
Leighs syndrome may predict mutations in SURF1 gene, while sensory ataxic neu-
ropathy in a patient with other mitochondrial signatures may point towards POLG1 
related disorder. It is likely that more and more phenotypes of mitochondrial neu-
ropathy will be unravelled in the near future as newer technologies such as whole 
exome sequencing are applied to patients with peripheral neuropathy. 
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Abstract:  
Objectives: Bilateral hypertrophic olivary degeneration on brain magnetic resonance 
imaging has been reported in a few metabolic, genetic and neurodegenerative disor-
ders including mitochondrial disorders. In this report we sought to analyse whether 
bilateral symmetrical inferior olivary nucleus hypertrophy is specifically associated 
with mitochondrial disorders in children. 
Patients and Methods: This retrospective study included 125 children [Mean age -7.6 
± 5 yrs; M:F - 2.6:1] diagnosed with various metabolic and genetic disorders during a 
period of 2005-2012. The routine MRI sequences (TI weighted images, T2 weighted 
images and Fluid attenuated inversion recovery sequences) were analyzed for the 
presence of bilateral symmetrical olivary hypertrophy and central tegmental tract or 
dentate nuclei signal changes.  The other imaging findings and the final diagnoses 
were noted. 
Results: The cohort included patients with Mitochondrial disease (n=50), Wilson 
disease (n=40), Glutaric aciduria Type 1 (n=14), Maple syrup urine disease (n=13), 
Giant axonal neuropathy (n=5) and L-2 Hydroxy Glutaric aciduria (n=3). Bilateral 
inferior olivary nucleus hypertrophy was noted in 10 patients. All belonged to the 
mitochondrial disease group and had a diagnosis of Leigh and Leigh like syndrome. 
This occurred both in association with and independent of central tegmental tract 
and dentate nucleus hypertrophy. 
Conclusions: Bilateral hypertrophic olivary degeneration on magnetic resonance 
imaging is relatively often, but not routinely seen in children with Leigh and Leigh 
like syndrome. The findings should prompt the physician to carry out investigations 
to rule out a mitochondrial disorder. 
Advances in knowledge: Bilateral inferior olivary nucleus hypertrophy on magnetic 
resonance imaging is more commonly seen in children with leigh and leigh like 
syndrome, compared to other metabolic disorders. Early detection of this finding by 
radiologists and physicians may facilitate targeted metabolic testing in these chil-
dren.  
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1. Introduction: 
Hypertrophic olivary degeneration is a rare form of neuronal degeneration that 
results from disruption of the afferent fibers to the inferior olive within the dentate-
rubro-olivary tract otherwise known as triangle of Guillain-Mollaret.1 The first de-
scription of the enlargement of inferior olivary nucleus is by Oppenheim, in his 
post-mortem study.2 Since then a number of reports describing the clinical, histo-
pathological and magnetic resonance imaging findings have been published.3-7 
A variety of insults can lead to hypertrophic olivary degeneration of which most 
commonly reported are haemorrhage, infarct, trauma, surgery or tumour.8-13 The 
lesions result in loss of synaptic input to the inferior olivary nucleus and results in 
trans-synaptic neuronal degeneration.5 This has been considered as a unique mor-
phologic form of trans-synaptic degeneration because it is associated with hypertro-
phy rather than atrophy, of the affected structure.14  Histopathologically it is charac-
terised by neuronal enlargement of the olivary neurons, neuronal loss, vacuolation, 
demyelination and a marked astrogliosis.3,5,7 It is most often unilateral when it is 
secondary to structural lesion though bilateral changes are recognized 8,15 and may 
occur if both the superior cerebellar peduncle and the central tegmental tracts are 
involved.16,17 
Bilateral hypertrophic olivary degeneration has been reported in a few metabol-
ic, genetic, neurodegenerative and toxic disorders.18-24 It has been previously noted 
that the presence of hypertrophic olivary degeneration in the appropriate clinical 
setting should alert the clinician to the possibility of a mitochondrial disorder.20 In 
addition, the reports on the hypertrophic olivary degeneration in paediatric patients 
are limited.15,25-27 In this report we sought to analyse whether bilateral symmetrical 
ION hypertrophy is specifically associated with mitochondrial disorders in children. 
2. Patients and Methods:  
This retrospective study was carried out in the departments of neurology and neu-
roimaging and interventional neuroradiology at a university hospital, in South India. 
The study included 125 children [Mean age - 7.6 ± 5 yrs; M:F - 2.6:1] diagnosed with 
various metabolic and genetic disorders seen over  a period of 8 years (2005-2012). 
The cohort included three groups: 1. Twenty five children with Leigh and Leigh like 
syndrome [Mean age: 3.4 ± 2.6 yrs; M:F= 3:1]; 2. Twenty five children with mito-
chondrial disorders other than Leigh syndrome [Mean age: 8.8 ± 4.3 years]; 3. Seven-
ty five  children with other metabolic and genetic disorders which included Wilson 
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disease, Glutaric Aciduria Type1, Maple syrup urine disease, Giant axonal Neuropa-
thy and L-2 Hydroxy Glutaric aciduria. These seventy-five patients were selected 
from a database of children with metabolic disorders with an MRI available for re-
view. The inclusion of the these disorders was based on their propensity to involve 
the brainstem, central tegmental tracts or dentate nuclei on magnetic resonance 
imaging. This inclusion criteria was adopted to assess the presence of hypertrophic 
olivary degeneration in relation to the other components of the Guillain-Mollaret 
Triangle. Metabolic disorders without propensity to involve the brainstem or den-
tate nuclei were excluded. 
All patients with Leighs and Leigh like syndrome fulfilled the criteria by Rah-
man et al.,29 All underwent sequencing of the complete mitochondrial genome and 
the SURF1, one of the most common nuclear genes consistently associated with 
Leigh syndrome and cytochrome c oxidase deficiency. Four of them showed muta-
tions in SURF1. Three of these patients had cytochrome c oxidase deficiency in both 
histopathology and respiratory chain enzyme assays. The fourth patient did not have 
the testing for cytochrome c oxidase deficiency. The clinical and imaging findings in 
these four patients have already been described.30,31  The diagnosis of  other mito-
chondrial disorders were based on the modified Walker criteria for definite mito-
chondrial disorders by Bernier et al.,29 All of them had  clinical features consistent 
with a mitochondrial encephalomyopathy along with one or more of the following: 
1. Histopathological evidence of ragged red fibers or cytochrome c oxidase deficien-
cy; 2. Residual respiratory chain complex activity of less than 20% in muscle tissue 
compared to controls using citrate synthase as the reference enzyme; 3. known 
pathogenic mutations in the mitochondrial or nuclear genome.  This group included 
Polymerase Gamma (POLG) related disorder (n=4); MELAS syndrome (Mitochon-
drial Encephalomyopathy Lactic acidosis and Stroke like episodes- n=3); Lebers he-
reditary optic neuropathy (LHON) plus syndrome (n=1); MERRF syndrome (Myo-
clonic epilepsy with ragged red fibers- n=2) and other non- syndromic mitochondri-
al disorders (n=15). 
The details of the non mitochondrial group and the criteria for diagnosis in each 
disease group are as follows. Wilsons disease [n=40; Age Range: 6-16 yrs; M: F = 
1.2:1]- presence of Kayser –Fleischer ring by slit lamp, low serum ceruloplasmin, 
and raised 24 hour urinary copper; Type 1 Glutaric aciduria [n=14; Age range: 8mo-
6yrs; M: F= 1:1.3]-Characteristic clinical and imaging findings with presence of ele-
vated glutaryl carnitine on tandem mass spectrometry and /or urinary organic acid 
estimation.]; Maple syrup urine disease [n=13, Age range: 14 days – 11 years;  M: F= 
1:1.6] – confirmed by elevated branched chain amino acids on tandem mass spec-
trometry of dried blood spots and /or high performance liquid chromatography ;  
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Giant axonal neuropathy [n=5, Age range: 4-6 yrs; M: F= 4:1] -Presence of character-
istic morphological features of frizzly hair, peripheral neuropathy, and cerebellar 
signs along with giant axons on sural nerve biopsy. L2 hydroxy glutaric aciduria 
[n=3, Age range 16 -18 yrs, M:F = 2:1]- Elevated L2-hydroxy glutaric acid on urinary 
organic acid estimation. 
Magnetic resonance imaging was done after obtaining informed consent on Sie-
mens-Magnetom vision 1.5 Tesla MRI scanner (Erlangen, Germany) using standard 
procedures and protocols. Spin echo T1-weighted (repetition time [TR]= 650ms, 
echo time [TE]=14ms) images in axial and sagittal plane were taken ,with acquisition 
time of 2.5mt, matrix of 256x256 and a 230 mm field of view. T2-weighted images 
(TR = 4000 ms, TE = 120 ms) were acquired in axial and coronal planes. Fluid atten-
uated and inversion recovery (FLAIR) sequences were obtained in axial plane (TR = 
9000 ms, TE = 119 ms, inversion time = 2457 ms). The slice thickness was 5 mm. 
MRI sequences included T1W (with and without contrast), T2W and FLAIR in all. 
For those who underwent imaging in the Achieva 3 T MR imaging scanner 
(Philips Medical Systems, Netherlands), MRI scans were obtained by first perform-
ing a three-plane localizer scan, followed by an axial turbo spin-echo T2-weighted 
scan (TR/TE 3270/80 ms, flip angle 90degrees, FOV 250x 250 mm, ACQ voxel size 
0.89/1.21/5.00 mm, slice thickness/gap 5mm/1mm); T2 weighted FLAIR sense ( 
TR/TE 11000/120MS, flip angle 90degrees, FOV 250 x 250 mm, ACQ voxel size 
0.96/1.79/5.00 mm, slice thickness/gap 5mm/1mm).3D MPRAGE volumetric acquisi-
tion of the whole brain were acquired (TR/TE= 8.3/3.8 ms, sense factor=1.5, flip 
angle = 8 degrees, FOV=256, ACQ voxel size 1/1/1 mm). 
Findings on magnetic resonance imaging at the level of the olives were evaluated 
by two neurologists (ABT, PSB) and one neuroradiologist (HRA) with emphasis on 
the lateral placement, signal intensity, and hypertrophy of the lesions. If the oval 
shape of the olive become round with an apparent bulge, it was classified as hyper-
trophic.5 Additional features noted include the presence of hyper intensity of den-
tate nuclei, central tegmental tract and midbrain signal changes. The clinicians were 
not blinded to the diagnoses. The neuroradiologists reviewed the images inde-
pendently. A consensus was reached when there was a disagreement. 
3. Results:   
Of the 125 magnetic resonance imaging scans reviewed ten showed bilateral hyper-
trophic olivary degeneration. The inferior olivary nuclei were demonstrated as areas 
of high signal intensity on the T2 weighted and Fluid attenuated inversion recovery 
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(FLAIR) images in all the patients (Fig1). The shape of the olivary nucleus was round 
in all patients with loss of serrated appearance (Fig.1). On T1 weighted images the 
nucleus appeared isointense. A focal enhancement of the hypertrophic olivary nu-
clei was noted in one patient. All the patients with the inferior olivary hypertrophy 
belonged to the mitochondrial disease group and had a diagnosis of Leigh and Leigh 
like syndrome as defined by the criteria by Rahman et al.,28 The phenotypic features 
of these ten patients are shown in Table 1. Of the 25 patients who fulfilled the diag-
nostic criteria for Leigh syndrome, there were five patients with Leigh syndrome 
secondary to SURF1 mutation (Four patients with mutation positive and the sibling 
of one of the patient with mutation). All the five showed inferior olivary hypertro-
phy. Two other patients with cytochrome c oxidase deficiency, in the non-
syndromic mitochondrial group, but without a leighs phenotype did not show evi-
dence of hypertrophic olivary degeneration. Dentate nucleus hyper intensity was 
noted in five patients, lesions of the pontine tegmentum in two and central tegmen-
tal tract in four patients in this group. The olivary degeneration occurred with or 
without central tegmental tract and dentate nucleus hyper intensity [Fig.2]. The 
duration of illness in these patients at the time of magnetic resonance imaging 
ranged from one month to five years. In two patients with leigh like syndrome (Pa-
tient 9 &10), the olivary degeneration was noted on follow up images.  
In the Wilson disease group though ten patients had bilateral central tegmental 
tract involvement neither dentate nucleus hyper intensity nor inferior olivary hy-
pertrophy was present. Out of the 14 patients with type 1 Glutaric aciduria, nine had 
both central tegmental tract and dentate nucleus hyperintensities and none had 
hypertrophic olivary degeneration. In the giant axonal neuropathy three patients 
had dentate nucleus hyper intensity but none had central tegmental tract or olivary 
nucleus hypertrophy. In Maple syrup urine disease there was extensive involvement 
of the brainstem, cerebellum and dentate nuclei in all patients associated with diffu-
sion restriction. The medullary signal changes were involving both the dorsal and 
ventral medulla in some patients and the inferior olivary nucleus could not be clear-
ly visible. All patients with L-2 hydroxy glutaric aciduria had dentate nucleus hyper 
intensity but did not have central tegmental tract or olivary nucleus involvement.
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Figure 1. MRI brain fluid-attenuated and inversion–recovery axial views in different patients showing 
bilateral symmetrical signal changes in the inferior olivary nucleus. The margins of the nuclei are round 
and an apparent bulge (indicated by arrows) is noted. 
Figure 2. MRI scan of the brain in Patient 6. Fluid-attenuated inversion–recovery coronal and axial views 
showing bilateral symmetrical signal changes in dentate nuclei and inferior olivary hypertrophy (arrows) 
in this patient with cytochrome c oxidase deficiency and SURF1 mutation. 
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Discussion:  
This report describes the occurrence of hypertrophic olivary degeneration in a co-
hort of children with metabolic and genetic disorders. Our results suggest that this 
finding is most often associated with a mitochondrial disorder in children especially 
Leigh and Leigh like syndrome. Reports on bilateral hypertrophic olivary degenera-
tion resulting from genetic or metabolic disorders are rare. There are a number of 
reports describing hypertrophy of the olivary nucleus in mitochondrial disorders.19,20  
In a series of 26 children with polymerase gamma (POLG) related disorders bilateral 
hypertrophic olivary degeneration was observed in two patients and one of them 
had the clinical correlate of palatal myoclonus.19 It has also been described in Leigh 
syndrome secondary to SURF1 mutations.20  Review of the previously published 
magnetic resonance imaging studies in Leigh syndrome patients identified few re-
ports describing the involvement of the olives.28,32-34  It is noteworthy that all but 
one of the patients in these reports had Cytochrome c oxidase deficiency and SURF1 
mutations. The only exception was the patient with Leigh syndrome secondary to 
pyruvate dehydrogenase deficiency in the report by Medina et al.34 In this cohort, 
the hypertrophic olivary degeneration was seen in 40% of the children with Leighs 
and Leigh like syndrome and was not observed in other groups of metabolic disor-
ders. Though all patients with SURF1 mutation had hypertrophic degeneration, it 
was also seen in patients without the mutations, indicating that it is not exclusively 
seen in this subtype of children with Leigh syndrome. In addition two children with 
cytochrome c deficiency but without the Leigh syndrome phenotype did not show 
this finding. Nevertheless, analysis of the whole cohort of children with metabolic 
and genetic disorders indicates that this imaging observation is more commonly seen 
in children with Leigh and Leigh like syndrome. None of the patients with mutation 
positive POLG related disorder had inferior olivary hypertrophy in the present 
study. 
The bilateral inferior olivary hypertrophy seen in these children was not always 
associated with lesions of central tegmental tract or dentate nucleus suggesting an 
independent involvement of these nuclei in mitochondrial disorders. Neuropatho-
logical studies in mitochondrial diseases have shown that the olivary cerebellar sys-
tem is involved in a variety of mitochondrial disorders and plays an important role 
in the pathogenesis of ataxia seen in these patients.35 This particular study involved 
14 patients with definite mitochondrial diseases. There was variable neuronal loss in 
the dentate nuclei, inferior olives and purkinje cell system in these patients along 
with severe deficiency of respiratory chain enzymes in the remaining neurons. This 
shows that the inferior olivary nucleus is vulnerable to energy deficiency in patients 
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with mitochondrial disorders. The magnetic resonance imaging correlates of these 
patients are not provided in the report. Nevertheless it will be interesting to see if 
the microscopic changes in these patients are associated with imaging changes. 
Neuropathological studies in Leigh syndrome patients also have highlighted the 
occurrence of neuronal loss and vacuolar degeneration in inferior olives.35-37 The 
finding was most often noted in those patients who presented after the first year of 
life. This was attributed to the delayed maturation of the olivary –cerebellar system 
in children which occurs most often after infancy. The fact that hypertrophic oli-
vary degeneration is present even in presence of neuronal loss is explained by patho-
logical studies. The characteristic features that define hypertrophic olivary degener-
ation are overall enlargement of the olive in which convolutions are obscured.4 The 
neurons appear large and deformed and show marked astroglial reaction. Goulier 
and Blackwood had demonstrated that there is enlargement of both grey and white 
matter and the increased width of the grey lamina is in part due to hypertrophy of 
the nerve cell bodies and processes.3 They suggest that the eventual atrophy of the 
abnormal neurons is not accompanied by shrinkage of the glial mass so that the 
enlarged outline of the olive persists. This may be the explanation of hypertrophied 
olives even when there is neuronal loss in mitochondrial disorders. 
The clinical correlates of the hypertrophic olivary degeneration in children and 
in patients with mitochondrial disorders have been variable. It was associated with 
palatal myoclonus in one of the two POLG related disorder patients described by 
Tzoulis et al.,19 In the report by kinghorn et al, a generalized tremor was noted in 
the child with SURF1 mutations but was not present in the other two patients.18 In 
the report of Sanverdi et al none of the four children with hypertrophic olivary 
degeneration had palatal myoclonus.14 In the current study two patients had a gen-
eralised tremor associated with ocular bobbing. In two patients the clinical picture 
was dominated by generalised dystonia refractory to treatment with most of the 
anti-dystonia medications. It is difficult to comment about this finding in other pa-
tients, because it was not systematically looked for in most of the young patients. 
The triangle of nerve tracts involved in the genesis of hypertrophic olivary de-
generation is referred to the triangle of Guillain and Mollaret.1 These dentato-rubro-
olivary fibers connect the ipsilateral red nucleus and inferior olive with the contra-
lateral dentate nucleus. Efferent fibers from the dentate nucleus course through the 
superior cerebellar peduncle, decussate in the brachium conjunctivum and then 
connect to the contralateral red nucleus. The efferent fibers from the red nucleus are 
connected to the olive through the central tegmental tract.  The inferior olive is 
then connected to the contralateral cerebellum via the inferior cerebellar peduncle 
thus forming a triangle. It is pointed out that deafferentiating the inferior olivary 
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nucleus is the key factor and typically lesions disrupting the superior cerebellar 
peduncle or central tegmental tract leads to hypertrophic olivary degeneration. The 
localisation of the olivary degeneration   depends on the site of the lesion. Lesions of 
the red nucleus or central tegmental tract causes the hypertrophy of the ipsilateral 
nucleus and alternatively the lesions of the superior cerebellar peduncle or dentate 
nucleus causes hypertrophic olivary degeneration on the contra lateral side.9,12 Bilat-
eral hypertrophy occurs when the lesion involves brachium conjunctivum, or inter-
rupts both the central tegmental tract and superior cerebellar peduncle.16  
In the cohort of children in the present study the hypertrophic olivary degenera-
tion was associated with lesions of the central tegmental tract and dentate nucleus in 
most of the patients, but also occurred independently. In patients with Wilson dis-
ease, though ten patients had involvement of the central tegmental tract, hypertro-
phy of the inferior olivary nucleus was not observed. Diffusion tensor imaging (DTI) 
studies in patients with inferior olivary nucleus hypertrophy have demonstrated 
signal changes in all anatomical components of the Guillain Mollaret triangle even 
when conventional magnetic resonance imaging did not show any signs of involve-
ment in the other components of Guillain Mollaret triangle 39,40. It was also shown 
that the DTI parameters can reflect the spatiotemporal evolution of transneuronal 
degeneration associated with HOD in a manner consistent with the known patho-
logic stages of HOD 26. In addition, susceptibility weighted imaging has been utilized 
to study the red nucleus degeneration and atrophy in children with hypertrophic 
olivary degeneration (HOD) after posterior fossa tumor resection.27 This indicates 
that quantitative imaging studies may better define the extent of the lesions in these 
patients and may be a future area of research. 
In conclusion, this study on 125 children with various metabolic and genetic dis-
orders suggests that bilateral hypertrophic olivary degeneration is relatively often, 
but not routinely seen in children with Leigh and Leigh like syndrome. Neverthe-
less, when compared to other metabolic disorders this finding was more commonly 
seen in children with Leigh and Leigh like syndrome. This occurred both inde-
pendently and in association with central tegmental tract and dentate nuclei in-
volvement. The findings suggest that bilateral inferior olivary hypertrophy should 
prompt the physician to carry out investigations to rule out a mitochondrial disor-
der.  
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Abstract 
Objectives: Studies exploring the outcome of epilepsy in patients with mitochondrial 
disorders are limited. This study examined the outcome of epilepsy in patients with 
mitochondrial disorders and its relation with the clinical phenotype, genotype and 
magnetic resonance imaging findings. Patients and Methods: The cohort was derived 
from the database of 67 patients with definite genetic diagnosis of mitochondrial 
disorders evaluated over a period of 11 years (2006-2016). Among this, 27 had epi-
lepsy and were included in final analysis. Data were analyzed with special reference 
to clinical phenotypes, genotypes, epilepsy characteristics, EEG findings, anti epilep-
tic drugs used, therapeutic response, and magnetic resonance imaging findings. Pa-
tients were divided into three groups according to the seizure frequency at the time 
of last follow up: Group I- Seizure free; Group II- Infrequent seizures; Group III- 
uncontrolled seizures. For each group the clinical phenotype, genotype, magnetic 
resonance imaging and duration of epilepsy were compared. Results: The pheno-
types & genotypes included Mitochondrial Encephalopathy Lactic Acidosis and 
Stroke like episodes (MELAS), m.3243A>G mutation (n=10), Myoclonic Epilepsy 
Ragged Red Fiber syndrome (MERRF), m.8344A>G mutation (n=4), Chronic Pro-
gressive External Ophthalmoplegia plus & POLG1 mutation (CPEO, n=6), episodic 
neuroregression due to nuclear mutations (n=6; NDUFV1 (n=3), NDUFA1, NDUFS2, 
MPV17-1 one each), and one patient with infantile basal ganglia stroke syndrome, 
mineralizing angiopathy & MT-ND5 mutations.  Seven patients (25.9%) were sei-
zure free, seven had infrequent seizures (25.9%), while thirteen (48.1%) had fre-
quent uncontrolled seizures at last follow up. Majority of the subjects in Group I 
(seizure free) had episodic neuroregression & leukoencephalopathy due to various 
nuclear mutations (85.7%) ;  Group II- CPEO, POLG1 variation and  a normal MRI 
(71%) and in group III - MELAS, m.3243A>G mutation and stroke like lesions on 
MRI (62%). 
Conclusions: A fair correlation exists between the outcome of epilepsy, clinical phe-
notypes, genotypes and magnetic resonance imaging findings in patients with mito-
chondrial disorders. The recognition of these patterns is important clinically because 
of the therapeutic and prognostic implications. 
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1. Introduction 
Mitochondria are important subcellular organelles, which are central for various 
cellular processes that include ATP production, intracellular Ca signaling, and gen-
eration of reactive oxygen species.1 Physiological experiments have provided robust 
evidence that there is a fine-tuned coupling between neuronal activity and mito-
chondrial function, and mitochondria are of central importance for the complex 
behavior of neurons.1 Epilepsy is part of the clinical presentation in a broad variety 
of mitochondrial disorders.2,3 The exact prevalence of mitochondrial epilepsy is not 
known, but seizures have been reported to occur in 35 to 60% of individuals with 
biochemically confirmed mitochondrial disease.4-7 Epilepsy may be the presenting 
feature of mitochondrial disorders but is often a part of multisystem clinical presen-
tation.5-8 Mitochondrial epilepsy occurs in early-onset as well as late-onset syndrom-
ic and nonsyndromic mitochondrial disorders.3 More importantly, clinical diagnosis 
of mitochondrial epilepsy has both prognostic and therapeutic implications. Early 
recognition enables the physician to choose appropriate drugs and avoid mitochon-
drial toxins thus saving the patient from life threatening complications.9 Prompt and 
aggressive seizure management may play a role in modifying the epileptogenic pro-
cess and improving survival.10  
The factors determining the course, prognosis and therapeutic response of epilep-
sy in patients with mitochondrial disorders are largely unknown. This study exam-
ined the pattern of seizure control and factors determining the outcome in patients 
with mitochondrial epilepsy. Specifically the study looked at the correlation be-
tween phenotype, genotype, MRI findings and duration of epilepsy with outcome. 
2. Patients and methods:  
The cohort was derived from the database of patients who underwent evaluation for 
mitochondrial etiology over a period of 10 years (2006-2016). Patients were recruit-
ed into the study when they satisfied the clinical criteria of mitochondrial disorder 
as suggested by Bernier et al11 and a comprehensive evaluation, including serum 
lactate, muscle histopathology, respiratory chain complex assays, brain magnetic 
resonance imaging, nerve conduction studies, electroencephalography (EEG) and 
evoked potential studies tailored to the clinical phenotype suggested a probable 
diagnosis of mitochondrial disorder. Standard definitions were used for phenotypic 
characterization of classical mitochondrial syndromes.12   
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Genetic evaluation: All patients with known pathogenic variations in mtDNA 
were diagnosed by complete mitochondrial genome sequencing. The patients with 
nuclear mutations were identified using targeted exome sequencing. The gene panel 
consisted of 6440 genes inclusive of all nuclear-encoded mitochondrial genes that 
are strongly associated with a disease on online Mendelian inheritance in man 
(OMIM). All variants identified by exome sequencing were verified by Sanger se-
quencing and further validated by segregation analysis in first-degree relatives. 
Detailed observations of magnetic resonance imaging findings and peripheral 
neuropathy in part of this cohort have already been published.12,13 There were 67 
patients with a definite genetic diagnosis of mitochondrial disorders. Among this, 27 
(Age range: 8 months-45 years, M: F- 1.8:1) had epilepsy and were included in final 
analysis. The phenotypic features, including characteristics of epilepsy, electroen-
cephalographic findings, details of the antiepileptic drugs received and the response, 
magnetic resonance imaging findings and genetic diagnoses were reviewed and cor-
related. Epilepsy was classified according to the 2017 revised International League 
against Epilepsy (ILAE) guidelines.14,15 The outcomes were collected prospectively by 
the clinical team (ABT, SS, PSB, MN,) and designated in relation to the total dura-
tion of the illness at last follow up. The outcomes were classified into three groups as 
defined by Kuzmanovski et al.,16 Group I- seizure free patients at the time of last 
follow up. Seizure freedom was defined as a period without seizures for a minimum 
of 12 months.17 Group II- Patients with intermittent seizures if they presented with 
only auras or infrequent non-disabling seizures such as eyelid myoclonia. Group III- 
uncontrolled seizures or drug resistant epilepsy failure of adequate trials of two tol-
erated, appropriately chosen and used antiepileptic drug schedules (whether as 
monotherapies or in combination) to achieve sustained seizure freedom. The insti-
tute ethics committee approved the study and all subjects gave written informed 
consent. 
Statistical Analysis: The data are presented as means, standard deviations or 
number and percentages. Phenotype and MRI finding were cross-tabulated with the 
three groups. Due to the small number of subjects Chi-square test was not attempt-
ed. Duration of illness was compared among the groups using Kruskal Wallis Test, as 
numbers of subjects in the groups were small. It indicated that the durations do not 
differ significantly among the groups 
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3. Results 
There were 27 patients (Age range: 7 months – 41 years, M: F- 2:1). Majority be-
longed to the pediatric age group (n=21, Age: 8.1±5.03 years). Mean age in adults 
(n=6) was 38.6 ±6.3 years. The phenotypes, genotypes, MRI and EEG findings and 
outcome in the whole group is provided in Table 1.  
3.1. Clinical Phenotypes:  
The clinical phenotypes included Mitochondrial Encephalopathy Lactic Acidosis 
and Stroke like episodes (MELAS, n=10), Myoclonic Epilepsy Ragged Red Fiber 
syndrome (MERRF, n=4), Chronic Progressive External Ophthalmoplegia plus 
(CPEO, n=6), Mitochondrial leukoencephalopathy (n=6), and one patient with in-
fantile basal ganglia stroke syndrome due to mineralizing angiopathy.  
3.2. Genetic findings:  
The genotypes of the patients included mutations in mitochondrial DNA (n=15); 
POLG1 (n=6); NDUFV1 (n=3), NDUFA1, NDUFS1, MPV17 one each  
3.3. Magnetic resonance imaging findings:  
MRI findings included Stroke- like- lesions (SLL: n=9, 33.3%, Fig.1, 2 &3); Leu-
koencephalopathy (LE: n=6, 22.2%, Fig.4); Cerebral/ cerebellar / brainstem atrophy 
(n=6, 22.2%); Normal MRI (n=5, 18.5%); Asymmetric basal ganglia infarcts due to 
mineralizing angiopathy (n=1, 3.7%).  
3.4. Epilepsy phenotypes & EEG findings:  
Seizure types included Focal onset aware seizures (n=17, 62.9%) focal onset impaired 
awareness seizures (n=12, 44.4%), focal to bilateral tonic clonic seizures 
(n=15,55.5%), generalized onset tonic clonic seizures (n=12, 44.4%), generalized 
onset myoclonic seizures (n=4, 14.8%), photosensitive eyelid myoclonia 
(n=5,18.5%). status epilepticus occurred in 11 (40.7%) and epilepsia partialis contin-
ua in eight (29.6%). Electroencephalogram findings included focal or multifocal 
spikes or sharp waves in 12 (44.4%), generalized polyspikes in 7 (25.9%) and normal 
sleep record in 5 (18.5%). 
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3.5. Treatment:  
All patients received weight appropriate dosages of anti-epileptic drugs along with 
mitochondrial cocktail. The most commonly used drugs were levetiracetam (n=21, 
77.7%), clobazam (n=16, 59.2%) and phenytoin (n=12, 44.4%). Other drugs used 
included carbamazepine, n=5; lamotrigine, n=4, topiramate and zonizamide one 
each. Prior to the diagnosis, three patients received sodium valproate. After the 
diagnosis it was replaced by levetiracetam and lamotrigine. The youngest child with 
m.3243A>G mutation had a myo-cerebro-hepatopathy syndrome precipitated by use 
of sodium valproate and propofol anesthesia for magnetic resonance imaging study.  
3.6. Outcome of Epilepsy:  
At the time of last follow up there were seven patients in the seizure free group 
(Group I: n=7, 25.9%), seven in the infrequent seizure group (Group II: n=7,25.9%), 
and thirteen in the frequent uncontrolled seizure group (Group III: n=13, 48.1%). 
Data on the outcome of epilepsy in relation to clinical phenotype, genotype and 
MRI findings are provided in Table 2. 
3.6.1. Group I (Seizure free group):  
Majority of the patients in this group presented with episodic or relapsing remitting 
neurological illness. Seizures were isolated and precipitated by febrile episodes. In 
some patients the relapse of the episodes were heralded by seizures. MRI in all 
showed features of mitochondrial leukoencephalopathy viz. multifocal confluent 
signal changes, diffusion restriction and contrast enhancement and lactate peak on 
MRS (Fig.4). Only cortical structure involved was bilateral hippocampi, which 
showed T2/FLAIR hyper intensities and diffusion restriction (Fig.4). The single pa-
tient in this group had the ND5 mutations. Seizures were infrequent and were well 
controlled on a single antiepileptic drug.  
3.6.2. Group II (Intermittent non disabling seizures):  
Majority of the patients in this group had CPEO, eyelid myoclonia, POLG1 mutation 
and abnormal MRI. Additional 2 patients had MELAS, m.3243A>G mutation who 
had only intermittent auras on follow up. 
3.6.3. Group III (Uncontrolled seizures):  
Majority of the subjects in this group had MELAS and m.3243A>G mutation. In six 
patients, epilepsy occurred during the stroke like episodes and corresponded to the 
side of the cortical lesion and focal epileptic activity corresponding to the side of 
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stroke like lesions [Fig 1a-d, Fig.2 a&b]. Those children with an earlier age of onset 
and longer duration of symptoms had multiple small cortical lesions and they had 
seizures independent of the stroke-like episodes and multifocal epileptic activity on 
EEG [Fig 3a-c]. The other patients in this group included patients with MERRF 
syndrome, m.8344G>A mutations & cerebral atrophy. All had a course similar to 
neurodegenerative illness with progressive cognitive decline, refractory myoclonus 
and generalized tonic clonic seizures on follow up. One additional patient who had 
CPEO, POLG1 mutation and ataxia also had a progressive degenerative course with 
psychiatric manifestations, refractory seizures. 
3.7. Phenotypes, Genotypes and Outcome of epilepsy: 
It can be seen that majority of the subjects in group I (85.7 %) had neuroregression 
& other nuclear mutations, group II (71 %) had CPEO & POLG1 variation and in 
group III (62 %) MELAS & m.3243 A>G mutation.  Phenotype seems to be different 
among the groups, however, due to the small number of subjects this could not be 
tested using Chi-square test. 
Majority of the subjects in group I had leukoencephalopathy (85.7%), group II 
(71 %) normal MRI, and Group III (61.5 %) had stroke like lesions on MRI (61.5%). 
MRI findings seem to differ according to seizure control, however, due to the small 
number of subjects this could not be tested using Chi-square test. 
Duration of illness was compared among the groups using Kruskal Wallis Test, as 
numbers of subjects in the groups were small. It indicated that the duration of epi-
lepsy do not differ significantly among the groups. 
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Table 2: Comparison of Phenotypes, genotypes, MRI findings and duration of epilepsy in 
three outcome groups of patients with mitochondrial Epilepsy 
Parameters 
GROUPS 
Total 
Group I  
Seizure 
Free (n=7) 
Group II 
Infrequent 
seizures 
(n=7) 
Group III 
Uncontrolled 
(n=13) 
Number (%) 
Phenotype MELAS - 2 (28.6) 8 (61.5) 10 (37) 
MERRF - - 4 (30.8) 4 (30.8) 
Infantile BG stroke 1 (14.3) - - - 
CPEO/ Epilepsy - 5 (71.4) 1 (7.7) 6 (22.2) 
Episodic 
neuroregression 
6 (85.7) - - - 
Genotype m.3243 A>G - 2 (28.6) 8 (61.5) 10 (37) 
m.8344G>A - - 4 (30.8)  
m.13514 1 (14.3) - -  
POLG1 - 5 (71.4) 1 (7.7)  
Other Nuclear 
mutations 
6 (85.8) - - 6 (22.2) 
MRI SLL - 1 (14.3) 8 (61.5) 9 (33.3) 
Leukoencephalopathy 6 (85.7) - - 6 (22.2) 
Atrophy - 1 (14.3) 5 (38.5) 6 (22.2) 
Normal - 5 (71.4) - 5 (22.2) 
BG stroke & 
Mineralising 
angiopathy 
1 (14.3) - - 1 (3.7) 
Duration 
of epilepsy  
Mean ± SD 4.43 ± 2.64 4.71 ± 5.38 6.15 ± 4.54 2 – value 
(p-value) 
1.892 
(0.388) 
Median (Range) 4 (1 - 8) 2 (1-13) 4 (2-17) 
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Fig.1 MRI brain in a 17 year old boy with MELAS syndrome secondary to m.3243 A>G mutation. (a) 
Axial FLAIR images during a stroke like episode showing signal changes in the parieto-occipital region on 
(R) side (arrow) (b) EEG during the episode shows periodic lateralised epileptiform discharges (PLEDS) 
from (R) posterior leads corresponding to the stroke like lesion(arrows) (c) Axial FLAIR images during 
another episode shows a stroke like lesion on (L) temporal region (d) EEG during this time demonstrates 
an electrographic seizure from the same region (arrows) 
 
 
Fig.2 MRI brain in a 5 year old girl with m.3243 A>G mutation. (a) Axial T2WI shows bilateral symmet-
rical signal changes in caudate (b) putamen and (R) parieto-occipital region suggesting a MELAS-Leighs 
overlap syndrome. EEG during the episode shows rhythmic high amplitude delta waves with superim-
posed spikes from the (R) posterior leads. 
 
 
Fig.3 MRI brain in a 13 year old girl with m.3243 A>G mutation with an earlier onset and longer duration 
of symptoms. (a) FLAIR axial view shows blateral symmetrical basal ganglia hyperintensities (b) multiple 
small stroke like lesions. (c) EEG shows multifocal epileptiform discharges. 
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Fig.4 MRI brain in a 2 year old girl with homozygous NDUFV1 variation. (a) FLAIR axial view showing 
bilateral symmetrical signal changes in white matter with microcystic changes (arrows) (b) & (c) DWI 
and ADC maps demonstrates restricted diffusion in the involved white matter(arrows) (d) FLAIR axial (e) 
DWI (f) ADC maps showing signal changes and restricted diffusion in bilateral hippocampi (arrows). (g) 
MRS shows lactate peak (arrows) 
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Discussion 
Epilepsy is frequent in patients with mitochondrial diseases, with varied prevalence 
reported in different studies.4,18 In children with respiratory chain enzyme deficien-
cies, diverse epileptic phenotypes and syndromes have been described.5,7 In the pre-
sent series, which included both adults and children, seizures were noted in 41.7% 
of patients. In a cohort of adults with mitochondrial disorders diagnosed using the 
Walkers criteria and of different diagnostic certainty the prevalence was only 14%.19 
In a recent series on adults with genetically characterized mitochondrial disorders 
23.1% of the patients had seizures.20 The present studies and the previous studies 
show that seizures constitute an important central nervous system manifestation in 
both adults and children with mitochondrial disorders. The strength of the present 
study includes the correlation between outcome of epilepsy and three important 
attributes of mitochondrial disorders viz. clinical phenotype, genotype and MRI 
findings.  
Group I or the seizure free group consisted of children with episodic neuro-
regression and leukoencephalopathy on MRI. All patients with leukoencephalopa-
thy had complex I nuclear variations except in one patient who had the MPV17 
variations. Of the nuclear subunits causing complex I deficiency, epilepsy has been 
associated with mutations in NDUFV1, NDUFS4, NDUFS8, and NDUFA1.21, 22 Myo-
clonic epilepsy has also been reported in complex I assembly defects.23 Myoclonic 
seizures in nuclear-encoded complex I deficiency were apparently responsive to 
antiepileptic drugs compared to patients with POLG related disorders.23, 24 Complex I 
defects are more potent generators of epilepsy than defects affecting the other com-
plexes, perhaps because this complex is working close to its maximum in neurons.1 
There were no cortical involvement on routine imaging in this group, however two 
patients showed signal changes in the hippocampus with restricted diffusion. The 
role of mitochondrial dysfunction in hippocampus has been studied in relation to 
the refractory complex partial seizures.25 But the role of hippocampal dysfunction in 
mitochondrial epilepsy have not been studied so far and needs further exploration. 
Even though the genetic etiology was heterogeneous in this group a pattern of con-
vergence existed at the level of magnetic resonance imaging and epilepsy outcome in 
these children. 
Patients with intermittent seizures or non-disabling seizures had CPEO, ataxia 
and neuropathy. Epilepsy is a common manifestation in POLG related disease and 
cause significant morbidity and mortality.10 It has been shown that the earliest factor 
leading to cellular dysfunction in POLG related epilepsy is mitochondrial deple-
tion.26 This in turn leads to loss of mitochondrial respiratory chain complexes and 
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defective energy metabolism. These results in two distinct pathological process 
namely neuronal degeneration and acute neuronal necrosis related to epileptic sei-
zures.26 It is noteworthy that all patients in this group had the p.L304R variation 
located in the exonuclease domain of the POLG1. All of them presented after the 
age of five years with slowly progressive external ophthalmoplegia and developed 
seizures within 2-3 years of onset mainly characterized by photosensitive eyelid 
myoclonia and intermittent generalized onset tonic clonic seizures. In contrast to 
the present study, in a recent review on POLG- related epilepsy the most common 
variation reported was p.A467T in the catalytic subunit.27 Further it was noted that 
homozygous or compound heterozygous variants located in   exonuclease domain 
were very rare and associated with severe disease and early death. Long term follow 
up of the patients with p.L304R variation is needed to validate this observation. 
Even though the variations located in the linker domain are noted to have later age 
of onset and longer survival the patient with the p.W748S variation also had a severe 
clinical course in the present study. Probably phenotypic characterization and fol-
low up in a large number of patients are required to delineate the exact phenotype 
genotype correlations in POLG-related epilepsy. 
Majority of the patients in the uncontrolled group had clinical phenotype of 
MELAS, m.3243A>G mutations and stroke like lesions on MRI. The characteristic 
feature in this group included focal onset aware and impaired awareness seizure, 
focal to bilateral tonic clonic, epilepsia partialis continua and status epilepticus. The 
highest percentage of the status epilepticus patients were noted in this group com-
pared with all other groups. The m.3243A>G mutation is described as one of the ‘hot 
spots’ associated with epilepsy phenotypes.2 The occurrence of seizures is due to the 
dominant cortical involvement in patients with m.3243A>G mutations.28 This may 
be related to the mutation load in different tissues. A particularly high mutation load 
has been observed in cerebral vascular smooth muscle cells in patients with 
m.3243A>G mutation.29 The most important factor contributing to the pathogenesis 
of stroke like episodes is focal neuronal hyper excitability leading to epileptic sei-
zures.30 The epileptic activity in turn causes marked increase in energy demand lead-
ing to cortical energy failure and has a role in the spread of stroke like lesions.31   
The second major group in patients with uncontrolled epilepsy was MERRF syn-
drome & m.8344G>A mutation and cerebral atrophy on MRI. An additional patient 
in this group had the POLG related disorder & homozygous W748S mutation. Pa-
tients with m.8344A>G mutations had progressive myoclonic epilepsy syndrome 
characterized by generalized onset tonic clonic seizure, myoclonic seizures ataxia 
and progressive cognitive decline as in previous studies.25 The single patient with 
POLG related disorder in this group had bilateral inferior olivary hypertrophy in 
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addition to the atrophic changes. Neuropathological studies have shown that 
Purkinje cells and neurons of the dentate nucleus and inferior olivary nuclei have a 
special vulnerability to the effects of the m.8344A >G mutation and POLG mutations 
as compared with other mtDNA mutations.32 All patients had a neurodegenerative 
course in this group. The molecular processes that lead to neuronal loss in various 
mitochondrial disorders remain elusive.33 However the autopsy studies have provid-
ed sufficient evidence for the neurodegenerative changes in mitochondrial disor-
ders.33 
Therapeutic response in patients with mitochondrial epilepsy is usually poor. 
The most common antiepileptic drugs used in the present cohort included le-
viteracetam and clobazam. Majority of the patients in this study also received mito-
chondrial cocktail medications. Studies have suggested that the anticonvulsants 
lamotrigine and levetiracetam may be neuroprotective, at least in experimental 
models of mitochondriopathies.34, 35  
In conclusion, this study highlights that a fair correlation exists between the out-
come of epilepsy, clinical phenotypes, genotypes and magnetic resonance imaging 
findings in patients with mitochondrial disorders. The recognition of these patterns 
is important clinically because of the therapeutic and prognostic implications. It is 
acknowledged that the small sample size in each group is a limitation. However the 
trends emerged in this study may be of use to the clinicians involved in the care of 
patients with mitochondrial disorders. 
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Abstract 
Background: There is emerging evidence implicating mitochondrial dysfunction in 
the pathogenesis of acquired demyelinating disorders such as multiple sclerosis. On 
the other hand, some of the primary mitochondrial disorders such as mitochondrial 
leukoencephalopathies exhibit evidence of neuroinflammation on MRI. The inter-
relationship between mitochondrial disorders and episodic CNS inflammation needs 
exploration because of the therapeutic implications.  
Objective: We sought to analyze the clinical course and MRI characteristics in a 
cohort of patients with mitochondrial leukoencephalopathy to determine features, if 
any, that mimic primary demyelinating disorders. Therapeutic implications of these 
findings are discussed.   
Patients and Methods: Detailed analysis of the clinical course, magnetic resonance 
imaging findings and therapeutic response was performed in 14 patients with mito-
chondrial leukoencephalopathy. The diagnosis was ascertained by clinical features, 
histopathology, spectrophotometric assays and exome sequencing.   
Results: Fourteen patients [Age at evaluation: 2-7 yrs, M:F-1:1] were included in the 
study. Clinical Features which mimicked acquired demyelinating disorder included 
acute onset focal deficits associated with encephalopathy [10/14, 71%], febrile illness 
preceding the onset [7/14, 50%] unequivocal partial or complete steroid responsive-
ness [11/11], episodic/ relapsing remitting neurological dysfunction [10/14, 71%] and 
a subsequent stable rather than a progressive course [12/14, 85%]. MRI characteris-
tics included confluent white matter lesions [14/14, 100%], diffusion restriction 
[11/14,78.5%], contrast enhancement [13/13,100%], spinal cord involvement 
[8/13,61.5%], lactate peak on MRS [13/13] and white matter cysts [13/14, 92.8%]. 
Conclusion: Clinical presentations of mitochondrial leukoencephalopathy often 
mimic an acquired demyelinating disorder. The therapeutic implications of these 
observations require further exploration.  
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1. Introduction  
White matter involvement is increasingly being recognized as a manifestation of 
mitochondrial disorders and the term mitochondrial leukoencephalopathy or leu-
kodystrophy has been used to designate these disorders.1 They are mainly defined by 
the MRI characteristics such as cystic lesions in the abnormal white matter, addi-
tional gray matter lesions, restricted diffusion, contrast enhancement, and elevated 
lactate on magnetic resonance spectroscopy of the brain.2 Clinically, patients with 
mitochondrial leukoencephalopathy most often present with monophasic or recur-
rent episodes of neurological regression.3 Acute onset neurological deficits in combi-
nation with large confluent white matter lesions on MRI often lead to diagnosis of 
an acquired demyelinating disorder such as acute disseminated encephalomyelitis 
(ADEM). In some disorders, predominant visual impairment and white matter le-
sions may suggest diagnosis of neuromyelitis optica spectrum disorders, which are 
further emphasized by the presence of spinal cord signal changes on MRI.  
On the other hand, it is increasingly being evident that mitochondrial abnormal-
ities are involved in the development and progression of multiple sclerosis (MS).4 
The most compelling evidence implicating the role of mtDNA comes from the ob-
servation of susceptibility of LHON [Leber’s hereditary optic neuropathy] patients to 
develop white matter lesions resembling MS.5 However studies interrogating the 
presence of LHON-associated mutations in patients with multiple sclerosis6,7 as well 
as those probing an increased MS risk in particular mitochondrial haplogroups8-11, 
have revealed conflicting results. An exploratory study on the mitochondrial DNA 
variations and haplogroups in children with acquired demyelinating syndromes 
(ADS) have raised the possibility that mtDNA variants or haplogroups may influence 
the age at onset and subsequent MS risk.12 These observations suggest that the link 
between mitochondrial dysfunction and ADS is unclear and needs to be explored 
further. 
Importance of MRI in the interpretation and diagnosis of mitochondrial leu-
koencephalopathies has been already emphasized. Even though the characteristics of 
mitochondrial leukoencephalopathy have been highlighted in literature, the thera-
peutic implications of these findings still needs to be elucidated. This study analyzed 
the clinical and MRI characteristics in a cohort of children with mitochondrial leu-
koencephalopathy so as to define the features that mimic acquired demyelinating 
disorders.  
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2. Patients and methods: 
The cohort was derived from a database of patients who underwent exome sequenc-
ing as part of a study on phenotype genotype correlations in mitochondrial disor-
ders, over a period of two years (2015-2017) See Supplementary Table. The institute 
ethics committee approved the study and all subjects gave written informed consent. 
3. Phenotypic characterization. 
Patients were recruited into the study if they satisfied the clinical criteria of mito-
chondrial disorder as suggested by Bernier et al13  and a comprehensive evaluation, 
including estimation of serum lactate, muscle histopathology, assay of respiratory 
chain complex enzymes, brain magnetic resonance imaging, nerve conduction stud-
ies, electroencephalography (EEG) and evoked potential studies that were tailored to 
the clinical phenotype suggested a probable diagnosis of mitochondrial disorder. 
Exome sequencing was performed using illumina sequencing platform and the gene 
panel consisted of 6440 genes inclusive of all nuclear-encoded mitochondrial genes 
that are strongly associated with a disease on OMIM (Online Mendelian Inheritance 
in Man). 
Among the 85 patients who underwent exome sequencing, 36 showed variations 
in mitochondrial disease related genes. Among these, 14 patients (Age range: 2-7 yrs, 
M: F- 1:1) displayed significant white matter involvement and qualified for a diag-
nosis of mitochondrial leukoencephalopathy and were included in final analysis. 
Their clinical features, MRI findings and therapeutic responses were analyzed retro-
spectively. All patients had significant white matter hyperintensities involving one 
or more of the white matter zones viz. periventricular, deep white matter and sub-
cortical white matter as well as involvement of multiple lobes [frontal, parietal, 
temporal and occipital white matter]. The sequences analyzed included T1 weighted 
(T1W), T2 weighted (T2W) and Fluid attenuated inversion recovery (FLAIR) se-
quences in all. Additional sequences included diffusion weighted images (DW1, 
n=13), Contrast images (n=13) & Magnetic resonance spectroscopy (n=13). Majority 
of the children received evaluation and treatment during the acute phase in periph-
eral hospitals. The information on the CSF studies and the details of the immuno-
modulation was retrieved from the referral notes and treating physician’s notes. All 
patients were evaluated and followed up by the same clinical team [PSB, ABT, MN 
&SS]. MRI findings were independently reviewed by two neurologists (PSB &ABT) 
and one neuroradiologist (HRA). 
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4. Results: 
The detailed clinical features, MRI characteristics, and immunomodulation and 
follow up are provided in Table 1. The genetic findings included variations in com-
plex I nuclear genes [NDUFA1(1); NDUFV1(4); NDUFS2 (2); LYRM (2); MPV17(1); 
BOLA3(2); IBA57(2)] The details of the genetic findings are provided in the supple-
mentary table. 
Clinical features: The age at onset of the symptoms in the patients ranged from 6 
months to 5.5 years (Mean ± SD - 1.67±1.3 yrs). In six children age of onset was in 
infancy. The period of follow up ranged from 1-7 years and the mean duration of 
illness at last follow up was 4.5±3.6 years. Majority had an acute presentation (n=10). 
History of an inciting event was present in 10 [febrile illness, n=8; jaundice, n=1; 
minor head trauma, n=1]. Infants in the cohort manifested with regression of ac-
quired milestones. Neurological examination showed pyramidal signs in all and ad-
ditional ataxia in four. Primary optic atrophy was present in eight (57%). Even 
though visual loss was the presenting manifestation in two patients optic disc swell-
ing was not reported.  Except for three patients who had insidious onset of symp-
toms all received immunomodulation presuming a diagnosis of an acquired demye-
linating syndrome and most common diagnosis considered was acute disseminated 
encephalomyelitis. The response to immunomodulation was either partial or com-
plete. In those with partial response the residual deficits were spasticity in the lower 
limbs and mild incoordination of the upper limbs. Even those patients, who did not 
have overt spasticity, had pyramidal signs in lower limbs. 
Relapses: Details of relapses are provided in Table 1. Ten patients had multiple epi-
sodes (median number of episodes -2). For seven patients the second episode oc-
curred within 2 months of the first episode. Three children had multiple episodes 
[patient 1,9 &10]. While the episodes were heralded by seizures in patient 1, there 
were no seizures in patient 9 and 10. 
Cerebrospinal Fluid (CSF) Examination: Results of the cerebrospinal fluid examina-
tion during the acute presentation was available in 11 patients. Pleocytosis was not-
ed in none while elevated CSF protein was noted in three. 
Magnetic resonance imaging findings: Description of the MRI findings is provided in 
Table1 and summary is provided in Table 2. MRI findings included large confluent 
white matter signal changes that showed diffusion restriction and patchy contrast 
enhancement in the acute phase and on follow up, in some patients. In those chil-
dren with discrete lesions in the initial scans, the signal changes tended to become 
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confluent and bilaterally symmetrical on follow up images (Fig.1A-C). Cysts inside 
the white matter were evident in all except one, either at the time of acute presenta-
tion or on follow up (Fig.2B). Corpus callosal involvement was prominent in all but 
involvement of internal capsule, brainstem and pyramidal tract were seen in only 
one patient each. Likewise the presence of signal changes in basal ganglia, thalamus 
and dentate was seen in only one patient each. 
Clinical and MRI findings in mitochondrial LE vs. acquired demyelinating syndrome: 
The clinical features and MRI findings in this cohort was compared with that of 
children with acute disseminated encephalomyelitis (ADEM). The cohorts included 
35 children with ADEM presented to our institute as well as with another cohort 
from India14 and two recent series on ADEM from Japan15 and UK16 .The age at on-
set, clinical features and MRI findings were compared and provided in Table 2. The 
patients with mitochondrial LE presented at a significantly younger age and had 
more chance of having residual motor deficits compared to children with ADEM (p 
value <0.05). Comparison of MRI features showed that presence of periventricular 
and deep white matter lesions, corpus callosal lesions, contrast enhancement and 
restricted diffusion were significantly higher compared to children with ADEM (p 
value <0.05). In contrast presence of subcortical/juxta cortical lesions were less 
common compared to ADEM. Even though the details of MRS and white matter 
cysts were not available for comparison in the ADEM series, both the features were 
consistently seen in mitochondrial LE.    
Clinical and MRI findings in Mitochondrial LE vs other mitochondrial disorders 
Clinical phenotypes in the rest of the children with mitochondrial disorders includ-
ed Leigh and Leigh like syndrome (n=15), encephalomyopathy (n=2), chronic pro-
gressive external ophthalmoplegia with epilepsy (n=4), and mitochondrial neurogas-
trointestinal encephalopathy (MNGIE, n=1). The MRI findings included bilateral 
symmetrical signal changes in the basal ganglia, brain stem and cerebellum (n=15) 
predominantly noted in children with Leigh and Leigh like syndrome. Normal MRI 
findings were noted in children with encephalomyopathy and chronic progressive 
external ophthalmoplegia. The child with MNGIE had bilateral symmetrical 
T2/FLAIR signal changes involving the periventricular and deep white matter with-
out any contrast enhancement or diffusion restriction. Subcortical fibers were 
spared. There was presence of lactate peak on MRS. 
The detailed case history and investigation results including brain biopsy find-
ings of one of the patients is described below to demonstrate the diagnostic and 
therapeutic challenge posed by these patients.  
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Patient 1: This 10 year old boy of Indian origin was the first child of non-
consanguineous parents with normal birth history and developmental milestones. 
He was apparently normal till 2.5 years when he developed ataxia, seizures and en-
cephalopathy following a febrile illness. CSF study was normal. MRI demonstrated 
T2/FLAIR hyper intense lesions involving both gray and white matter with contrast 
enhancement (Fig.2A-C). He received pulse methyl prednisolone for presumptive 
diagnosis of acute disseminated encephalomyelitis and made complete clinical re-
covery. Thereafter he presented with multiple relapsing remitting neurological epi-
sodes characterized by seizures, hemiparesis and ataxia associated with relapsing 
remitting white matter lesions on MRI (Table 1, Fig.2D-H). He was referred to our 
institute at the age of 6 years during the fifth episode. 
Review of the evaluations done elsewhere revealed high serum alanine, lactic ac-
id metabolites on urinary organic acid estimation and an elevated serum lactate on 
multiple occasions. Muscle biopsy showed complex I deficiency on spectrophoto-
metric enzyme assays. Complete mitochondrial DNA sequencing revealed only pol-
ymorphisms. Targeted sequencing of complex I nuclear genes revealed a previously 
reported hemizygous variation in NDUFA1 (c.94G>C, p.G32R), which was con-
firmed by Sanger sequencing. His mother and sister carried the same variation.  
Biopsy from the right frontal cortex revealed a small fragment of cortex with 
white matter (Fig.3A). Extensive loss of myelin was seen on Luxol Fast 
Blue stain (Fig.3B). A few preserved strands of myelinated axons traversing the 
white matter was seen. In contrast, there was relative preservation of axonal tracts 
in the demyelinated segment (Fig.3C). Tissue response in the form of scattered CD68 
labelled ramified microglia and few clusters of histiocytes were detected within the 
zone of demyelination (Fig.3D), in addition to fibrillary gliosis and several hyper-
trophic reactive astrocytes (Fig.3F). There was no perivenular demyelination or 
foamy histiocytes. 
Prior to presentation to us, he had received methyl prednisolone injection during 
each episode followed by short and tapered steroid treatment. He also received 
Inj.Interferon for a brief period of time presuming a diagnosis of pediatric MS. In 
view of the relapsing remitting neurological episodes responsive to steroid therapy, 
the initial diagnosis considered was an acquired demyelinating disorder. In view of 
the multiple relapses, patient was initiated on monthly pulses of methyl predniso-
lone. He also received high dose vitamins. After the genetic report, the patient was 
maintained only on high dose vitamins. The patient remained relapse-free thereafter 
and is being maintained on high dose vitamins from the age of eight years.  
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Table 2: Comparison of Clinical and MRI Features in Patients with Mitochondrial Leu-
koencephalopathy with Cohorts of Patients with ADEM  
Parameters Mito LE 
(Present 
study) 
ADEM-India 
(Same 
institute) 
ADEM- India 
(Singhi et al) 
ADEM-Japan 
(Yamaguchi et 
al) 
ADEM-UK 
(Absoud et al) 
No of patients  N=14 N=35 N=52 N=66 N=40 
Mean Age at 
onset  
1.67 ± 1.3 yrs 8.2 ± 4.1 yrs* 6.14±3.17 yrs* 5.5 ± 3.8 yrs* Median age 
-5.3yrs  
Gender [M:F] 1:1 1.2:1 2.7:1 2:1 1.5:1 
Febrile illness 7  [50%] 31  [88.8%]* 13  [25%] 45/66 [68%] NA 
Neurological 
Features 
     
Encephalopathy 9  [64.2%] 35  [100%] Majority 66/66 [100%] 40  [100%] 
Pyramidal signs 14  [100%] 13  [37%]* 42  [80.7%] NA 24  [60%]* 
Ataxia 7  [50%] 8  [25 %] 6  [11.5%]* NA 18  [45%] 
Visual loss 3  [21.4%] 5  [14 %] 11  [21.2%] 7/66 [11%] 3  [0.1%]* 
Optic atrophy  8  [57  %] NA NA NA NA 
Seizures 8  [57.1%] 8  [22%]* 19  [36.5%] 21      [32%] 8  [20%]* 
CSF pleocytosis Nil 18  [32%] Majority 56/66 [85%] 23  [58 %] 
MRI Findings      
Periventricular 
lesions 
14  [100%] 11  [31%]* NA 20/66 [30%]* 9  [22.5%]* 
Lobar/DeepWM 14  [100%] 18  [51%]* NA NA 24  [60%]* 
Parameters Mito LE 
(Present 
study) 
ADEM-India 
(Same 
institute) 
ADEM- India 
(Singhi et al) 
ADEM-Japan 
(Yamaguchi et 
al) 
ADEM-UK 
(Absoud et al) 
Subcortical/ 
Juxtacortical 
6  [15%] 29  [68%]* NA 41/61 [67%]* 20  [50%]* 
Cerebral cortex Nil 7  [20%] NA 28/61 [46 %] 14  [35%] 
Corpus callosum 14  [100%] 9  [25.7%]* 7  [13.5%]* 11/61 [18 %]* 3  [0.1%]* 
Thalamus 2  [14.3%] 8  [23%] 16  [30.8%] 30/61 [49%]* 24  [60%]* 
Basal Ganglia 1  [7.0%] 6  [17%] 9  [17.3%]  
Cerebellum 4  [28.6%] 9  [25.7%] 14  [26.9%] 20/66 [30%] 17  [42%] 
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Table 2: Continued 
Parameters Mito LE 
(Present 
study) 
ADEM-India 
(Same  
institute)   
ADEM- India 
(Singhi et al) 
ADEM-Japan 
(Yamaguchi et 
al) 
ADEM-UK 
(Absoud et al) 
Brainstem 2     [14.3%] 14     [40%] 9    [17.3%] 19/66[29%] 22     [55%]* 
Spinal cord 8     [61.5%] 4/6  [66%] 5    [9.6%]* 16/42[38%] 8/12[67%] 
Contrast 
enhancement 
13/13[100%] 13/27[48%]* 5    [48%]* NA NA 
Diffusion 
restriction 
11/14[78.5%] 8/26[30%]* NA NA NA 
Lactate peak on 
MRS 
13/13[100%] NA NA NA NA 
White matter 
cysts  
13/14[92.8%] NA NA NA NA 
Residual deficits  12     [92.3%] 2     [5.7%]* 20    [38.7%]* 11    [16.7%]* NA 
Death 1/13[7.6%] 1/35[2.9%] none none 1    [2.5%] 
*P<0.05, Abbreviations: ADEM-Acute disseminated encephalomyelitis; NA-Not available; WM-white 
matter; CSF-cerebro spinal fluid; MRS-Magnetic resonance spectroscopy 
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Fig.1: MRI Brain in a 2-year-old child with Mitochondrial leukoencephalopathy and mutations in IBA57 
(Patient 14). A) T2W axial image at the time of first presentation shows large asymmetrical confluent 
white matter signal changes B-D) Follow up study shows rarefied white matter on T2W axial view (B), 
cysts inside the affected white matter on FLAIR(C), contrast enhancement (D) 
Fig.2: MRI brain in patient 1 with NDUFA1 variation 
A-C –MRI at 2.5 yrs at the time of initial presentation shows multiple discrete white matter and gray
matter T2/FLAIR hyper intensities with contrast enhancement. 
D-F- MRI during the third episode at the age of 4.5 yrs shows large asymmetrical white matter lesions
with contrast enhancement and patchy restricted diffusion 
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G. The lesions shows tendency to become symmetrical and diffuse on follow up imaging at 7.5 yrs H. 
MRS shows lactate peak  
 
Fig.3 Brain biopsy findings in Patient 1 (A- F):  
Brain biopsy included a small fragment of right frontal cortex with white matter (A) which reveals exten-
sive loss of myelin (B). Note few preserved strands of myelinated axons traversing the white matter (ar-
rows, B). In contrast, there is relative preservation of axonal tracts in the demyelinated segment (C). 
Tissue response in the form of scattered CD68 labelled ramified microglia and few clusters of histiocytes 
are seen within this zone (D) and several hypertrophic reactive astrocytes with fibrillary gliosis (F) 
[A:H&E; B: Luxol Fast Blue (LFB); C: Neurofilament; D: CD68; F:GFAP. Magnification= scale bar (200 
micron)] 
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Supplementary Table: Genetic Findings in children with Mitochondrial Leukoencephalopathy 
 Age/Gender Gene Zygosity Nucleotide 
change 
Aminoacid change 
1 6yrs/M NDUFA1 Hemizygous c.94G>C p.Gly32Arg 
2 3yrs/F NDUFV1 Homozygous c.1156C>T p.Arg386Cs 
3 2yrs/M NDUFV1 Homozygous c.1156C>T p.Arg386Cs 
4 2yrs/F NDUFV1 
  
 
Homozygous c.1156C>T 
 
p.Arg386Cys 
+NDUFS8 
p.Ala200Thr 
5 9mo/M NDUFV1 Homozygous c.1156C>T p.Arg386Cs 
6 13mo/M NDUFS2 
 
Comp. 
Heterozygous 
c.236A>C+ 
c.1324C>T 
p.Asn79Thr + 
p.His442Tyr 
7 3yrs/F NDUFS1 Homozygous c.2032T>G p.Tyr678Asp 
9 2yrs/F LYRM7 Homozygous c.2 T>C p.M1T 
10 7yrs/M LYRM7 Homozygous c.25C>T p.Gln9Ter 
8 6yrs/F MPV17 Homozygous c.148C>T p.Arg50Trp 
11 *2yrs/F BOLA3 Homozygous c.295C>T p.R99W 
12 *1.5yrs/M BOLA3 Homozygous c.295C>T p.R99W 
13 1.5yrs/M IBA57 
  
Compound 
Heterozygous 
c.738C>G + 
c.802C>T 
p.Asn246Lys 
+ p.Arg268Cys 
14 2yrs/M IBA57 
  
Compound 
Heterozygous) 
c.706C>T + c.656 
A>G 
p.Pro236 ser+ 
p.Tyr219Cys 
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Discussion 
We have described a cohort of children with mitochondrial leukoencephalopathy 
with special reference to clinical course, therapeutic response and MRI findings. 
Even though there are descriptions on clinical and MRI features of mitochondrial 
leukoencephalopathies in the literature, the specific evidence of neuroinflammation 
with therapeutic implications are relatively unknown highlighting the novelty of 
the present study.  
The diagnoses most often considered by the referring physicians were acute dis-
seminated encephalomyelitis (ADEM) or multiphasic ADEM. This was substantiated 
by the presence of acute onset focal deficit associated with encephalopathy as de-
fined by international pediatric multiple sclerosis criteria.17, 18 History of febrile ill-
ness preceding the onset, unequivocal steroid responsiveness, and a subsequent sta-
ble course albeit with deficits rather than a progressive degenerative course also 
corroborated the diagnosis of an acquired demyelinating disorder. However, com-
parison of the clinical features with other cohorts of children with ADEM brought 
out the differences from the primary demyelinating disorder. One of the important 
differentiating features was an early age of presentation as compared to children 
with primary demyelinating disorder. The usual age of onset of ADEM in children 
ranges from 5 to 8 years.17, 18 On the other hand patients with mitochondrial LE 
presented either in the infantile or late infantile period and some of them had insid-
ious rather than acute presentation. The second point pertains to the presence of 
primary optic atrophy in many patients at the time of initial presentation. Even 
though the information on optic atrophy was not available for comparison in the 
demyelination groups, primary optic atrophy was present in more than half of the 
patients in this series at the time of presentation. Thirdly, children with mitochon-
drial LE most often had residual motor deficits on follow up even though they 
showed complete or partial clinical response to steroids in the acute phase. On the 
other hand residual motor deficits are less commonly reported in ADEM.15,16 Sei-
zures were a major part of the episodes and sometimes the heralding event in some 
patients as exemplified in the patient with NDUFA1 variation. The difference was 
significant compared to two out of three ADEM cohorts and may be another useful 
differentiating point. 
The clinical features in other mitochondrial phenotypes and that of mitochon-
drial leukoencephalopathy also showed distinct differences. Systemic features such 
as peripheral neuropathy, auditory involvement, and myopathic features were ab-
sent in children with leukoencephalopathy. The clinical features were related to 
long tract involvement in comparison to other phenotypes. This also may pose a 
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major diagnostic dilemma for suspecting a mitochondrial etiology in patients pri-
marily presenting with neuroregression and leukoencephalopathy. But familiarity 
with the MRI patterns compared to other leukodystrophies may help the physician 
to suspect a mitochondrial etiology. 
MRI in the acute phase demonstrated large asymmetrical confluent lesions simu-
lating acute disseminated encephalomyelitis or tumefactive MS. The lesions most 
often involved the frontal and parietal region and the periventricular and deep 
white matter and corpus callosum compared to subcortical or juxta cortical regions 
and thalamus in children with acquired demyelinating disorders. Contrast en-
hancement, diffusion restriction, presence of lactate peak and white matter cysts 
were consistently seen in mitochondrial LE. The evidence of inflammation on MRI 
is one of the important defining feature of mitochondrial leukoencephalopathies1. 
Restricted diffusion without contrast enhancement is most often seen in ischemia 
and is attributed to cytotoxic edema. Delayed restricted diffusion with contrast en-
hancement has been described in tumefactive MS lesions.19 In lesions with restricted 
diffusion, presence of gadolinium enhancement has been used as a differentiating 
feature between acute demyelinating lesions and ischemia.20 This has been attribut-
ed to intramyelinic edema or myelin vacuolation as in toxic demyelination or inborn 
error of metabolism.21 Another alternative explanation is that the myelin breakdown 
may reduce the water movement in the extracellular space because of the reduced 
fiber tract organization.22 The presence of concomitant contrast enhancement along 
with restricted diffusion in mitochondrial leukoencephalopathies may suggest that 
the pathology is similar to acute demyelinating lesions. 
The therapeutic implications of these findings in mitochondrial disorders have 
not been fully explored. The most important being the utility of glucocorticoid ad-
ministration in acute stages, as in acute demyelinating disorders. Steroid responsive-
ness in patients with mitochondrial leukoencephalopathy has been described in 
patients with LYRM mutations and DARS associated leukoencephalopathy.3, 23 Re-
markable corticosteroid response and dependence have been described in patients 
with MELAS.24 The similarity in clinical presentation and overlap with primary 
demyelinating disorder such as MS is already emphasized in literature.5,25,26 In the 
sole autopsy study available in patients with LHON-MS, the inflammatory responses 
are highlighted in detail.26 Introduction of corticosteroids in this patient intermit-
tently did improve the visual and neurological dysfunction suggesting an early im-
munological mechanism. It was proposed that mitochondrial dysfunction might 
occasionally aggravate or initiate the autoimmune process.26 It remains to be seen if 
maintenance of the steroid therapy as in other immune mediated disorders can keep 
a stable course in children with mitochondrial LE. The report of the relapsing remit-
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ting MS-like illness in a child with NDUFA1 variation may support this hypothesis. 
The patient received steroids for achieving as well as maintaining remission. After 
the remission is maintained, the patient remained clinically stable on mitochondrial 
cocktail medications. As suggested in the study by Kowacs et al26 the mitochondrial 
dysfunction in this patient might have initiated the immune response, which got 
stabilized by the use of steroids. Various mechanisms have been postulated by which 
glucocorticoids exert its effect on mitochondria.27-29 
In conclusion, this study highlights that episodic neuroinflammation is a feature 
of mitochondrial leukoencephalopathies as evidenced by the clinical presentation 
and MRI features. These features may overlap with acquired demyelinating disor-
ders. The role of glucocorticoids in inducing and maintaining remission during the 
neurological episodes in patients with mitochondrial leukoencephalopathy needs to 
be explored further in prospective studies. 
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Magnetic Resonance Imaging (MRI) plays an important role in the phenotypic char-
acterization of patients with mitochondrial disorders by providing information on 
timing, extent and progression of neuronal injury. Studies on phenotype-genotype 
correlations are critical in understanding and identifying the range of disease mani-
festations in mitochondrial disorders. This in turn helps to fasten the diagnostic 
process, monitor the disease progression and objectively assess intervention effects. 
The overall aim of the thesis was to correlate MRI both to genetic defects and to 
disease manifestations, in order to guide prognosis and therapy. Specific aims were: 
1. To correlate magnetic resonance imaging findings in patients with mitochondrial 
disorders and peripheral neuropathy with the underlying genetic defect; 2. To dis-
criminate mitochondrial disorders from other metabolic disorders by specific imag-
ing findings; 3. To apply MRI for predicting prognosis and monitor therapy in spe-
cific subsets of patients 
MRI based phenotype genotype correlations  
Correlating genetic data with neuroimaging phenotypes is an emerging approach in 
neuroscience to better understand the complex imaging appearance of inherited 
metabolic disorders, and mitochondrial disease in particular. This approach is useful 
to neuroscientists by providing better genetic neuroimaging integration and to clini-
cians by providing a better diagnostic tool. MRI demonstration of CNS changes sup-
plements the clinical information and helps defining the phenotype-genotype corre-
lations for more effective treatment and prognostic information.1  Newer MRI tech-
niques also help to define the metabolism, and hemodynamics.2,3 Previous studies on 
MRI in mitochondrial disorders have suggested that certain anatomical patterns can 
indicate the underlying etiology.4 Limited studies have so far attempted to identify 
correlations between the MRI findings and genetic defect.5   
Chapter 1 provides an overview of the MRI findings in various mitochondrial pa-
tients, carrying different genetic defects, and demonstrates the advances made in the 
diagnostic evaluation in patients with mitochondrial disorders. The target areas 
involved in mitochondrial disorders are: 1. Deep gray matter structures including 
basal ganglia, thalamus and brainstem consistent with Leigh and Leigh-like syn-
drome; 2. White matter [Leukoencephalopathy]; 3. Cerebral cortex [stroke like le-
sions]. Cerebral and cerebellar atrophy may occur in isolation or in association with 
involvement of the target areas.1 Definite correlations between genotype and MRI 
patterns are emerging, including LSBL due to DARS2 mutations, LTBL due to 
EARS2 mutations, SDH related leukoencephalopathy, leukoencephalopathy due to 
LYRM and NUBPL mutations, ‘putaminal eye’ pattern in MEGDEL syndrome due to 
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SERAC1 mutations and stroke like lesions in complex I deficiency due to mtDNA 
mutations, MELAS, POLG1 and ubiquinone deficiency. Given the rarity of mito-
chondrial disorders, these studies are essential to strengthen the phenotype genotype 
correlations in the diagnostic evaluation and interpretation of growing exome se-
quencing data.  
In chapter 2, we explored the spectrum of MRI findings in patients with mitochon-
drial disorders in relation to the underlying genetic defects. The genotypes covered 
three groups, mtDNA point mutations & deletions and mutations in the POLG1 & 
SURF1 genes. The MRI patterns reflected the myriad of central nervous system 
manifestations in patients with mitochondrial disorders and included stroke-like 
lesions, laminar cortical necrosis, signal changes in basal ganglia, thalamus, dentate 
and brain stem nuclei, cerebral and cerebellar white matter signal changes, cerebral 
and cerebellar atrophy, intracerebral calcification and lactic acidosis. Comparison of 
the MRI findings in the three groups showed that cerebral and cerebellar atrophy, 
cortical signal changes and basal ganglia mineralization were seen mostly in patients 
with mtDNA mutations. Brainstem signal changes with or without striatal lesions 
were characteristically noted in SURF1 group. There was no consistent imaging 
pattern in POLG1 group. Stroke like lesions and basal ganglia mineralization were 
noted only in patients with m.3243A>G mutation. The preferential occurrence of 
stroke like lesions in patients with mtDNA mutations has been highlighted earlier.5 
Chapter 2 also emphasizes the role of MRI based phenotypic characterization in 
non-syndromic mitochondrial disorders. Four of the six patients who underwent 
spinal cord imaging demonstrated signal changes in the cord. This is noteworthy 
since the signal changes in spinal cord may superficially support a diagnosis of neu-
romyelitis optica syndrome and give rise to diagnostic errors especially if the patient 
has additionally optic nerve involvement. Knowing that such a specific tract in-
volvement can occur in mitochondrial disorders may help the physician in making 
an early diagnosis. Spinal cord involvement in the context of mitochondrial disor-
ders has been classically described in patients with leukoencephalopathy with brain-
stem and spinal cord involvement and elevated lactate due to a DARS2 or DARS 
mutation. For mutations in the DARS gene hypomyelination with brainstem and 
spinal cord abnormalities and leg spasticity (HBSL) has been reported as well.6 The 
dorsal columns and spinothalamic tracts are selectively involved in this disorder. 
Spinal cord involvement as the only manifestation is exceptional for mitochondrial 
disorders and previously described in a patient with the m.3460G>A mutation.7 
Spinal cord degeneration confined to posterior column has been reported also in 
POLG mutations.8 Dominant spinal cord involvement was described in a patient 
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with the m.11788G>A mutation, who presented with spastic dystonic syndrome and 
optic atrophy. As emphasized chapter 2, the recognition of mitochondrial etiology in 
patients with isolated spinal cord involvement has both therapeutic and prognostic 
implications. A useful differentiating point is the diffuse involvement of the cord in 
primary demyelinating disorders compared to the selective tract involvement in 
mitochondrial disorders. Description of more patients is required to confirm this 
observation. 
Infantile basal ganglia stroke syndrome following minor trauma is another phe-
notype of mitochondrial disorder identified in the study. The CT scan in these pa-
tients shows punctate basal ganglia calcification and asymmetric basal ganglia in-
farcts. The syndrome is otherwise specified as infantile basal ganglia stroke syn-
drome secondary to mineralizing angiopathy.9 The patient with both the 
m.13513A>G mutation and the basal ganglia stroke syndrome points towards a role 
for mitochondrial dysfunction in this peculiar stroke syndrome and mineralizing 
angiopathy.10 So far, the genetic etiology in this particular syndrome has been elu-
sive. In chapter 2 I also discussed the application of advanced imaging techniques in 
the evaluation of patients with mitochondrial disorders. Susceptibility weighted 
imaging (SWI) studies revealed mineralization in 13/22, 59% of the patients who 
underwent SWI. The pattern of mineralization was heterogeneous and included 
bilateral globus pallidus, punctate calcification involving the striatum and dense 
calcification of caudate and putamen. It is noteworthy that all patients with 
m.3243A>G mutation had mineralization revealed by SWI. This finding supports the 
earlier studies that globus pallidus mineralization is the earliest imaging finding in 
MELAS.11 Pathological studies have shown that the calcification usually involves the 
blood vessel walls and neuronal populations are spared leading to mineralizing angi-
opathy.  
Specific MRI findings and role in diagnostic evaluation  
The vulnerability of specific neuronal groups in mitochondrial disorders led to dif-
ferent anatomical patterns on MRI and recognition of these patterns helped in phe-
notypic characterization. Prominent among them were leukoencephalopathies 
caused by mitochondrial as well as non-mitochondrial genes. Symmetrical involve-
ment of the deep ganglionic and brainstem nuclei was observed in a number of dis-
orders and in mitochondrial disorders it defined the Leighs syndrome. In Chapter 3 
we investigated if specific anatomical structure involvement on MRI could differen-
tiate mitochondrial disorders from other metabolic and genetic disorders with simi-
lar MRI findings. The aim was to facilitate targeted metabolic and genetic testing, in 
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order to facilitate rapid and specific treatment. One hundred and twenty-five MRI 
scans from patients with different metabolic disorders were reviewed for the pres-
ence of hypertrophic olivary degeneration (HOD). Presence of HOD was noted ex-
clusively in patients with Leigh and Leigh-like syndrome secondary to mitochondri-
al etiology. The findings reflected the selective vulnerability of specific neuronal 
groups in patients with mitochondrial disorders.12 The characteristic multifocal 
symmetrical destructive lesions in neuraxis demonstrated marked glial hyperplasia 
macrophage incursion and vascular proliferation with relative sparing of neurons.13 
It has been postulated that the non random pattern of damage in the neuraxis will 
depend on the severity of enzyme defect, developmental age of the individual and 
functional activity of the different neuronal cell group.12,13 Literature review also 
supported the involvement of inferior olivary nucleus on MRI in many mitochon-
drial disorders compared to other inherited metabolic disorders.14-18 This is analo-
gous to the observation in neuropathological studies by Cavanagh et al who ob-
served that“ in no other condition of which the author is aware are the inferior ol-
ives destroyed with such regularity, so that this phenomenon may be unique to 
Leigh’s disease and perhaps other analogous metabolic disorders”.19 Apart from the 
diagnostic significance, it remains to be seen if the unique involvement of inferior 
olives in mitochondrial disorders has therapeutic or prognostic significance. 
MRI based phenotype genotype correlations in Mitochondrial Epilepsy 
A detailed study of mitochondrial epilepsy (chapter 5) revealed interesting observa-
tions on the correlations between the outcome of epilepsy, phenotype genotype and 
magnetic resonance imaging findings. The MRI findings could be grouped into four 
major groups, stroke like lesions, atrophic changes, leukoencephalopathy and those 
with normal findings. Each of these four MRI groups had a fairly homogeneous 
clinical course, exemplifying the possible application of MRI in prognostication of 
mitochondrial epilepsy. Patients with stroke like lesions on MRI were associated 
with an episodic course and exacerbations characterized by epilepsia partialis con-
tinua. Seizures in this group were difficult to control even with multiple anti-
epileptic medications in optimal dosages. On the other hand, patients with atrophic 
changes on MRI had myoclonic seizures mainly and the course simulated a progres-
sive degenerative disorder. The group with leukoencephalopathy had only intermit-
tent seizures, which could be easily controlled with anti-epileptic drugs in all pa-
tients. Even though the MRI predominantly showed leukoencephalopathy, signal 
changes with restricted diffusion were noted in the hippocampus in two patients.  
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The phenotypes of patients with normal MRI had homogeneous clinical and ge-
netic findings. The clinical features were dominated by chronic progressive external 
ophthalmoplegia and a photosensitive eyelid myoclonia akin to Jevons’s syndrome. 
Even though two patients had status epilepticus after presentation they had a stable 
course afterwards. Epilepsy with eyelid myoclonia (EMA) has been proposed to 
denote the onset of frequent eyelid myoclonia induced by eye closure and photic 
stimulation beginning in childhood.20 The molecular basis of EMA has not been 
characterized yet. Family studies in EMA were suggestive of complex inheritance 
with genetically overlapping with both classical genetic generalized epilepsy and 
generalized epilepsy with febrile seizure plus syndrome.20 The presence of epilepsy 
with eyelid myoclonia in patients with a specific POLG1 mutation and normal MRI 
suggests mitochondrial dysfunction as underlying pathology in epilepsy with eyelid 
myoclonia.  
Mitochondrial dysfunction has been implicated as a potential cause of epileptic 
seizures and therapy-resistant forms of severe epilepsy.21 Mitochondrial complex I 
deficiency has been demonstrated in the epileptic foci of patients with temporal lobe 
epilepsy.22 Possible explanations for the role of mitochondria in epileptogenesis in-
clude: 1. Mitochondrial oxidative phosphorylation is the major source of adenosine 
triphosphate in neurons; 2. Mitochondria participate in cellular Ca2+ homeostasis and 
thus can modulate neuronal excitability and synaptic transmission; 3. Mitochondria 
are intimately involved in pathways leading to the neuronal cell death characteristic 
for the areas of epileptogenesis.21  
Phenotype-Genotype correlations of peripheral neuropathy in 
Mitochondrial Disorders 
Phenotype-genotype correlations in patients with mitochondrial disorders are most 
often decided by the different systems involved. Peripheral neuropathy occurs as 
part of the multisystem involvement in many mitochondrial disorders. A subset of 
patients with mitochondrial disorders have peripheral neuropathy as the sole or 
unique manifestation and these are known as the mitochondrial CMTs. Mitochon-
drial ATP production supports important neuronal functions as maintaining the 
energy milieu, synapse assembly, generation of action potentials and synaptic trans-
mission in peripheral nerves. Chapter 3 analyzed the characteristics of peripheral 
neuropathy in a cohort of patients with mitochondrial disorders. The patients in this 
cohort belonged to three groups, mtDNA point mutations, POLG1 and SURF1. Pe-
ripheral nerve involvement was mainly axonal in nature even though the SURF1 
group had predominantly demyelinating neuropathy. This was mostly subclinical in 
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nature and aided in diagnosis by defining the multiaxial involvement in patients. For 
example, presence of peripheral neuropathy in a patient with progressive myoclonic 
epilepsy [PME] should prompt the physician to investigate mitochondrial etiology 
rather than other causes of PME such as lafora body disease or neuronal lipofuscino-
sis. The sensory ataxic neuropathy in patients with POLG1 is also noteworthy. Sen-
sory ataxic neuropathy in routine clinical practice is most often caused by acquired 
etiologies such as autoimmune vasculitis and nutritional disorders.  Recognition of a 
genetic etiology has important prognostic and therapeutic connotations. Knowledge 
of major phenotypes of mitochondrial neuropathies is important to make an early 
diagnosis.  
From a pathophysiological perspective, the differential involvement of sensory 
versus motor fibers and axonal versus myelin system in different types of mitochon-
drial disorders is intriguing. A chronic distal sensory axonal neuropathy is the most 
commonly reported mitochondrial neuropathy in syndromic mitochondrial disor-
ders.23,24 This is likely to be the result of a “chronic energy deprivation syndrome”.12 
Neurons with long axons that carry the burden of large volumes of axonal cytoplasm 
or axonal membrane are more vulnerable to the chronic energy deprivation. Neu-
rons are the only cells that extend over great distances. The growth of the axons to 
considerable distance depends on the relatively fast movement of the intracellular 
material and organelles, capacity of the cells to synthesize these materials and to 
regulate the synthesis.25 They are also among the most actively synthesizing cells 
and most of the energy is directed toward maintaining the axons. Energy utilized for 
the signaling process is less. Primary sensory cells being the largest are at greatest 
risk during energy deprivation and thus are most commonly affected. An acute neu-
ropathy in the context of mitochondrial disorders is rare and only a single paper 
reported acute reversible axonal dysfunction related to energy failure in peripheral 
nerves during stroke-like episodes in MELAS.26  
The pathophysiology of neuropathy in the POLG1 and SURF1 groups was also 
different. The sensory ataxia in POLG1 patients attributed mainly to a sensory neu-
ropathy.27 The electrophysiological investigations showed reduced sensory nerve 
action potential with preserved conduction velocity. Neuropathological studies 
demonstrated severe respiratory chain enzyme deficiency and neuronal cells in the 
dorsal root ganglion due to mitochondrial DNA depletion and deletion.27 In SURF1 
patients a demyelinating form of neuropathy was seen as reported previously. Ultra-
structural examination of the sural nerve biopsy showed that myelin sheaths had 
only few lamellae and occasionally large axons were completely devoid of myelin 
sheath. A large number of mitochondria, some of which were enlarged and rounded 
cristae were found in Schwann cells.28 
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The mitochondrial CMT group is more consistent with a “chronic energy depri-
vation syndrome”. The role of mitochondrial fission and fusion defects in these 
transport systems are increasingly being identified. Mouse experiments have provid-
ed further evidence that heterooligomeric complexes between MFN1 &MFN2 are 
important for control of mitochondrial fusion. The additional functions include 
mitochondria tethering and control of mitochondrial transport in axons. It has been 
demonstrated in animal experiments that MFN2 has an essential role in regulating 
the terpenoid biosynthesis pathway, required to maintain mitochondrial coenzyme 
Q levels for optimal function of the respiratory chain. In addition it was shown that 
the coenzyme Q deficiency and the respiratory chain deficiency were partially res-
cued by coenzyme Q10 supplementation.29 Isolated case reports highlighted benefi-
cial effects of CoQ supplementation in patients with MFN2 mutations.30  
MRI-based prognostic predictions 
The diagnostic process in patients with mitochondrial disorders is challenging be-
cause of the multisystem involvement, variable age of onset and genetic heterogene-
ity. The lengthy and complicated diagnostic evaluation, which most often involves 
invasive procedures, is stressful for the family. Even though the improvement in 
next-generation sequencing technology has shortened and simplified the diagnostic 
process considerably, generating a genetic diagnosis in 60-70% of the patients within 
months, cases with variants of unknown significance remain. Also, an accurate 
prognosis, based on confirmed pathogenic variants is often not possible, due to the 
clinical variability of these diseases, the often family-specific mutations and the lack 
of data on natural history. And although it opens-up opportunities for prevention by 
prenatal or preimplantation genetic diagnosis, patients and their parents are often 
motivated to get an investigation that would lead to more accurate prognosis and 
probable intervention options.31 Nevertheless, confirming a diagnosis ensure proper 
management, surveillance of complications, identify relatives at risk and allow more 
accurate risk estimation. Even though the diagnostic evaluation has progressed a lot 
in terms of finding out the genetic basis, information on the course and prognosis 
still remain grey areas and is the biggest challenge in patient management. 
Prognosis of mitochondrial disorders is difficult, both within the families and be-
tween families with same mutation, because the disease course largely depends on 
the type of disease and organ system involved and limited knowledge exists on the 
impact of key modifying factors.32 Factors, which decide the prognosis in an individ-
ual patient, include, among others, the age of onset (pediatric patients being more 
severely affected than adult patients), physical fitness, duration of illness, various 
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complications and their outcome. Because of these factors the exact prognosis of a 
mitochondrial disease in an individual patient is more often decided by a single mi-
tochondrial disease related event or complications within a range, defined by indi-
vidual entities or genetic basis.32 Routine surveillance and early recognition of organ 
system involvement and complications are important for prognosis and applying and 
monitoring treatment. 
In this regard MRI, because of its non-invasive nature and the ability to define 
the anatomical pattern of brain injury overtime can play an important role in pre-
dicting the clinical course and monitoring treatment response in individual patients. 
The advantages of the newer imaging techniques to define the metabolic states of 
the brain and white matter integrity will further enhance their usefulness. Although 
analysis of clinical features and prognosis in relation to the MRI findings was only 
limitedly possible from the available literature, a few studies did address this issue. 
The available data indicated that certain MRI phenotypes were associated with a 
good prognosis and a stable clinical course. This was especially evident in patients 
with a leukoencephalopathy phenotype.33,34 Mitochondrial leukoencephalopathy 
associated with cytochrome oxidase deficiency and APOPT1 gene mutations ap-
peared to be highly variable in onset, but irrespective of the severity of onset and 
initial evaluation, both the MRI lesions and clinical progression stabilized with a 
chronic long survival clinical course.35 All patients in the report were alive with the 
oldest one being in the third decade. The improvements in clinical course are par-
alled by an improvement in the MRI findings. The correlation of a variable clinical 
course with MRI lesions has also been reported in cohorts of patients with mutations 
in other genes.36,37 In children with early onset leukoencephalopathy with thalamus 
and brainstem involvement and elevated lactate and the same EARS2 mutation, two 
groups were identified based on the prognosis. The variation in the clinical pheno-
types corresponded to the severity of MRI phenotypes.36 Striking improvement on 
MRI paralleling the improvement in clinical course was also reported in another 
patient with EARS2 mutations and an intermediate severity.34 This also holds true 
for the well-characterized leukoencephalopathy with brainstem and spinal cord 
involvement and elevated lactate due to DARS2 mutations. The neonatal and late 
infantile forms have a severe clinical course, in contrast to the adolescent and adult 
onset patients, the clinical severity correlating with the extent of white matter signal 
changes.37 Similarly a continuous development was noted in patients with leu-
koencephalopathy caused by NUBPL mutations, the chaperone involved in the iron-
sulfur cluster assembly in complex I.38 The developmental progress in the patient 
was correlated with improvements in corpus callosal and cerebral white matter sig-
nal changes, although there were progressive cerebellar and brainstem abnormali-
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ties, which did not correlate. A mild or stable clinical course was described in pa-
tients with leukoencephalopathy on MRI and NDUFV1 mutations.39 The paper 
highlighted that mitochondrial encephalopathy associated with white matter signal 
changes was not necessarily associated with a severe course. A follow up MRI was 
not available to correlate imaging to the stable course. All these reports exemplify to 
a certain extent, the prognostic implications of MRI findings in mitochondrial disor-
ders, where the severity of the disease course correlatesd with the severity of the 
MRI abnormalities.  
Demonstrating additional lesions on MRI, which were unusual in patients with a 
particular genotype should alert the physician about a different course in a given 
patient as indicated in chapter 2. In two children with the m.3243A>G mutation, 
MRI revealed additional basal ganglia lesions along with the stroke like lesions sug-
gesting diagnosis of MELAS-Leigh-overlap syndrome. Both children developed se-
vere swallowing difficulties over-time indicating brainstem involvement typical of 
Leigh syndrome children. Even though a follow-up MRI or autopsy studies were not 
available in these two children to objectively demonstrate the brainstem lesions, the 
clinical features and severity and subsequent fatal outcome in these two children 
early in the disease course indicated progressive involvement of the brain stem as 
depicted in previous studies on clinic-anatomic correlations of respiratory abnormal-
ities in Leigh syndrome.40,41 These studies also demonstrated that the Leigh syn-
drome children with brainstem lesions have a worse prognosis than children with 
dominant basal ganglia lesions.41 Likewise, disappearance of brainstem lesions have 
been correlated with improvement in clinical symptoms in patients with Leigh-like 
syndrome.10 These findings suggest that anticipation of the clinical course and ap-
propriate intervention based on MRI findings can improve the prognosis.  
Chapter 2 also discussed follow-up MRIs and their correlation with the clinical 
course in a subset of patients. These studies showed progressive MRI changes and 
new anatomical areas of involvement. A shift from the episodic stroke-like lesions to 
progressive degenerative course was correlated with the atrophic changes on MRI in 
patients with the m.3243A>G mutation. Neuropathological studies on human post-
mortem CNS tissues provided insight into the distribution and severity of neuronal 
degeneration in patients harboring mitochondrial DNA defects.42 The neuronal de-
generation on MRI is reflected as cerebral and cerebellar atrophy. The atrophic 
changes on MRI noted in MELAS, POLG1 and MERRF patients in chapter 2 and 
chapter 5 correlated with progressive cognitive decline and degenerative course on 
follow up. This is also supported by neuropathological studies. In a series of 15 
brains from genetically diverse mitochondrial diseases, atrophy was noted in ME-
LAS, POLG1 and MERRF patients.42 The duration of illness or imaging data of these 
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patients were not mentioned and correlation with prognosis is therefore not possi-
ble. Study of the mechanisms underpinning neurodegenerative changes in primary 
mitochondrial disorders may improve the understanding of the role of mitochondria 
in neurodegeneration. MRI Volumetric studies and nuclear imaging studies can 
additionally support these studies. These findings highlight the importance of fol-
low-up images in prognostication of patients with mitochondrial disorders.  
MRI-based therapeutic interventions 
In general, therapeutic implications of specific characteristics on MRI in subgroups 
of mitochondrial diseases need further exploration. In Chapter 5, we investigated 
the prognostic and therapeutic implications of MRI findings in patients with mito-
chondrial epilepsy. Our hypothesis was that the MRI findings might correlate with 
the therapeutic response in mitochondrial epilepsy. Of the 27 patients with epilepsy, 
the seizures were well controlled only in the subgroup of patients with leu-
koencephalopathy, which most often required immunotherapy only. The study also 
suggested that patients with stroke like lesions on MRI needed more intensive 
treatment than other subgroups of patients with either normal or atrophic changes 
on MRI. 
One of the most important characteristics of MRI in mitochondrial leukoenceph-
alopathies is the evidence of inflammation in several cases, as discussed in chapter 6. 
Similarity in clinical presentation and MRI findings in mitochondrial leukoencepha-
lopathies, which overlap with primary demyelinating disorders such as acute dis-
seminated encephalomyelitis or multiple sclerosis, were emphasized. The overlap or 
co-existence of mitochondrial disorders with acquired demyelinating disorders is 
well known for patients with LHON-MS. The entity LHON-MS denotes the coexist-
ence of LHON and multiple sclerosis like MRI in the same individual.43 Autopsy 
study in a patient with LHON-MS highlighted the inflammatory response.44 The 
inflammatory changes were characterized by macrophages and lymphocytes within 
the lesion, which diffusely infiltrated the parenchyma and formed an inflammatory 
rim at the actively demyelinating edge of the lesion. Introduction of corticosteroids 
in this patient intermittently improved the visual and neurological dysfunction, 
suggesting an early immunological mechanism. It was proposed that mitochondrial 
dysfunction might occasionally aggravate or initiate the autoimmune process.44 
Similar to the LHON-MS patients, MRI in mitochondrial leukoencephalopathy 
also exhibited signs of inflammatory response as evidenced by contrast enhancement 
and restricted diffusion in the acute stages. This is most often seen in ischemia and is 
attributed to cytotoxic edema. Delayed restricted diffusion with contrast enhance-
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ment has been described in tumefactive MS lesions.45 Lesions with restricted diffu-
sion and  presence of gadolinium enhancement have been shown to distinguish 
acute demyelinating lesions from ischemia.46  This has been attributed to intramye-
linic edema or myelin vacuolization as well as to toxic demyelination or inborn 
error of metabolism.47 Another explanation was that the myelin breakdown could 
reduce the water movement in the extracellular space, because of the reduced fiber 
tract organization.48 The presence of concomitant contrast enhancement along with 
restricted diffusion in mitochondrial leukoencephalopathies may suggest that the 
pathology is similar to acute demyelinating lesions and may suggest cytotoxic ede-
ma.  
The therapeutic implications of this clinical and MRI evidence of neuroinflam-
mation in patients with mitochondrial leukoencephalopathies have not been ex-
plored extensively. Most important will be the utility of glucocorticoid administra-
tion in acute stages, similar to management of acute demyelinating disorders. There 
is data on steroid responsiveness during times of deterioration in patients with mito-
chondrial leukoencephalopathy even though description of the treatment regime is 
limited.49 Remarkable corticosteroid response and dependence has been described in 
patients with MELAS and it has been recommended that corticosteroid therapy 
should be considered as a standard treatment.50 In a patient with MELAS, DWI and 
PET studies have demonstrated that the primary pathophysiological process leading 
to neuronal injury is actually a poorly regulated compensatory hyperperfusion re-
sponse.51The regional hyperperfusion leads to apoptotic cell death through progres-
sion from vasogenic to cytotoxic edema. The authors suggested that the prompt 
diagnosis and institution of treatment in the hyperperfusion stage might prevent 
progression to cytotoxic edema averting permanent neurological deficit. Studies 
have also shown corticosteroid receptors in mitochondria and increasing evidence 
that mitochondria are controlled by the action of glucocorticoids.52 Expression of 
mitochondrial genes is regulated by interaction of glucocorticoids with nuclear 
genes or by direct action of glucocorticoids on mtDNA and its respiratory chain. 
Glucocorticoids stimulate the mitochondrial transcription by the mitochondrial 
glucocorticoid receptor affecting respiratory chain biosynthesis.53 Glucocorticoids 
can enhance the mitochondrial biogenesis and modulate the extrinsic pathway of 
apoptosis.54 A number of other reports also highlight the beneficial effects of cortico-
steroids during the acute exacerbation and to prevent clinical deterioration.55 In 
patients with leukoencephalopathy there seems to intermittent responsiveness to 
steroids administration even though the information in the reports are limited. It 
remains to be seen if maintenance of the steroid therapy as in other immune medi-
ated disorders can keep a stable course. The report of the relapsing remitting MS-
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like illness in a child with a NDUFA1 mutation described in chapter 6 may support 
this hypothesis. The child received a maintenance dose of steroids and remained 
clinically stable on mitochondrial cocktail medicines. The brain biopsy findings also 
demonstrated an inflammatory response. This may support the hypothesis that the 
primary lesions in mitochondrial leukoencephalopathies simulate demyelinating 
lesions and may respond to immunomodulation. 
MRI-based therapy monitoring 
Several therapeutic strategies for mitochondrial disorders are being developed and 
are in the preclinical stages and the biggest challenge is the lack of validated bi-
omarkers to monitor the efficacy of treatment.56 Imaging findings are increasingly 
being identified and used for monitoring the progress in neuromuscualr disorders.57 
The potential application of MRI as a ‘rate biomarker’ in mitochondrial disorders 
still needs to be explored. It has been pointed out that the common brain MRI fea-
tures of mitochondrial disorders are not specific and highly variable making them 
unsuitable as a biomarker.56 But the potential application of MRI in assessing the 
disease progression and its usefulness in monitoring treatment has not been explored 
in large longitudinal studies so far. As evident from the review of the MRI findings 
in different genotypes of mitochondrial disorders in chapter 1, large homogenous 
patient groups can be achieved based on the neuroimaging findings.  
An array of imaging modalities provides a non-invasive quantitative measure-
ment of disease progression, which can be used for monitoring therapy. Eventhough 
elevated lactate is an established finding of brain MRS, there are only limited studies 
available which studied the effect of pharmaceutical agents on lactate levels.58-61 A 
recent study on H-MRS in a large cohort of clinically heterogeneous individuals 
with the m.3243A>G mutation has shown that lactate and total choline levels were 
reliable biomarkers for predicting the risk of individual mutation carriers to develop 
the MELAS phenotype.62 Another study used Tc99m-HMPAO, a SPECT imaging 
biomarker of cerebral blood flow to monitor the effect of EPI-743 treatment in mi-
tochondrial disorders. The study demonstrated significant correlation between 
change in cerebellar uptake of HMPAO and clinical improvement in all the patients. 
The role of MRI in treatment monitoring has also been demonstrated in a serial MRI 
studies after L-Arginine infusion therapy.63 These studies provide promising data to 
use MRI for therapy monitoring, which needs follow-up in larger patient cohorts.  
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Therapeutic Perspectives for mitochondrial disease 
Symptomatic management of patients with mitochondrial disorders requires evalua-
tion by a multidisciplinary team including neurologists, cardiologists, ophthalmolo-
gist and rehabilitations specialists. The evaluations include periodic cardiac assess-
ment with echocardiogram and cardiac MRI, eye examination including optical 
coherence tomography for conditions, which affect the eyes primarily such as 
Leber’s hereditary neuropathy and optic atrophy plus syndrome. Epilepsy is com-
mon in patients with mitochondrial disorders and periodic EEG monitoring is re-
quired to identify the abnormalities and start treatment at the earliest possible mo-
ment. Respiratory assessment to find out the respiratory dysfunction early in the 
course to treat hypoxia is also an important part of management strategies. Treat-
ment of tone abnormalities especially hypotonia, dystonia and hypertonia, necessi-
tates consultation with a rehabilitation specialist.  
The last couple of years have witnessed tremendous advancement in the under-
standing of the inherent complexities of the mitochondrial biology. In-depth studies 
have helped to elucidate the genetic causes and pathogenic mechanisms of mito-
chondrial disorders at an increasing pace over the last 25 years. The role of mito-
chondrial dysfunction in several other common neurological disorders is slowly 
unfolding. including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyo-
trophic lateral sclerosis (ALS), Huntington’s disease (HD), Friedreich ataxia and 
Hereditary Spastic Paraplegia.64 Several pathophysiological mechanisms which im-
plicate mitochondrial dysfunction in these disorders are put forward ranging from 
direct gene defects to perturbation in mitochondrial dynamics.65 Translation of this 
huge body of knowledge to the patient’s management is the next step. It is envisaged 
that the knowledge on the pathological mechanisms underlying both primary and 
secondary mitochondrial impairment may prompt the development of more effec-
tive evidence based therapeutic strategies. Even though the neurological progression 
over several decades in these disorders pose substantial morbidity, the current ther-
apeutic strategies mainly concentrate on symptomatic management and improving 
the quality of life. A recent Cochrane review found no evidence of an effective in-
tervention for any mitochondrial disorder.66 Nevertheless, specific treatment is 
available in a number of disorders such as CoQ10 replacement therapy in patients 
with mutations CABC1 and ETFDH67, riboflavin therapy in patients with mutations 
of ACAD968 and thiamin therapy in patients with SLC19A3 mutations, which pre-
vents fatal Leigh syndrome69. The huge clinical, biochemical and genetic heteroge-
neity, which is the hallmark of mitochondrial disorders, is the major hindrance for 
collection of homogeneous cohorts of patients to establish the efficacy of a treat-
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ment. It remains to be seen if the convergence at the level of magnetic resonance 
imaging findings can overcome these barriers to certain extent. As discussed earlier 
the prognosis and therapy should be tailored to each patient and depends on indi-
vidual clinical scenario, in which the gene defect complemented with MRI may be 
decisive. The potential of MRI findings to formulate this form of ‘personalized medi-
cine’ is promising, but needs to be further explored. 
The first attempts at treating mitochondrial disorders involved strategies to en-
hance the functioning of respiratory chain complex, which included compounds 
which increased substrate availability, augment the electron transfer within the 
respiratory chain, energy buffering and bypass the respiratory chain components.70 
Compounds aimed at increasing the substrate availability include carnitine [which 
enhances the delivery of fatty acids], niacin [precursor of NADH which transfers 
electrons from intermediate metabolites to respiratory chain) and thiamine [which 
enhances pyruvate dehydrogenase activity thereby increasing the availability of 
pyruvate]. Agents which augment the electron transfer within the respiratory chain 
include riboflavin [precursor to flavin adenine dinucleotide [FAD]- electron carrier 
attached to complex I & II], coenzyme Q, an electron carrier from complex I & II to 
complex III. There are compounds based on COQ and vitamin E such as idebenone 
and EPI-743, which increases the penetration of electron carrier to mitochondria. 
Substances which can bypass the function of specific respiratory chain include suc-
cinate (a citric acid cycle intermediate that donates electrons directly to FAD thus 
partially bypassing complex I), vitamin C&K [bypass complex III]. Reduction of free 
radicals through anti oxidants is another approach and include vitamin C, E, lipoic 
acid and dimethyl glycine. Increased ROS production occurs as a consequence of 
respiratory chain dysfunction and is the rational basis for the use of antioxidants in 
the therapy of mitochondrial disorders. Other compounds which have been used 
include L- Arginine for the treatment of stroke like episodes. It acts through the 
vasoactive effects mediated by the nitric oxide pathway, as L-arginine is a substrate 
for the Nitric oxide synthase (NO). The exact mechanism of action of L-Arginine in 
stroke-like episodes still needs to be resolved. Administration of L-Arginine has 
been shown to improve the regional perfusion in stroke like lesions in patients with 
MELAS, but the efficacy for treating MELAS patients is still not unambiguously 
demonstrated.63  
Various experimental therapies are being developed and include methods to in-
crease the mitochondrial biogenesis, controlling autophagy and manipulating mito-
chondrial heteroplasmy.70 
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Increasing mitochondrial biogenesis 
Mitochondrial biogenesis is increases the individual mitochondrial mass and mtDNA 
and mitochondrial copy number in a cell to increase the production of ATP as a 
response to increased energy expenditure. Mitochondrial diseases become manifest 
when the residual activity of the defective gene product, either mitochondrial or 
nuclear encoded, falls below a critical threshold. This may suggest that even partial 
restoration of the activity may be sufficient to rescue or at least ameliorate the phe-
notype.71 Mitochondrial biogenesis is an important factor deciding the severity of 
phenotype. Increased mitochondrial DNA copy number and mitochondrial biogene-
sis have been demonstrated in LHON carriers, compared to controls and affected 
patients, thereby supporting the notion that a high mitochondrial copy number 
protects carriers from developing clinical disease.72 The agents, which have been 
tried, include benzafibrate, and the AMPK agonist AICAR. AICAR has been shown 
the most effective compound in inducing mitochondrial biogenesis in complex I 
deficient cells, whereas benzafibrate gave erratic results.73   
Controlling autophagy- Role of mTOR inhibitors   
Rapamycin, an mTor inhibitor, has been used to treat the Ndufs4-/- mouse which 
lacks the 18kDa Ndufs4 subunit of complex I. Mutations of NDUFS4 are associated 
with autosomal recessive, severe infantile Leigh disease in humans and with rapidly 
progressive, early fatal neurological failure in the Ndufs4−/−mouse model.74 Chronic 
treatment with Rapamycin, which activates autophagy, significantly delayed both 
disease progression and fatal outcome in the Ndufs4-/- knock out mouse. Metabo-
lomic analysis of Ndufs4−/−brains showed accumulation of pyruvate, lactate, and 
glycolytic intermediates, as well as reduced free amino acids, free fatty acids, nucleo-
tides, and products of nucleotide catabolism, increased oxidative stress markers, and 
reduced levels of GABA and dopamine. While Rapamycin corrected many of these 
metabolic abnormalities, no effects were noted on complex1 activity. 
Manipulating mtDNA heteroplasmy 
Pathogenic mutations of mtDNA are often heteroplasmic. It is envisaged that elimi-
nating or reducing the mutated DNA below the threshold of disease manifestation 
would be a promising therapeutic intervention. In cellular models this has been 
achieved by the use of mitochondrially targeted restriction endonucleases, zinc fin-
ger-endonucleases, or TALENs.71 Delivery of restriction enzymes into mitochondria 
is a novel strategy for gene therapy of special form of mitochondrial diseases. This 
has been used in m.8399T>G NARP mutations which form a unique restriction site 
which is specific to restriction endonuclease Smal.75 Mitochondrially targeted re-
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combinant Smal variant was able to reduce the m.8993T>G mutation load in hetero-
plasmic mutant hybrids. This also resulted in repopulation of cells withwild type 
mtDNA, restoration of mtDNA membrane potential and increase in intracellular 
ATP levels. The disadvantage is that, this is applicable only when a unique re-
striction site is created by an mtDNA mutation. Alternate methods are use of mito-
chondrial TALENS and zinc finger endonucleases, both of which have been proven 
to eliminate heteroplasmic mutant mtDNA in cybrid cells carrying the m.8993T>G 
NARP mutation or the common deletions.76,77  
- Prevention of transmission  
Due to the inherent complexities of the mitochondrial genetics genetic counsel-
ing and prenatal diagnosis is difficult, not so much for nuclear gene mutation, but 
predominantly for primary mitochondrial DNA mutations. For de novo muta-
tions with low recurrence risk, prenatal testing can be offered, whereas for in-
herited heteroplasmic mutations preimplantation genetic diagnosis (PGD) gener-
ally is the best option. 78 Novel options under development include nuclear ge-
nome transfer involving maternal spindle transfer and pronuclear transfer which 
is suitable for both homoplasmic and heteroplasmic mutations. Even though 
these options appear exciting, they raise significant ethical issues and should be 
applied on an individual basis. 78,79 
- Gene Therapy 
Molecular-based therapies have been hardly tried in mitochondrial disorders. 
Adeno-associated viral vectors mediated gene transfer have been tried in animal 
models of Ethyl malonic encephalopathy, MNGIE and MPV17 related disor-
ders.80,82 Gene therapy for mitochondrial DNA disorders is challenging. Alternate 
methods of “allotopic expression” have been tried in complex I subunits with a 
view to treat the most common mitochondrial DNA disorder LHON.83.84 
- Nucleoside Bypass Therapy 
This is a form of treatment advocated for conditions with imbalanced nucleotide 
pools including mitochondrial DNA depletion syndromes. Among the mitochon-
drial depletion syndromes, TK2 deficiency has been specifically targeted.85 Thy-
midine kinase is a mitochondrial enzyme required for phosphorylation of the 
pyramidine nucleosides (thymidine  & deoxycytidine) to generate deoxy thymi-
dine monophosphate and deoxycytidine monophosphate.86 Mutations in TK2 im-
pair the mitochondrial nucleoside or nucleotide salvage pathways.87 TK2H126N 
knock-in mutant mouse (Tk2-/-) models manifest a phenotype strikingly similar 
to human infantile encephalomyopathy characterized by onset at 10 days with 
decreased ambulation, unstable gait, coarse tremor, growth retardation and 
mtDNA depletion progressing to early death.88 Oral administration of deoxycyti-
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dine monophosphate (dCMP) and deoxy thymidine monophosphate (dTMP) de-
layed the disease onset, reduced the disease severity and prolonged the life span 
in mouse models.85 Further experiments have shown that the same results are 
achieved by administration of deoxythymidine (dT) or deoxycytidine(dC).89 This 
“nucleoside bypass therapy” (NBT) is expected to be an effective therapy not only 
for TK2 deficiency but also for other mitochondrial depletion syndromes.  
Despite the lack of effective disease modifying treatment for mitochondrial disor-
ders, there are lots of supportive treatment options that can be offered to the patient. 
Based on the current evidence and the extensive genotypic and phenotypic variabil-
ity, the treatment approach needs to be individualized. Clinical course and compli-
cations in individual patient needs to be anticipated and appropriate preventive 
measures needs to be taken. Even though it has been suggested that the therapy in 
patients with mitochondrial disorders should be based on molecular pathways rather 
than phenotypes or genotypes, feasibility of a combined approach needs to be stud-
ied. The role of MRI in individualizing the treatment and follow up evaluations in a 
given patient needs to be explored in systematic manner in large longitudinal stud-
ies.  
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Magnetic resonance imaging has been used extensively in the evaluation and follow 
up of neurometabolic disorders especially mitochondrial disorders. It offers a non-
invasive way of assessing the structural, functional and metabolic state of the central 
nervous system and an easily available diagnostic modality in the early stages of 
evaluation. There are only few large studies, which focus on the magnetic resonance 
imaging findings in patients with mitochondrial disorders. More importantly the 
therapeutic and prognostic implications of specific MRI findings in routine clinical 
practice remains largely unexplored. Moreover the role of MRI in defining the phe-
notypes thereby providing valuable corroborative evidence for the potential patho-
genic variants identified in exome sequencing is also emerging. With this back-
ground the study aimed to explore the prognostic and therapeutic significance of 
MRI findings in mitochondrial disorders. We studied the phenotype genotype corre-
lations with special reference to MRI findings in specific subsets of mitochondrial 
disorders in order to guide prognosis and therapy [chapter 2], correlated peripheral 
neuropathy with underlying genetic defects [chapter 3], evaluated if specific imaging 
findings can discriminate mitochondrial disorders from other metabolic disorders 
[chapter 4], analyzed MRI findings in specific subset of patients to find out factors 
which can predict prognosis and monitor therapy [chapter 5&6]. Chapter 7 discusses 
the relevance of the findings in a broader perspective of application in the clinical 
practice and future research. 
Chapter 1 is introductory and reviews the current literature on the MRI findings in 
various mitochondrial disorders. The MRI findings of mitochondrial disorders in the 
context of ever expanding genotypes in the era of next generation sequencing were 
studied. Most of the studies report the cross sectional findings and detailed descrip-
tions are lacking. Inspite of the myriad of genes and variations involved, the chapter 
demonstrated the convergence at the level of MRI findings amidst the clinical het-
erogeneity. The findings mainly converged to three important groups viz.bilateral 
symmetrical involvement of deep ganglionic structures suggestive of Leigh and 
Leigh like syndrome; leukoencephalopathy and stroke like lesions. In chapter 2, we 
analyzed the MRI findings in detail in a cohort of genetically defined patients with 
mitochondrial disorders. The study gives a detailed description of the anatomical 
pattern of CNS involvement identified by routine MRI sequences such as T1W, 
T2W and FLAIR sequences and the findings on various quantitative MR imaging 
studies such as DW1, MRS and SWI. Even though the study included only a limited 
number of genotypes it brought out a detailed description of the structural altera-
tions in three different genotypes of mitochondrial disorders. Analysis of the special 
sequences revealed, basal ganglia mineralization, lactate peak on magnetic resonance 
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spectrometry and diffusion restriction reflecting the various pathophysiological 
processes in these patients. Comparison of the magnetic resonance imaging findings 
in the three groups showed that cerebral atrophy and cerebellar atrophy, cortical 
signal changes and basal ganglia mineralization were seen mostly in patients with 
mitochondrial mutations. Brainstem signal changes with or without striatal lesions 
were characteristically noted in SURF1 group. There were no consistent MRI find-
ings in patients in POLG1 group. The value of MRI based phenotypic characteriza-
tion in non-syndromic mitochondrial disorders also has been emphasized in this 
chapter. The specific tract involvement of spinal cord in a patient with primary 
LHON mutation and identification of a mitochondrial variation in infantile onset 
basal ganglia stroke syndrome and mineralizing angiopathy are noteworthy. Follow-
up images in a limited number of patients revealed that the findings are dynamic 
and revealed either progressive atrophy or involvement of new anatomical areas 
emphasizing   the need for regular follow up evaluations. Next in chapter 3 we stud-
ied genetic basis of peripheral neuropathy in mitochondrial disorders and estab-
lished correlations. Axonal neuropathy involving either sensory, motor or sensory 
motor nerves was the commonest nerve conduction abnormality identified. A de-
myelinating neuropathy was seen predominantly in patients with SURF1 mutations. 
Neuropathy was subclinical in majority of the patients and helped defining the mul-
tiaxial nature of the disease. It is intriguing to note the differential involvement of 
axons and myelin in mitochondrial disorders and their relationship with specific 
genetic variations. Even though the axonal involvement can be explained based on 
the chronic energy deprivation theory, the involvement of myelin especially in 
those with SURF1 variations is fascinating. This calls for more detailed studies to 
interrogate the interrelationship between SURF1 and peripheral myelin integrity.  
In addition to studying the phenotype genotype correlations we also evaluated 
the role of specific MRI findings in differentiating mitochondrial disorders from 
other inherited metabolic disorders [chapter 4]. Bilateral symmetrical involvement 
of the basal ganglia and brainstem defining Leigh syndrome is an important MR 
imaging phenotype in mitochondrial disorders. Assigning a mitochondrial etiology 
will facilitate targeted metabolic and genetic testing leading to rapid and specific 
treatment. In chapter 4 analyses of MRI findings in a large cohort of 125 children 
with special reference to inferior olivary hypertrophy was done. The study empha-
sized the presence of inferior olivary involvement in Leigh syndrome secondary to 
mitochondrial disorders compared to other metabolic disorders. The study also 
found that that the presence of inferior olivary involvement occurred independently 
and not always associated with central tegmental tract or dentate nuclei involve-
ment, implying the vulnerability of inferior olivary nuclei to mitochondrial dys-
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function. Apart from the role of MRI in defining the phenotype genotype correla-
tions we also examined the prognostic and therapeutic implications of MRI findings 
in two subset of mitochondrial disorders namely mitochondrial epilepsy and mito-
chondrial leukoencephalopathies. In chapter 5, MRI findings in 27 patients with 
mitochondrial disorders and epilepsy were correlated with treatment response and 
long-term outcome. Clinical, genotype and MRI correlations included focal seizures, 
epilepsia partialis continua, status epilepticus and episodic progression in patients 
with stroke like lesions and m.3243A>G mutations; progressive degenerative course 
in patients with cerebral and cerebellar atrophy mostly secondary to m.8344G>A 
mutation; Chronic progressive external ophthalmoplegia, photosensitive eye lid 
myoclonus and status epilepticus in patients with normal MRI and POLG1 muta-
tions; Intermittent partial and generalized seizures in leukoencephalopathy of heter-
ogeneous genetic etiology. The study highlighted that the anatomical patterns on 
MRI in patients with mitochondrial epilepsy may predict the genotype and pheno-
types and recognition of these patterns may help clinicians in prognostication and 
therapy. In chapter 6, detailed analysis of the clinical course, MRI findings and ther-
apeutic response to immunomodulation was performed in 14 patients with mito-
chondrial leukoencephalopathy. Clinical features which mimicked acquired demye-
linating disorder included acute onset focal deficits associated with encephalopathy, 
febrile illness preceding the onset, unequivocal partial or complete steroid respon-
siveness, episodic/ relapsing remitting neurological dysfunction and a subsequent 
stable rather than a progressive course. MRI characteristics included multifocal 
asymmetric confluent white matter lesions, diffusion restriction, contrast enhance-
ment, spinal cord involvement, and lactate peak on MRS. The study concluded that 
episodic neuroinflammation is a feature of mitochondrial leukoencephalopathies 
which may overlap with that of acquired demyelinating disorders in children. The 
response to immunomodulation was noteworthy and the therapeutic implications of 
these observations need to be explored in further studies. Chapter 7 discusses the 
relevance of our findings in the current scenario of paradigm shift in the diagnostic 
evaluation of mitochondrial disorders brought out by next generation sequencing. 
The chapter emphasizes the need for incorporating MRI studies in natural history 
studies. It also discusses the hitherto unexplored field of application of MRI findings 
in prognostication and therapy of patients with mitochondrial disorders and brings 
out avenues for future studies. Chapter 7 also discusses the emerging treatment op-
tions in mitochondrial disorders and the role of MRI in guiding and monitoring 
treatment response. 
In this thesis, application of routine MRI in diagnostics, mainly based on pheno-
type genotype correlations has been studied in addition to its application in prognos-
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tication and therapy in limited subsets of patients. It is envisaged that extension of 
these studies to more subgroup of patients and the systematic application of ad-
vanced imaging techniques may bring out new avenues on the role of MRI in man-
agement of patients with mitochondrial disorders. These studies should lead to the 
routine and methodical use of MRI in natural history studies and also therapy moni-
toring. 
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Mitochondrial disorders, considered as the most common inborn error of metabo-
lism in children and most prevalent group of inherited neurological disorders in 
adults, often cause multisystem dysfunction leading to a characteristically complex 
clinical picture with significant morbidity and mortality.1,2 While the inherent het-
erogeneity and complexity associated with these disorders pose diagnostic and man-
agement challenges to the physicians involved in the care of patients, the diagnosis 
or suspected diagnosis of a mitochondrial disorder, pose considerable challenges to 
the families as well.3 Firstly, the diagnostic evaluation in patients with suspected 
mitochondrial disorders is “time-consuming, logistically demanding, cost-intensive, 
and often associated with inconclusive or negative results, and above all, it is fre-
quently not initiated at all, why many of these patients go undetected for years or 
forever”.4 Secondly, even though there has been tremendous advancement in under-
standing the genetic basis of mitochondrial disorders in recent years, the infor-
mation on the course and prognosis still remain the biggest challenge in patient 
management. Thirdly in view of the propensity to affect the central nervous system, 
chronic disability is the rule which cause considerable economic burden to families 
as well as to the health care system.3 Taking all these factors together, the individual 
disease burden is extensive, resulting in substantial direct and indirect health care 
costs to the patient and society as a whole.1  
The studies in this thesis are relevant to address the above-mentioned issues 
faced by the families of patients with mitochondrial disorders. Our data (chapter 2-
5) demonstrates that Brain MRI is an invaluable tool in guiding diagnosis, prognosis 
and therapy in mitochondrial disorders. This is important for clinical practice of 
adult and paediatric neurologists, geneticists, radiologists and for patients, patient 
organizations and advocacy groups themselves. Our results have substantial implica-
tions for evaluation, assessment of intervention outcomes and may guide evidence 
based management guidelines.  
Shortening the diagnostic odyssey thereby reducing the cost of diagnostic process 
The work described in this thesis examined three important aspects of mitochondri-
al disorders, the clinical phenotype, genetic basis and most importantly the Brain 
MRI findings. We first critically analyzed the brain MRI findings of mitochondrial 
disorders reported in literature. We then proceeded to characterize the MRI findings 
in specific genotypes in a relatively large cohort of patients to establish correlations 
between specific genotypes and MRI phenotypes. This study provides valuable data 
on the MRI phenotypes in a rare group of disorders (chapter 2). Mitochondrial dis-
orders are rare and not many physicians are familiar with the clinical and MRI find-
ings to suspect the diagnosis at an early stage. MRI is one of the earliest and easily 
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available tools available to the clinician and knowledge of the various MRI findings 
and their correlation with the phenotype and genotype is of paramount importance 
in the diagnostic evaluation of patients and for optimal patient care. MRI helps the 
physician to suspect the diagnosis early in the clinical course and target the investi-
gations in specific directions thereby reducing the cost and length of investigations.  
In other words, for the clinician, it gives a cost effective way of analyzing the prob-
lem, nature and extent of the CNS involvement and provides an easy objective 
measure of involvement of the CNS to be communicated to the patients and families. 
While genetic diagnoses remain the ultimate end of the diagnostic odyssey in mi-
tochondrial disorders, brain MRI plays an important role in shortening and finetun-
ing this process. Our data (chapter 4) suggests ways to differentiate mitochondrial 
disorders from other neurometabolic disorders through specific findings on MRI, 
thereby helping the physician to target the genetic investigations and management , 
which is especially important in the many countries, where whole exome sequenc-
ing is not the diagnostic standard yet. The correlations described in the thesis help to 
direct the genetic testing and suggest the genes of interest thereby reducing the turn 
around time for targeted or exome sequencing. MRI also helps to define the pheno-
types in individual patients better, thereby providing the valuable corroborative 
evidence for the potential pathogenic variants identified in exome sequencing stud-
ies. This in turn helps to reduce the cost of investigations and will be of direct bene-
fit to patients and patient’s families.. The exact economic impacts of these findings 
are difficult to ascertain, but it reduces the time to diagnosis considerably.  
Defining the course, prognosis and treatment 
As discussed in the thesis (chapter 7), defining the prognosis and course at a given 
point of time is the biggest challenge faced by the physician. The disease course 
largely depends on the organ system involved with the nature of the genetic varia-
tions being an important factor. We show in the thesis (chapter 5&6) that the MRI 
phenotype might be used in the prognostication of mitochondrial disorders. Our 
data showed that certain MRI phenotypes such as leukoencephalopathy is associated 
with a better prognosis. It also showed that presence of additional lesions on MRI 
such as brain stem signal changes might decide the outcome in individual patients 
(chapter 2). As noted in the thesis “MRI, because of its non-invasive nature and the 
ability to define the anatomical pattern of brain injury overtime can play an im-
portant role in predicting the clinical course and monitoring treatment response in 
individual patients.” Most importantly, we expect that our work will pave the way 
for the use of MRI in natural history studies. This has implications for patients and 
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patient organizations in view of the objective nature in which the information can 
be communicated to the patients and their families.  
One of the biggest challenges in developing a clinically relevant treatment strat-
egy in mitochondrial disorders is  lack of objective and validated outcome measures.6 
Our data advocate the use of MRI. The outcome in certain mitochondrial disorders 
tends to correlate with the structural changes on MRI and there is an apparent con-
vergence at the level of MRI findings even when the genotypes are different. It 
would, therefore, be an attractive option to construct MRI homogenous groups for 
clinical trials. So far, MRI has not been included as an outcome measure in mito-
chondrial treatment trials. Since the inception of this study another group has de-
veloped and validated a scoring system for MRI in mitochondrial disorders which 
can be used for rating disease progression and outcome after intervention in clinical 
trials.5 In this way, the studies presented in this thesis have broader implications for 
pharmaceutical companies, involved in the development of new therapies and drug 
trials. 
In addition to the role of MRI in facilitating prognosis and therapy, we also ex-
amined three important neurological features in mitochondrial disease which in-
clude peripheral neuropathy, epilepsy and leukoencephalopathy. All the three fea-
tures are important factors leading to chronic disability in mitochondrial disorders. 
Epilepsy is one of the key manifestations of neurological diseases caused by patho-
genic mutations in many genes affecting mitochondrial function.7 It is one of the 
important features limiting the quality of life in many mitochondrial disorders espe-
cially MERRF and MELAS syndromes.8 In addition secondary mitochondrial dys-
function has been described in various epileptic disorders.9 Epilepsy being one of the 
common problems faced by the neurologist, characteristics of epilepsy associated 
with mitochondrial dysfunction improve both evaluation and management. The 
analysis of course and prognosis in relation to phenotype, genotype and MRI find-
ings after a long period of follow up is one of the strengths of this thesis. Our data 
describe the most commonly used medications and the therapeutic response in spe-
cific subsets of patients and could be converted into management guidelines in mito-
chondrial epilepsy.  
A potential relationship between immunological activation and mitochondrial 
dysfunction (chapter 6) in mitochondrial leukoencephalopathies is a relatively un-
explored domain of mitochondrial medicine. Eventhough this has been suggested 
before, especially in multiple sclerosis and related disorders and LHON-MS, we have 
demonstrated that immune activation does exist in primary mitochondrial disorders. 
This has been amply substantiated by the MRI findings and therapeutic response to 
immune suppressive agents and a long-term follow up. These findings have implica-
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tions for the treatment of mitochondrial disorders, bringing out novel options, 
which has implications for the mitochondrial community as a whole and can con-
tribute to the development of management guidelines in patients with mitochondri-
al leukoencephalopathy.  
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